id	sid	tid	token	lemma	pos
dpc-4769	1	1	dermatology	dermatology	NOUN
dpc-4769	1	2	:	:	PUNCT
dpc-4769	1	3	practical	practical	ADJ
dpc-4769	1	4	and	and	CCONJ
dpc-4769	1	5	conceptual	conceptual	ADJ
dpc-4769	1	6	original	original	ADJ
dpc-4769	1	7	article	article	NOUN
dpc-4769	1	8	|	|	ADV
dpc-4769	1	9	dermatol	dermatol	ADJ
dpc-4769	1	10	pract	pract	NOUN
dpc-4769	1	11	concept	concept	NOUN
dpc-4769	1	12	.	.	PUNCT
dpc-4769	2	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	2	2	1	1	NUM
dpc-4769	2	3	a	a	DET
dpc-4769	2	4	prospective	prospective	ADJ
dpc-4769	2	5	real	real	ADJ
dpc-4769	2	6	-	-	PUNCT
dpc-4769	2	7	life	life	NOUN
dpc-4769	2	8	multicenter	multicenter	NOUN
dpc-4769	2	9	study	study	NOUN
dpc-4769	2	10	of	of	ADP
dpc-4769	2	11	tildrakizumab	tildrakizumab	NOUN
dpc-4769	2	12	200	200	NUM
dpc-4769	2	13	mg	mg	NOUN
dpc-4769	2	14	in	in	ADP
dpc-4769	2	15	patients	patient	NOUN
dpc-4769	2	16	with	with	ADP
dpc-4769	2	17	moderate	moderate	ADJ
dpc-4769	2	18	-	-	PUNCT
dpc-4769	2	19	severe	severe	ADJ
dpc-4769	2	20	psoriasis	psoriasis	NOUN
dpc-4769	2	21	:	:	PUNCT
dpc-4769	2	22	who	who	PRON
dpc-4769	2	23	is	be	AUX
dpc-4769	2	24	the	the	DET
dpc-4769	2	25	ideal	ideal	ADJ
dpc-4769	2	26	 	 	SPACE
dpc-4769	2	27	patient	patient	NOUN
dpc-4769	2	28	?	?	PUNCT
dpc-4769	3	1	eugenia	eugenia	PROPN
dpc-4769	3	2	veronica	veronica	PROPN
dpc-4769	3	3	di	di	PROPN
dpc-4769	3	4	brizzi1	brizzi1	PROPN
dpc-4769	3	5	,	,	PUNCT
dpc-4769	3	6	stefano	stefano	PROPN
dpc-4769	3	7	caccavale1	caccavale1	PROPN
dpc-4769	3	8	,	,	PUNCT
dpc-4769	3	9	roberta	roberta	PROPN
dpc-4769	3	10	di	di	PROPN
dpc-4769	3	11	caprio1	caprio1	PROPN
dpc-4769	3	12	,	,	PUNCT
dpc-4769	3	13	francesco	francesco	PROPN
dpc-4769	3	14	cusano2	cusano2	PROPN
dpc-4769	3	15	,	,	PUNCT
dpc-4769	3	16	rocco	rocco	X
dpc-4769	3	17	de	de	X
dpc-4769	3	18	pasquale3	pasquale3	PROPN
dpc-4769	3	19	,	,	PUNCT
dpc-4769	3	20	valeria	valeria	PROPN
dpc-4769	3	21	falcomatà4	falcomatà4	PROPN
dpc-4769	3	22	,	,	PUNCT
dpc-4769	3	23	caterina	caterina	PROPN
dpc-4769	3	24	foti5	foti5	PROPN
dpc-4769	3	25	,	,	PUNCT
dpc-4769	3	26	claudia	claudia	NOUN
dpc-4769	3	27	giofrè6	giofrè6	NOUN
dpc-4769	3	28	,	,	PUNCT
dpc-4769	3	29	emanuela	emanuela	PROPN
dpc-4769	3	30	gubinelli7	gubinelli7	PROPN
dpc-4769	3	31	,	,	PUNCT
dpc-4769	3	32	giampiero	giampiero	PROPN
dpc-4769	3	33	mazzocchetti8	mazzocchetti8	PROPN
dpc-4769	3	34	,	,	PUNCT
dpc-4769	3	35	massimiliano	massimiliano	PROPN
dpc-4769	3	36	nicolini9	nicolini9	PROPN
dpc-4769	3	37	,	,	PUNCT
dpc-4769	3	38	giovanni	giovanni	PROPN
dpc-4769	3	39	palazzo10	palazzo10	PROPN
dpc-4769	3	40	,	,	PUNCT
dpc-4769	3	41	leonardo	leonardo	PROPN
dpc-4769	3	42	pescitelli11	pescitelli11	PROPN
dpc-4769	3	43	,	,	PUNCT
dpc-4769	3	44	rosa	rosa	PROPN
dpc-4769	3	45	valentina	valentina	PROPN
dpc-4769	3	46	puca12	puca12	PROPN
dpc-4769	3	47	,	,	PUNCT
dpc-4769	3	48	oriele	oriele	PROPN
dpc-4769	3	49	sarno12	sarno12	PROPN
dpc-4769	3	50	,	,	PUNCT
dpc-4769	3	51	anna	anna	PROPN
dpc-4769	3	52	balato1	balato1	NOUN
dpc-4769	3	53	1	1	NUM
dpc-4769	3	54	dermatology	dermatology	NOUN
dpc-4769	3	55	unit	unit	NOUN
dpc-4769	3	56	,	,	PUNCT
dpc-4769	3	57	university	university	PROPN
dpc-4769	3	58	of	of	ADP
dpc-4769	3	59	campania	campania	PROPN
dpc-4769	3	60	“	"	PUNCT
dpc-4769	3	61	l.	l.	PROPN
dpc-4769	3	62	vanvitelli	vanvitelli	PROPN
dpc-4769	3	63	”	"	PUNCT
dpc-4769	3	64	2	2	NUM
dpc-4769	3	65	department	department	NOUN
dpc-4769	3	66	of	of	ADP
dpc-4769	3	67	dermatology	dermatology	NOUN
dpc-4769	3	68	,	,	PUNCT
dpc-4769	3	69	san	san	PROPN
dpc-4769	3	70	pio	pio	PROPN
dpc-4769	3	71	hospital	hospital	PROPN
dpc-4769	3	72	,	,	PUNCT
dpc-4769	3	73	benevento	benevento	PROPN
dpc-4769	3	74	,	,	PUNCT
dpc-4769	3	75	italy	italy	PROPN
dpc-4769	3	76	3	3	NUM
dpc-4769	3	77	u.o	u.o	PROPN
dpc-4769	3	78	.	.	PROPN
dpc-4769	3	79	dermatologia	dermatologia	PROPN
dpc-4769	3	80	,	,	PUNCT
dpc-4769	3	81	ospedale	ospedale	PROPN
dpc-4769	3	82	san	san	PROPN
dpc-4769	3	83	marco	marco	PROPN
dpc-4769	3	84	,	,	PUNCT
dpc-4769	3	85	catania	catania	PROPN
dpc-4769	3	86	,	,	PUNCT
dpc-4769	3	87	italy	italy	PROPN
dpc-4769	3	88	4	4	NUM
dpc-4769	3	89	great	great	ADJ
dpc-4769	3	90	metropolitan	metropolitan	ADJ
dpc-4769	3	91	hospital	hospital	NOUN
dpc-4769	3	92	bianchi	bianchi	PROPN
dpc-4769	3	93	melacrino	melacrino	PROPN
dpc-4769	3	94	morelli	morelli	PROPN
dpc-4769	3	95	,	,	PUNCT
dpc-4769	3	96	reggio	reggio	PROPN
dpc-4769	3	97	calabria	calabria	PROPN
dpc-4769	3	98	,	,	PUNCT
dpc-4769	3	99	italy	italy	PROPN
dpc-4769	3	100	5	5	NUM
dpc-4769	3	101	section	section	NOUN
dpc-4769	3	102	of	of	ADP
dpc-4769	3	103	dermatology	dermatology	NOUN
dpc-4769	3	104	,	,	PUNCT
dpc-4769	3	105	department	department	NOUN
dpc-4769	3	106	of	of	ADP
dpc-4769	3	107	biomedical	biomedical	ADJ
dpc-4769	3	108	science	science	NOUN
dpc-4769	3	109	and	and	CCONJ
dpc-4769	3	110	human	human	ADJ
dpc-4769	3	111	oncology	oncology	NOUN
dpc-4769	3	112	,	,	PUNCT
dpc-4769	3	113	university	university	NOUN
dpc-4769	3	114	of	of	ADP
dpc-4769	3	115	bari	bari	NOUN
dpc-4769	3	116	,	,	PUNCT
dpc-4769	3	117	bari	bari	NOUN
dpc-4769	3	118	,	,	PUNCT
dpc-4769	3	119	italy	italy	PROPN
dpc-4769	3	120	6	6	NUM
dpc-4769	3	121	u.o.c	u.o.c	NOUN
dpc-4769	3	122	.	.	PUNCT
dpc-4769	3	123	dermatology	dermatology	NOUN
dpc-4769	3	124	unit	unit	NOUN
dpc-4769	3	125	,	,	PUNCT
dpc-4769	3	126	“	"	PUNCT
dpc-4769	3	127	papardo	papardo	ADJ
dpc-4769	3	128	”	"	PUNCT
dpc-4769	3	129	hospital	hospital	NOUN
dpc-4769	3	130	,	,	PUNCT
dpc-4769	3	131	messina	messina	PROPN
dpc-4769	3	132	,	,	PUNCT
dpc-4769	3	133	italy	italy	PROPN
dpc-4769	3	134	7	7	NUM
dpc-4769	3	135	istituto	istituto	X
dpc-4769	3	136	dermopatico	dermopatico	NOUN
dpc-4769	3	137	dell’immacolata	dell’immacolata	NOUN
dpc-4769	3	138	,	,	PUNCT
dpc-4769	3	139	irccs	irccs	NOUN
dpc-4769	3	140	,	,	PUNCT
dpc-4769	3	141	rome	rome	PROPN
dpc-4769	3	142	,	,	PUNCT
dpc-4769	3	143	italy	italy	PROPN
dpc-4769	3	144	8	8	NUM
dpc-4769	3	145	uosd	uosd	PROPN
dpc-4769	3	146	dermatologia	dermatologia	PROPN
dpc-4769	3	147	asl1	asl1	PROPN
dpc-4769	3	148	pescara	pescara	PROPN
dpc-4769	3	149	,	,	PUNCT
dpc-4769	3	150	65124	65124	NUM
dpc-4769	3	151	pescara	pescara	PROPN
dpc-4769	3	152	,	,	PUNCT
dpc-4769	3	153	italy	italy	PROPN
dpc-4769	3	154	9	9	NUM
dpc-4769	3	155	carlo	carlo	PROPN
dpc-4769	3	156	urbani	urbani	PROPN
dpc-4769	3	157	hospital	hospital	PROPN
dpc-4769	3	158	,	,	PUNCT
dpc-4769	3	159	jesi	jesi	PROPN
dpc-4769	3	160	,	,	PUNCT
dpc-4769	3	161	ancona	ancona	PROPN
dpc-4769	3	162	,	,	PUNCT
dpc-4769	3	163	italy	italy	PROPN
dpc-4769	3	164	10	10	NUM
dpc-4769	3	165	dermatology	dermatology	NOUN
dpc-4769	3	166	,	,	PUNCT
dpc-4769	3	167	ospedale	ospedale	ADJ
dpc-4769	3	168	distrettuale	distrettuale	NOUN
dpc-4769	3	169	“	"	PUNCT
dpc-4769	3	170	a.	a.	NOUN
dpc-4769	3	171	lo	lo	PROPN
dpc-4769	3	172	dico	dico	PROPN
dpc-4769	3	173	”	"	PUNCT
dpc-4769	3	174	,	,	PUNCT
dpc-4769	3	175	matera	matera	PROPN
dpc-4769	3	176	,	,	PUNCT
dpc-4769	3	177	italy	italy	PROPN
dpc-4769	3	178	11	11	NUM
dpc-4769	3	179	unit	unit	NOUN
dpc-4769	3	180	of	of	ADP
dpc-4769	3	181	dermatology	dermatology	NOUN
dpc-4769	3	182	,	,	PUNCT
dpc-4769	3	183	department	department	NOUN
dpc-4769	3	184	of	of	ADP
dpc-4769	3	185	surgery	surgery	NOUN
dpc-4769	3	186	and	and	CCONJ
dpc-4769	3	187	translational	translational	ADJ
dpc-4769	3	188	medicine	medicine	NOUN
dpc-4769	3	189	,	,	PUNCT
dpc-4769	3	190	university	university	NOUN
dpc-4769	3	191	of	of	ADP
dpc-4769	3	192	florence	florence	NOUN
dpc-4769	3	193	,	,	PUNCT
dpc-4769	3	194	florence	florence	NOUN
dpc-4769	3	195	,	,	PUNCT
dpc-4769	3	196	italy	italy	PROPN
dpc-4769	3	197	12	12	NUM
dpc-4769	3	198	department	department	NOUN
dpc-4769	3	199	of	of	ADP
dpc-4769	3	200	dermatology	dermatology	NOUN
dpc-4769	3	201	and	and	CCONJ
dpc-4769	3	202	dermosurgery	dermosurgery	NOUN
dpc-4769	3	203	,	,	PUNCT
dpc-4769	3	204	aosg	aosg	VERB
dpc-4769	3	205	san	san	PROPN
dpc-4769	3	206	giuseppe	giuseppe	PROPN
dpc-4769	3	207	moscati	moscati	PROPN
dpc-4769	3	208	,	,	PUNCT
dpc-4769	3	209	83100	83100	NUM
dpc-4769	3	210	avellino	avellino	NOUN
dpc-4769	3	211	,	,	PUNCT
dpc-4769	3	212	italy	italy	PROPN
dpc-4769	3	213	key	key	ADJ
dpc-4769	3	214	words	word	NOUN
dpc-4769	3	215	:	:	PUNCT
dpc-4769	3	216	tildrakizumab	tildrakizumab	NOUN
dpc-4769	3	217	200	200	NUM
dpc-4769	3	218	mg	mg	NOUN
dpc-4769	3	219	,	,	PUNCT
dpc-4769	3	220	psoriasis	psoriasis	NOUN
dpc-4769	3	221	,	,	PUNCT
dpc-4769	3	222	anti	anti	ADJ
dpc-4769	3	223	-	-	ADJ
dpc-4769	3	224	il23	il23	ADJ
dpc-4769	3	225	,	,	PUNCT
dpc-4769	3	226	psoriasis	psoriasis	NOUN
dpc-4769	3	227	treatment	treatment	NOUN
dpc-4769	3	228	,	,	PUNCT
dpc-4769	3	229	obesity	obesity	NOUN
dpc-4769	3	230	,	,	PUNCT
dpc-4769	3	231	dose	dose	NOUN
dpc-4769	3	232	escalation	escalation	NOUN
dpc-4769	3	233	citation	citation	NOUN
dpc-4769	3	234	:	:	PUNCT
dpc-4769	3	235	di	di	NOUN
dpc-4769	3	236	brizzi	brizzi	PROPN
dpc-4769	3	237	ev	ev	PROPN
dpc-4769	3	238	,	,	PUNCT
dpc-4769	3	239	caccavale	caccavale	PROPN
dpc-4769	3	240	s	s	PROPN
dpc-4769	3	241	,	,	PUNCT
dpc-4769	3	242	di	di	X
dpc-4769	3	243	caprio	caprio	PROPN
dpc-4769	3	244	r	r	PROPN
dpc-4769	3	245	,	,	PUNCT
dpc-4769	3	246	et	et	PROPN
dpc-4769	3	247	al	al	PROPN
dpc-4769	3	248	.	.	PUNCT
dpc-4769	4	1	a	a	DET
dpc-4769	4	2	prospective	prospective	ADJ
dpc-4769	4	3	real	real	ADJ
dpc-4769	4	4	-	-	PUNCT
dpc-4769	4	5	life	life	NOUN
dpc-4769	4	6	multicenter	multicenter	NOUN
dpc-4769	4	7	study	study	NOUN
dpc-4769	4	8	of	of	ADP
dpc-4769	4	9	tildrakizumab	tildrakizumab	NOUN
dpc-4769	4	10	200	200	NUM
dpc-4769	4	11	mg	mg	NOUN
dpc-4769	4	12	in	in	ADP
dpc-4769	4	13	patients	patient	NOUN
dpc-4769	4	14	with	with	ADP
dpc-4769	4	15	moderate	moderate	ADJ
dpc-4769	4	16	-	-	PUNCT
dpc-4769	4	17	severe	severe	ADJ
dpc-4769	4	18	psoriasis	psoriasis	NOUN
dpc-4769	4	19	:	:	PUNCT
dpc-4769	4	20	who	who	PRON
dpc-4769	4	21	is	be	AUX
dpc-4769	4	22	the	the	DET
dpc-4769	4	23	ideal	ideal	ADJ
dpc-4769	4	24	patient	patient	NOUN
dpc-4769	4	25	?	?	PUNCT
dpc-4769	5	1	dermatol	dermatol	NOUN
dpc-4769	5	2	pract	pract	PROPN
dpc-4769	5	3	concept	concept	NOUN
dpc-4769	5	4	.	.	PUNCT
dpc-4769	6	1	2024;14(4):e2024284	2024;14(4):e2024284	X
dpc-4769	6	2	.	.	PUNCT
dpc-4769	7	1	doi	doi	PROPN
dpc-4769	7	2	:	:	PUNCT
dpc-4769	7	3	https://doi.org/10.5826/	https://doi.org/10.5826/	PROPN
dpc-4769	7	4	dpc.1404a284	dpc.1404a284	PROPN
dpc-4769	7	5	accepted	accept	VERB
dpc-4769	7	6	:	:	PUNCT
dpc-4769	7	7	september	september	PROPN
dpc-4769	7	8	25	25	NUM
dpc-4769	7	9	,	,	PUNCT
dpc-4769	7	10	2024	2024	NUM
dpc-4769	7	11	;	;	PUNCT
dpc-4769	7	12	published	publish	VERB
dpc-4769	7	13	:	:	PUNCT
dpc-4769	7	14	october	october	PROPN
dpc-4769	7	15	2024	2024	NUM
dpc-4769	8	1	copyright	copyright	NOUN
dpc-4769	8	2	:	:	PUNCT
dpc-4769	8	3	©	©	PROPN
dpc-4769	8	4	2024	2024	NUM
dpc-4769	8	5	di	di	NOUN
dpc-4769	8	6	brizzi	brizzi	NOUN
dpc-4769	8	7	et	et	PROPN
dpc-4769	8	8	al	al	PROPN
dpc-4769	8	9	.	.	PUNCT
dpc-4769	9	1	this	this	PRON
dpc-4769	9	2	is	be	AUX
dpc-4769	9	3	an	an	DET
dpc-4769	9	4	open	open	ADJ
dpc-4769	9	5	-	-	PUNCT
dpc-4769	9	6	access	access	NOUN
dpc-4769	9	7	article	article	NOUN
dpc-4769	9	8	distributed	distribute	VERB
dpc-4769	9	9	under	under	ADP
dpc-4769	9	10	the	the	DET
dpc-4769	9	11	terms	term	NOUN
dpc-4769	9	12	of	of	ADP
dpc-4769	9	13	the	the	DET
dpc-4769	9	14	creative	creative	ADJ
dpc-4769	9	15	commons	common	NOUN
dpc-4769	9	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4769	9	17	license	license	NOUN
dpc-4769	9	18	(	(	PUNCT
dpc-4769	9	19	by	by	ADP
dpc-4769	9	20	-	-	PUNCT
dpc-4769	9	21	nc-4.0	nc-4.0	NOUN
dpc-4769	9	22	)	)	PUNCT
dpc-4769	9	23	,	,	PUNCT
dpc-4769	9	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4769	9	25	,	,	PUNCT
dpc-4769	9	26	which	which	PRON
dpc-4769	9	27	permits	permit	VERB
dpc-4769	9	28	unrestricted	unrestricted	ADJ
dpc-4769	9	29	noncommercial	noncommercial	ADJ
dpc-4769	9	30	use	use	NOUN
dpc-4769	9	31	,	,	PUNCT
dpc-4769	9	32	distribution	distribution	NOUN
dpc-4769	9	33	,	,	PUNCT
dpc-4769	9	34	and	and	CCONJ
dpc-4769	9	35	reproduction	reproduction	NOUN
dpc-4769	9	36	in	in	ADP
dpc-4769	9	37	any	any	DET
dpc-4769	9	38	medium	medium	NOUN
dpc-4769	9	39	,	,	PUNCT
dpc-4769	9	40	provided	provide	VERB
dpc-4769	9	41	the	the	DET
dpc-4769	9	42	original	original	ADJ
dpc-4769	9	43	authors	author	NOUN
dpc-4769	9	44	and	and	CCONJ
dpc-4769	9	45	source	source	NOUN
dpc-4769	9	46	are	be	AUX
dpc-4769	9	47	credited	credit	VERB
dpc-4769	9	48	.	.	PUNCT
dpc-4769	10	1	funding	funding	NOUN
dpc-4769	10	2	:	:	PUNCT
dpc-4769	10	3	none	none	NOUN
dpc-4769	10	4	.	.	PUNCT
dpc-4769	11	1	competing	compete	VERB
dpc-4769	11	2	interests	interest	NOUN
dpc-4769	11	3	:	:	PUNCT
dpc-4769	11	4	none	none	NOUN
dpc-4769	11	5	.	.	PUNCT
dpc-4769	12	1	authorship	authorship	NOUN
dpc-4769	12	2	:	:	PUNCT
dpc-4769	12	3	all	all	DET
dpc-4769	12	4	authors	author	NOUN
dpc-4769	12	5	have	have	AUX
dpc-4769	12	6	contributed	contribute	VERB
dpc-4769	12	7	significantly	significantly	ADV
dpc-4769	12	8	to	to	ADP
dpc-4769	12	9	this	this	DET
dpc-4769	12	10	publication	publication	NOUN
dpc-4769	12	11	.	.	PUNCT
dpc-4769	13	1	corresponding	correspond	VERB
dpc-4769	13	2	author	author	NOUN
dpc-4769	13	3	:	:	PUNCT
dpc-4769	13	4	eugenia	eugenia	PROPN
dpc-4769	13	5	veronica	veronica	PROPN
dpc-4769	13	6	di	di	PROPN
dpc-4769	13	7	brizzi	brizzi	PROPN
dpc-4769	13	8	,	,	PUNCT
dpc-4769	13	9	md	md	PROPN
dpc-4769	13	10	,	,	PUNCT
dpc-4769	13	11	dermatology	dermatology	NOUN
dpc-4769	13	12	unit	unit	NOUN
dpc-4769	13	13	,	,	PUNCT
dpc-4769	13	14	university	university	PROPN
dpc-4769	13	15	of	of	ADP
dpc-4769	13	16	campania	campania	PROPN
dpc-4769	13	17	,	,	PUNCT
dpc-4769	13	18	via	via	ADP
dpc-4769	13	19	pansini	pansini	NOUN
dpc-4769	13	20	5	5	NUM
dpc-4769	13	21	,	,	PUNCT
dpc-4769	13	22	80131	80131	NUM
dpc-4769	13	23	naples	naples	PROPN
dpc-4769	13	24	italy	italy	PROPN
dpc-4769	13	25	.	.	PUNCT
dpc-4769	14	1	e	e	X
dpc-4769	14	2	-	-	NOUN
dpc-4769	14	3	mail	mail	NOUN
dpc-4769	14	4	:	:	PUNCT
dpc-4769	14	5	eugeniaveronica.dibrizzi@gmail.com	eugeniaveronica.dibrizzi@gmail.com	X
dpc-4769	14	6	2	2	NUM
dpc-4769	14	7	original	original	ADJ
dpc-4769	14	8	article	article	NOUN
dpc-4769	14	9	|	|	ADV
dpc-4769	14	10	dermatol	dermatol	ADJ
dpc-4769	14	11	pract	pract	NOUN
dpc-4769	14	12	concept	concept	NOUN
dpc-4769	14	13	.	.	PUNCT
dpc-4769	15	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	15	2	introduction	introduction	NOUN
dpc-4769	15	3	psoriasis	psoriasis	NOUN
dpc-4769	15	4	is	be	AUX
dpc-4769	15	5	a	a	DET
dpc-4769	15	6	chronic	chronic	NOUN
dpc-4769	15	7	,	,	PUNCT
dpc-4769	15	8	recurring	recur	VERB
dpc-4769	15	9	inflammatory	inflammatory	ADJ
dpc-4769	15	10	condition	condition	NOUN
dpc-4769	15	11	of	of	ADP
dpc-4769	15	12	the	the	DET
dpc-4769	15	13	skin	skin	NOUN
dpc-4769	15	14	,	,	PUNCT
dpc-4769	15	15	impacting	impact	VERB
dpc-4769	15	16	around	around	ADP
dpc-4769	15	17	2	2	NUM
dpc-4769	15	18	-	-	SYM
dpc-4769	15	19	4	4	NUM
dpc-4769	15	20	%	%	NOUN
dpc-4769	15	21	of	of	ADP
dpc-4769	15	22	people	people	NOUN
dpc-4769	15	23	worldwide	worldwide	ADV
dpc-4769	15	24	[	[	X
dpc-4769	15	25	1,2	1,2	NUM
dpc-4769	15	26	]	]	PUNCT
dpc-4769	15	27	.	.	PUNCT
dpc-4769	16	1	it	it	PRON
dpc-4769	16	2	typically	typically	ADV
dpc-4769	16	3	manifests	manifest	VERB
dpc-4769	16	4	as	as	ADP
dpc-4769	16	5	sharply	sharply	ADV
dpc-4769	16	6	defined	define	VERB
dpc-4769	16	7	erythematous	erythematous	ADJ
dpc-4769	16	8	topped	top	VERB
dpc-4769	16	9	with	with	ADP
dpc-4769	16	10	white	white	ADJ
dpc-4769	16	11	scales	scale	NOUN
dpc-4769	16	12	.	.	PUNCT
dpc-4769	17	1	these	these	PRON
dpc-4769	17	2	are	be	AUX
dpc-4769	17	3	commonly	commonly	ADV
dpc-4769	17	4	located	locate	VERB
dpc-4769	17	5	on	on	ADP
dpc-4769	17	6	the	the	DET
dpc-4769	17	7	elbows	elbow	NOUN
dpc-4769	17	8	,	,	PUNCT
dpc-4769	17	9	knees	knee	NOUN
dpc-4769	17	10	,	,	PUNCT
dpc-4769	17	11	scalp	scalp	NOUN
dpc-4769	17	12	,	,	PUNCT
dpc-4769	17	13	and	and	CCONJ
dpc-4769	17	14	lower	low	ADJ
dpc-4769	17	15	back	back	ADV
dpc-4769	17	16	,	,	PUNCT
dpc-4769	17	17	known	know	VERB
dpc-4769	17	18	as	as	ADP
dpc-4769	17	19	plaque	plaque	NOUN
dpc-4769	17	20	psoriasis	psoriasis	NOUN
dpc-4769	17	21	.	.	PUNCT
dpc-4769	18	1	nonetheless	nonetheless	ADV
dpc-4769	18	2	,	,	PUNCT
dpc-4769	18	3	psoriasis	psoriasis	NOUN
dpc-4769	18	4	can	can	AUX
dpc-4769	18	5	present	present	VERB
dpc-4769	18	6	in	in	ADP
dpc-4769	18	7	various	various	ADJ
dpc-4769	18	8	forms	form	NOUN
dpc-4769	18	9	,	,	PUNCT
dpc-4769	18	10	including	include	VERB
dpc-4769	18	11	erythrodermic	erythrodermic	ADJ
dpc-4769	18	12	,	,	PUNCT
dpc-4769	18	13	guttate	guttate	ADJ
dpc-4769	18	14	,	,	PUNCT
dpc-4769	18	15	and	and	CCONJ
dpc-4769	18	16	pustular	pustular	ADJ
dpc-4769	18	17	types	type	NOUN
dpc-4769	18	18	[	[	X
dpc-4769	18	19	3	3	NUM
dpc-4769	18	20	]	]	PUNCT
dpc-4769	18	21	.	.	PUNCT
dpc-4769	19	1	it	it	PRON
dpc-4769	19	2	is	be	AUX
dpc-4769	19	3	also	also	ADV
dpc-4769	19	4	linked	link	VERB
dpc-4769	19	5	with	with	ADP
dpc-4769	19	6	several	several	ADJ
dpc-4769	19	7	comorbidities	comorbiditie	NOUN
dpc-4769	19	8	,	,	PUNCT
dpc-4769	19	9	such	such	ADJ
dpc-4769	19	10	as	as	ADP
dpc-4769	19	11	psoriatic	psoriatic	ADJ
dpc-4769	19	12	arthritis	arthritis	NOUN
dpc-4769	19	13	(	(	PUNCT
dpc-4769	19	14	psa	psa	NOUN
dpc-4769	19	15	)	)	PUNCT
dpc-4769	19	16	,	,	PUNCT
dpc-4769	19	17	heart	heart	NOUN
dpc-4769	19	18	disease	disease	NOUN
dpc-4769	19	19	,	,	PUNCT
dpc-4769	19	20	diabetes	diabetes	NOUN
dpc-4769	19	21	,	,	PUNCT
dpc-4769	19	22	chronic	chronic	ADJ
dpc-4769	19	23	inflammatory	inflammatory	ADJ
dpc-4769	19	24	diseases	disease	NOUN
dpc-4769	19	25	of	of	ADP
dpc-4769	19	26	the	the	DET
dpc-4769	19	27	bowel	bowel	NOUN
dpc-4769	19	28	,	,	PUNCT
dpc-4769	19	29	and	and	CCONJ
dpc-4769	19	30	mental	mental	ADJ
dpc-4769	19	31	health	health	NOUN
dpc-4769	19	32	disorders	disorder	NOUN
dpc-4769	19	33	,	,	PUNCT
dpc-4769	19	34	highlighting	highlight	VERB
dpc-4769	19	35	its	its	PRON
dpc-4769	19	36	nature	nature	NOUN
dpc-4769	19	37	as	as	ADP
dpc-4769	19	38	a	a	DET
dpc-4769	19	39	systemic	systemic	ADJ
dpc-4769	19	40	condition	condition	NOUN
dpc-4769	19	41	[	[	X
dpc-4769	19	42	4,5	4,5	NUM
dpc-4769	19	43	]	]	PUNCT
dpc-4769	19	44	.	.	PUNCT
dpc-4769	20	1	psoriasis	psoriasis	NOUN
dpc-4769	20	2	impacts	impact	NOUN
dpc-4769	20	3	not	not	PART
dpc-4769	20	4	only	only	ADV
dpc-4769	20	5	the	the	DET
dpc-4769	20	6	physical	physical	ADJ
dpc-4769	20	7	health	health	NOUN
dpc-4769	20	8	of	of	ADP
dpc-4769	20	9	patients	patient	NOUN
dpc-4769	20	10	but	but	CCONJ
dpc-4769	20	11	also	also	ADV
dpc-4769	20	12	profoundly	profoundly	ADV
dpc-4769	20	13	affects	affect	VERB
dpc-4769	20	14	their	their	PRON
dpc-4769	20	15	psychological	psychological	ADJ
dpc-4769	20	16	well	well	NOUN
dpc-4769	20	17	-	-	PUNCT
dpc-4769	20	18	being	being	NOUN
dpc-4769	20	19	,	,	PUNCT
dpc-4769	20	20	social	social	ADJ
dpc-4769	20	21	interactions	interaction	NOUN
dpc-4769	20	22	,	,	PUNCT
dpc-4769	20	23	and	and	CCONJ
dpc-4769	20	24	overall	overall	ADJ
dpc-4769	20	25	quality	quality	NOUN
dpc-4769	20	26	of	of	ADP
dpc-4769	20	27	life	life	NOUN
dpc-4769	21	1	[	[	X
dpc-4769	21	2	6,7	6,7	NUM
dpc-4769	21	3	]	]	PUNCT
dpc-4769	21	4	.	.	PUNCT
dpc-4769	22	1	the	the	DET
dpc-4769	22	2	management	management	NOUN
dpc-4769	22	3	of	of	ADP
dpc-4769	22	4	moderate	moderate	ADJ
dpc-4769	22	5	-	-	PUNCT
dpc-4769	22	6	to	to	ADP
dpc-4769	22	7	-	-	PUNCT
dpc-4769	22	8	severe	severe	ADJ
dpc-4769	22	9	psoriasis	psoriasis	NOUN
dpc-4769	22	10	,	,	PUNCT
dpc-4769	22	11	a	a	DET
dpc-4769	22	12	chronic	chronic	ADJ
dpc-4769	22	13	systemic	systemic	ADJ
dpc-4769	22	14	inflammatory	inflammatory	ADJ
dpc-4769	22	15	skin	skin	NOUN
dpc-4769	22	16	disease	disease	NOUN
dpc-4769	22	17	,	,	PUNCT
dpc-4769	22	18	represents	represent	VERB
dpc-4769	22	19	a	a	DET
dpc-4769	22	20	significant	significant	ADJ
dpc-4769	22	21	challenge	challenge	NOUN
dpc-4769	22	22	in	in	ADP
dpc-4769	22	23	dermatological	dermatological	ADJ
dpc-4769	22	24	practice	practice	NOUN
dpc-4769	22	25	[	[	X
dpc-4769	22	26	8	8	NUM
dpc-4769	22	27	]	]	PUNCT
dpc-4769	22	28	.	.	PUNCT
dpc-4769	23	1	the	the	DET
dpc-4769	23	2	advent	advent	NOUN
dpc-4769	23	3	of	of	ADP
dpc-4769	23	4	biologic	biologic	NOUN
dpc-4769	23	5	therapies	therapy	NOUN
dpc-4769	23	6	has	have	AUX
dpc-4769	23	7	revolutionized	revolutionize	VERB
dpc-4769	23	8	the	the	DET
dpc-4769	23	9	treatment	treatment	NOUN
dpc-4769	23	10	landscape	landscape	NOUN
dpc-4769	23	11	,	,	PUNCT
dpc-4769	23	12	offering	offer	VERB
dpc-4769	23	13	new	new	ADJ
dpc-4769	23	14	hope	hope	NOUN
dpc-4769	23	15	for	for	ADP
dpc-4769	23	16	patients	patient	NOUN
dpc-4769	23	17	with	with	ADP
dpc-4769	23	18	moderate	moderate	ADJ
dpc-4769	23	19	-	-	PUNCT
dpc-4769	23	20	to	to	ADP
dpc-4769	23	21	-	-	PUNCT
dpc-4769	23	22	severe	severe	ADJ
dpc-4769	23	23	forms	form	NOUN
dpc-4769	23	24	of	of	ADP
dpc-4769	23	25	the	the	DET
dpc-4769	23	26	disease	disease	NOUN
dpc-4769	23	27	.	.	PUNCT
dpc-4769	24	1	among	among	ADP
dpc-4769	24	2	these	these	DET
dpc-4769	24	3	therapies	therapy	NOUN
dpc-4769	24	4	,	,	PUNCT
dpc-4769	24	5	tildrakizumab	tildrakizumab	NOUN
dpc-4769	24	6	,	,	PUNCT
dpc-4769	24	7	a	a	DET
dpc-4769	24	8	humanized	humanize	VERB
dpc-4769	24	9	monoclonal	monoclonal	NOUN
dpc-4769	24	10	antibody	antibody	NOUN
dpc-4769	24	11	designed	design	VERB
dpc-4769	24	12	to	to	PART
dpc-4769	24	13	selectively	selectively	ADV
dpc-4769	24	14	target	target	VERB
dpc-4769	24	15	the	the	DET
dpc-4769	24	16	p19	p19	ADJ
dpc-4769	24	17	subunit	subunit	NOUN
dpc-4769	24	18	of	of	ADP
dpc-4769	24	19	interleukin	interleukin	NOUN
dpc-4769	24	20	23	23	NUM
dpc-4769	24	21	(	(	PUNCT
dpc-4769	24	22	il-23	il-23	NOUN
dpc-4769	24	23	)	)	PUNCT
dpc-4769	24	24	,	,	PUNCT
dpc-4769	24	25	has	have	AUX
dpc-4769	24	26	emerged	emerge	VERB
dpc-4769	24	27	as	as	ADP
dpc-4769	24	28	a	a	DET
dpc-4769	24	29	transformative	transformative	ADJ
dpc-4769	24	30	therapy	therapy	NOUN
dpc-4769	24	31	in	in	ADP
dpc-4769	24	32	the	the	DET
dpc-4769	24	33	treatment	treatment	NOUN
dpc-4769	24	34	landscape	landscape	NOUN
dpc-4769	24	35	of	of	ADP
dpc-4769	24	36	moderate	moderate	ADJ
dpc-4769	24	37	-	-	PUNCT
dpc-4769	24	38	to	to	ADP
dpc-4769	24	39	-	-	PUNCT
dpc-4769	24	40	severe	severe	ADJ
dpc-4769	24	41	plaque	plaque	NOUN
dpc-4769	24	42	psoriasis	psoriasis	NOUN
dpc-4769	24	43	.	.	PUNCT
dpc-4769	25	1	by	by	ADP
dpc-4769	25	2	inhibiting	inhibit	VERB
dpc-4769	25	3	il-23	il-23	NOUN
dpc-4769	25	4	,	,	PUNCT
dpc-4769	25	5	a	a	DET
dpc-4769	25	6	cytokine	cytokine	NOUN
dpc-4769	25	7	critical	critical	ADJ
dpc-4769	25	8	to	to	ADP
dpc-4769	25	9	the	the	DET
dpc-4769	25	10	pathogenesis	pathogenesis	NOUN
dpc-4769	25	11	of	of	ADP
dpc-4769	25	12	psoriasis	psoriasis	NOUN
dpc-4769	25	13	,	,	PUNCT
dpc-4769	25	14	tildrakizumab	tildrakizumab	NOUN
dpc-4769	25	15	effectively	effectively	ADV
dpc-4769	25	16	reduces	reduce	VERB
dpc-4769	25	17	the	the	DET
dpc-4769	25	18	activation	activation	NOUN
dpc-4769	25	19	and	and	CCONJ
dpc-4769	25	20	proliferation	proliferation	NOUN
dpc-4769	25	21	of	of	ADP
dpc-4769	25	22	th17	th17	NOUN
dpc-4769	25	23	cells	cell	NOUN
dpc-4769	25	24	,	,	PUNCT
dpc-4769	25	25	leading	lead	VERB
dpc-4769	25	26	to	to	ADP
dpc-4769	25	27	a	a	DET
dpc-4769	25	28	decrease	decrease	NOUN
dpc-4769	25	29	in	in	ADP
dpc-4769	25	30	the	the	DET
dpc-4769	25	31	production	production	NOUN
dpc-4769	25	32	of	of	ADP
dpc-4769	25	33	pro	pro	ADJ
dpc-4769	25	34	-	-	ADJ
dpc-4769	25	35	inflammatory	inflammatory	ADJ
dpc-4769	25	36	cytokines	cytokine	NOUN
dpc-4769	25	37	and	and	CCONJ
dpc-4769	25	38	subsequent	subsequent	ADJ
dpc-4769	25	39	improvement	improvement	NOUN
dpc-4769	25	40	in	in	ADP
dpc-4769	25	41	cutaneous	cutaneous	ADJ
dpc-4769	25	42	lesions	lesion	NOUN
dpc-4769	25	43	[	[	X
dpc-4769	25	44	9,10	9,10	NUM
dpc-4769	25	45	]	]	X
dpc-4769	25	46	.	.	PUNCT
dpc-4769	26	1	the	the	DET
dpc-4769	26	2	advised	advised	ADJ
dpc-4769	26	3	dosage	dosage	NOUN
dpc-4769	26	4	of	of	ADP
dpc-4769	26	5	tildrakizumab	tildrakizumab	NOUN
dpc-4769	26	6	involves	involve	VERB
dpc-4769	26	7	a	a	DET
dpc-4769	26	8	100	100	NUM
dpc-4769	26	9	-	-	PUNCT
dpc-4769	26	10	mg	mg	NOUN
dpc-4769	26	11	subcutaneous	subcutaneous	ADJ
dpc-4769	26	12	(	(	PUNCT
dpc-4769	26	13	sc	sc	NOUN
dpc-4769	26	14	)	)	PUNCT
dpc-4769	26	15	injection	injection	NOUN
dpc-4769	26	16	at	at	ADP
dpc-4769	26	17	baseline	baseline	NOUN
dpc-4769	26	18	and	and	CCONJ
dpc-4769	26	19	at	at	ADP
dpc-4769	26	20	week	week	NOUN
dpc-4769	26	21	4	4	NUM
dpc-4769	26	22	,	,	PUNCT
dpc-4769	26	23	followed	follow	VERB
dpc-4769	26	24	by	by	ADP
dpc-4769	26	25	administration	administration	NOUN
dpc-4769	26	26	every	every	DET
dpc-4769	26	27	12	12	NUM
dpc-4769	26	28	weeks	week	NOUN
dpc-4769	26	29	.	.	PUNCT
dpc-4769	27	1	nonetheless	nonetheless	ADV
dpc-4769	27	2	,	,	PUNCT
dpc-4769	27	3	within	within	ADP
dpc-4769	27	4	the	the	DET
dpc-4769	27	5	european	european	ADJ
dpc-4769	27	6	context	context	NOUN
dpc-4769	27	7	,	,	PUNCT
dpc-4769	27	8	a	a	DET
dpc-4769	27	9	200	200	NUM
dpc-4769	27	10	mg	mg	NOUN
dpc-4769	27	11	dose	dose	NOUN
dpc-4769	27	12	is	be	AUX
dpc-4769	27	13	recommended	recommend	VERB
dpc-4769	27	14	for	for	ADP
dpc-4769	27	15	individuals	individual	NOUN
dpc-4769	27	16	with	with	ADP
dpc-4769	27	17	specific	specific	ADJ
dpc-4769	27	18	attributes	attribute	NOUN
dpc-4769	27	19	,	,	PUNCT
dpc-4769	27	20	such	such	ADJ
dpc-4769	27	21	as	as	ADP
dpc-4769	27	22	a	a	DET
dpc-4769	27	23	higher	high	ADJ
dpc-4769	27	24	body	body	NOUN
dpc-4769	27	25	weight	weight	NOUN
dpc-4769	27	26	[	[	X
dpc-4769	27	27	11	11	NUM
dpc-4769	27	28	]	]	PUNCT
dpc-4769	27	29	and	and	CCONJ
dpc-4769	27	30	also	also	ADV
dpc-4769	27	31	in	in	ADP
dpc-4769	27	32	patients	patient	NOUN
dpc-4769	27	33	with	with	ADP
dpc-4769	27	34	high	high	ADJ
dpc-4769	27	35	disease	disease	NOUN
dpc-4769	27	36	burden	burden	NOUN
dpc-4769	27	37	.	.	PUNCT
dpc-4769	28	1	clinical	clinical	ADJ
dpc-4769	28	2	trials	trial	NOUN
dpc-4769	28	3	and	and	CCONJ
dpc-4769	28	4	real	real	ADJ
dpc-4769	28	5	-	-	PUNCT
dpc-4769	28	6	world	world	NOUN
dpc-4769	28	7	evidence	evidence	NOUN
dpc-4769	28	8	have	have	AUX
dpc-4769	28	9	underscored	underscore	VERB
dpc-4769	28	10	the	the	DET
dpc-4769	28	11	efficacy	efficacy	NOUN
dpc-4769	28	12	of	of	ADP
dpc-4769	28	13	both	both	DET
dpc-4769	28	14	dosages	dosage	NOUN
dpc-4769	28	15	of	of	ADP
dpc-4769	28	16	tildrakizumab	tildrakizumab	NOUN
dpc-4769	28	17	in	in	ADP
dpc-4769	28	18	achieving	achieve	VERB
dpc-4769	28	19	significant	significant	ADJ
dpc-4769	28	20	clinical	clinical	ADJ
dpc-4769	28	21	improvements	improvement	NOUN
dpc-4769	28	22	[	[	X
dpc-4769	28	23	12,13,14	12,13,14	NUM
dpc-4769	28	24	]	]	PUNCT
dpc-4769	28	25	.	.	PUNCT
dpc-4769	29	1	metrics	metric	NOUN
dpc-4769	29	2	such	such	ADJ
dpc-4769	29	3	as	as	ADP
dpc-4769	29	4	the	the	DET
dpc-4769	29	5	psoriasis	psoriasis	NOUN
dpc-4769	29	6	area	area	NOUN
dpc-4769	29	7	and	and	CCONJ
dpc-4769	29	8	severity	severity	NOUN
dpc-4769	29	9	index	index	NOUN
dpc-4769	29	10	(	(	PUNCT
dpc-4769	29	11	pasi	pasi	NOUN
dpc-4769	29	12	)	)	PUNCT
dpc-4769	29	13	scores	score	NOUN
dpc-4769	29	14	and	and	CCONJ
dpc-4769	29	15	the	the	DET
dpc-4769	29	16	dermatology	dermatology	NOUN
dpc-4769	29	17	life	life	NOUN
dpc-4769	29	18	quality	quality	NOUN
dpc-4769	29	19	index	index	NOUN
dpc-4769	29	20	(	(	PUNCT
dpc-4769	29	21	dlqi	dlqi	PROPN
dpc-4769	29	22	)	)	PUNCT
dpc-4769	29	23	scores	score	NOUN
dpc-4769	29	24	have	have	AUX
dpc-4769	29	25	consistently	consistently	ADV
dpc-4769	29	26	shown	show	VERB
dpc-4769	29	27	substantial	substantial	ADJ
dpc-4769	29	28	improvements	improvement	NOUN
dpc-4769	29	29	,	,	PUNCT
dpc-4769	29	30	indicating	indicate	VERB
dpc-4769	29	31	not	not	PART
dpc-4769	29	32	only	only	ADV
dpc-4769	29	33	a	a	DET
dpc-4769	29	34	reduction	reduction	NOUN
dpc-4769	29	35	in	in	ADP
dpc-4769	29	36	the	the	DET
dpc-4769	29	37	severity	severity	NOUN
dpc-4769	29	38	of	of	ADP
dpc-4769	29	39	skin	skin	NOUN
dpc-4769	29	40	lesions	lesion	NOUN
dpc-4769	29	41	but	but	CCONJ
dpc-4769	29	42	also	also	ADV
dpc-4769	29	43	a	a	DET
dpc-4769	29	44	marked	mark	VERB
dpc-4769	29	45	enhancement	enhancement	NOUN
dpc-4769	29	46	in	in	ADP
dpc-4769	29	47	patients	patient	NOUN
dpc-4769	29	48	’	'	PUNCT
dpc-4769	29	49	quality	quality	NOUN
dpc-4769	29	50	of	of	ADP
dpc-4769	29	51	life	life	NOUN
dpc-4769	29	52	.	.	PUNCT
dpc-4769	30	1	importantly	importantly	ADV
dpc-4769	30	2	,	,	PUNCT
dpc-4769	30	3	both	both	CCONJ
dpc-4769	30	4	the	the	DET
dpc-4769	30	5	100	100	NUM
dpc-4769	30	6	mg	mg	NOUN
dpc-4769	30	7	and	and	CCONJ
dpc-4769	30	8	200	200	NUM
dpc-4769	30	9	mg	mg	ADJ
dpc-4769	30	10	doses	dose	NOUN
dpc-4769	30	11	of	of	ADP
dpc-4769	30	12	tildrakizumab	tildrakizumab	NOUN
dpc-4769	30	13	have	have	AUX
dpc-4769	30	14	demonstrated	demonstrate	VERB
dpc-4769	30	15	a	a	DET
dpc-4769	30	16	favorable	favorable	ADJ
dpc-4769	30	17	safety	safety	NOUN
dpc-4769	30	18	profile	profile	NOUN
dpc-4769	30	19	,	,	PUNCT
dpc-4769	30	20	with	with	ADP
dpc-4769	30	21	adverse	adverse	ADJ
dpc-4769	30	22	events	event	NOUN
dpc-4769	30	23	being	be	AUX
dpc-4769	30	24	infrequent	infrequent	ADJ
dpc-4769	30	25	and	and	CCONJ
dpc-4769	30	26	generally	generally	ADV
dpc-4769	30	27	mild	mild	ADJ
dpc-4769	30	28	to	to	PART
dpc-4769	30	29	moderate	moderate	VERB
dpc-4769	30	30	in	in	ADP
dpc-4769	30	31	nature	nature	NOUN
dpc-4769	30	32	[	[	X
dpc-4769	30	33	12	12	NUM
dpc-4769	30	34	-	-	SYM
dpc-4769	30	35	16	16	NUM
dpc-4769	30	36	]	]	PUNCT
dpc-4769	30	37	.	.	PUNCT
dpc-4769	31	1	objective	objective	NOUN
dpc-4769	31	2	the	the	DET
dpc-4769	31	3	aim	aim	NOUN
dpc-4769	31	4	of	of	ADP
dpc-4769	31	5	the	the	DET
dpc-4769	31	6	study	study	NOUN
dpc-4769	31	7	was	be	AUX
dpc-4769	31	8	to	to	PART
dpc-4769	31	9	define	define	VERB
dpc-4769	31	10	the	the	DET
dpc-4769	31	11	patient	patient	ADJ
dpc-4769	31	12	characteristics	characteristic	NOUN
dpc-4769	31	13	that	that	PRON
dpc-4769	31	14	indicate	indicate	VERB
dpc-4769	31	15	the	the	DET
dpc-4769	31	16	initiation	initiation	NOUN
dpc-4769	31	17	of	of	ADP
dpc-4769	31	18	a	a	DET
dpc-4769	31	19	200	200	NUM
dpc-4769	31	20	mg	mg	ADJ
dpc-4769	31	21	dosage	dosage	NOUN
dpc-4769	31	22	of	of	ADP
dpc-4769	31	23	tildrakizumab	tildrakizumab	NOUN
dpc-4769	31	24	in	in	ADP
dpc-4769	31	25	a	a	DET
dpc-4769	31	26	real	real	ADJ
dpc-4769	31	27	-	-	PUNCT
dpc-4769	31	28	life	life	NOUN
dpc-4769	31	29	setting	setting	NOUN
dpc-4769	31	30	.	.	PUNCT
dpc-4769	32	1	methods	method	NOUN
dpc-4769	32	2	this	this	DET
dpc-4769	32	3	prospective	prospective	ADJ
dpc-4769	32	4	study	study	NOUN
dpc-4769	32	5	collected	collect	VERB
dpc-4769	32	6	data	datum	NOUN
dpc-4769	32	7	on	on	ADP
dpc-4769	32	8	adult	adult	NOUN
dpc-4769	32	9	patients	patient	NOUN
dpc-4769	32	10	affected	affect	VERB
dpc-4769	32	11	by	by	ADP
dpc-4769	32	12	moderate	moderate	ADJ
dpc-4769	32	13	-	-	PUNCT
dpc-4769	32	14	to	to	ADP
dpc-4769	32	15	-	-	PUNCT
dpc-4769	32	16	severe	severe	ADJ
dpc-4769	32	17	plaque	plaque	NOUN
dpc-4769	32	18	psoriasis	psoriasis	NOUN
dpc-4769	32	19	from	from	ADP
dpc-4769	32	20	march	march	PROPN
dpc-4769	32	21	2023	2023	NUM
dpc-4769	32	22	to	to	ADP
dpc-4769	32	23	march	march	PROPN
dpc-4769	32	24	2024	2024	NUM
dpc-4769	32	25	at	at	ADP
dpc-4769	32	26	13	13	NUM
dpc-4769	32	27	italian	italian	ADJ
dpc-4769	32	28	dermatology	dermatology	NOUN
dpc-4769	32	29	units	unit	NOUN
dpc-4769	32	30	with	with	ADP
dpc-4769	32	31	specialized	specialized	ADJ
dpc-4769	32	32	psoriasis	psoriasis	NOUN
dpc-4769	32	33	units	unit	NOUN
dpc-4769	32	34	.	.	PUNCT
dpc-4769	33	1	conducted	conduct	VERB
dpc-4769	33	2	in	in	ADP
dpc-4769	33	3	alignment	alignment	NOUN
dpc-4769	33	4	with	with	ADP
dpc-4769	33	5	the	the	DET
dpc-4769	33	6	helsinki	helsinki	PROPN
dpc-4769	33	7	declaration	declaration	PROPN
dpc-4769	33	8	’s	’s	PART
dpc-4769	33	9	guidelines	guideline	NOUN
dpc-4769	33	10	,	,	PUNCT
dpc-4769	33	11	written	write	VERB
dpc-4769	33	12	informed	informed	ADJ
dpc-4769	33	13	consent	consent	NOUN
dpc-4769	33	14	was	be	AUX
dpc-4769	33	15	secured	secure	VERB
dpc-4769	33	16	from	from	ADP
dpc-4769	33	17	all	all	DET
dpc-4769	33	18	patients	patient	NOUN
dpc-4769	33	19	for	for	ADP
dpc-4769	33	20	the	the	DET
dpc-4769	33	21	utilization	utilization	NOUN
dpc-4769	33	22	of	of	ADP
dpc-4769	33	23	data	datum	NOUN
dpc-4769	33	24	gathered	gather	VERB
dpc-4769	33	25	through	through	ADP
dpc-4769	33	26	regular	regular	ADJ
dpc-4769	33	27	clinical	clinical	ADJ
dpc-4769	33	28	examinations	examination	NOUN
dpc-4769	33	29	inclusion	inclusion	NOUN
dpc-4769	33	30	criteria	criterion	NOUN
dpc-4769	33	31	were	be	AUX
dpc-4769	34	1	age	age	NOUN
dpc-4769	34	2	≥	≥	NUM
dpc-4769	34	3	18	18	NUM
dpc-4769	34	4	years	year	NOUN
dpc-4769	34	5	with	with	ADP
dpc-4769	34	6	a	a	DET
dpc-4769	34	7	diagnosis	diagnosis	NOUN
dpc-4769	34	8	of	of	ADP
dpc-4769	34	9	moderate	moderate	ADJ
dpc-4769	34	10	-	-	PUNCT
dpc-4769	34	11	to	to	ADP
dpc-4769	34	12	-	-	PUNCT
dpc-4769	34	13	severe	severe	ADJ
dpc-4769	34	14	introduction	introduction	NOUN
dpc-4769	34	15	:	:	PUNCT
dpc-4769	34	16	tildrakizumab	tildrakizumab	NOUN
dpc-4769	34	17	,	,	PUNCT
dpc-4769	34	18	a	a	DET
dpc-4769	34	19	humanized	humanize	VERB
dpc-4769	34	20	monoclonal	monoclonal	NOUN
dpc-4769	34	21	antibody	antibody	NOUN
dpc-4769	34	22	targeting	target	VERB
dpc-4769	34	23	the	the	DET
dpc-4769	34	24	p19	p19	ADJ
dpc-4769	34	25	subunit	subunit	NOUN
dpc-4769	34	26	of	of	ADP
dpc-4769	34	27	interleukin	interleukin	NOUN
dpc-4769	34	28	23	23	NUM
dpc-4769	34	29	(	(	PUNCT
dpc-4769	34	30	il-23	il-23	NOUN
dpc-4769	34	31	)	)	PUNCT
dpc-4769	34	32	,	,	PUNCT
dpc-4769	34	33	has	have	AUX
dpc-4769	34	34	shown	show	VERB
dpc-4769	34	35	promise	promise	NOUN
dpc-4769	34	36	in	in	ADP
dpc-4769	34	37	the	the	DET
dpc-4769	34	38	management	management	NOUN
dpc-4769	34	39	of	of	ADP
dpc-4769	34	40	moderate	moderate	ADJ
dpc-4769	34	41	-	-	PUNCT
dpc-4769	34	42	to	to	ADP
dpc-4769	34	43	-	-	PUNCT
dpc-4769	34	44	severe	severe	ADJ
dpc-4769	34	45	plaque	plaque	NOUN
dpc-4769	34	46	psoriasis	psoriasis	NOUN
dpc-4769	34	47	,	,	PUNCT
dpc-4769	34	48	offering	offer	VERB
dpc-4769	34	49	potential	potential	ADJ
dpc-4769	34	50	improvements	improvement	NOUN
dpc-4769	34	51	in	in	ADP
dpc-4769	34	52	clinical	clinical	ADJ
dpc-4769	34	53	outcomes	outcome	NOUN
dpc-4769	34	54	and	and	CCONJ
dpc-4769	34	55	quality	quality	NOUN
dpc-4769	34	56	of	of	ADP
dpc-4769	34	57	life	life	NOUN
dpc-4769	34	58	.	.	PUNCT
dpc-4769	35	1	objectives	objective	NOUN
dpc-4769	35	2	:	:	PUNCT
dpc-4769	35	3	the	the	DET
dpc-4769	35	4	study	study	NOUN
dpc-4769	35	5	aimed	aim	VERB
dpc-4769	35	6	to	to	PART
dpc-4769	35	7	identify	identify	VERB
dpc-4769	35	8	patient	patient	ADJ
dpc-4769	35	9	characteristics	characteristic	NOUN
dpc-4769	35	10	that	that	PRON
dpc-4769	35	11	indicate	indicate	VERB
dpc-4769	35	12	the	the	DET
dpc-4769	35	13	initiation	initiation	NOUN
dpc-4769	35	14	of	of	ADP
dpc-4769	35	15	a	a	DET
dpc-4769	35	16	200	200	NUM
dpc-4769	35	17	mg	mg	ADJ
dpc-4769	35	18	dosage	dosage	NOUN
dpc-4769	35	19	of	of	ADP
dpc-4769	35	20	tildrakizumab	tildrakizumab	NOUN
dpc-4769	35	21	in	in	ADP
dpc-4769	35	22	a	a	DET
dpc-4769	35	23	real	real	ADJ
dpc-4769	35	24	-	-	PUNCT
dpc-4769	35	25	world	world	NOUN
dpc-4769	35	26	setting	setting	NOUN
dpc-4769	35	27	,	,	PUNCT
dpc-4769	35	28	focusing	focus	VERB
dpc-4769	35	29	on	on	ADP
dpc-4769	35	30	factors	factor	NOUN
dpc-4769	35	31	that	that	PRON
dpc-4769	35	32	enhance	enhance	VERB
dpc-4769	35	33	treatment	treatment	NOUN
dpc-4769	35	34	effectiveness	effectiveness	NOUN
dpc-4769	35	35	and	and	CCONJ
dpc-4769	35	36	safety	safety	NOUN
dpc-4769	35	37	.	.	PUNCT
dpc-4769	36	1	methods	method	NOUN
dpc-4769	36	2	:	:	PUNCT
dpc-4769	36	3	this	this	DET
dpc-4769	36	4	prospective	prospective	ADJ
dpc-4769	36	5	study	study	NOUN
dpc-4769	36	6	included	include	VERB
dpc-4769	36	7	54	54	NUM
dpc-4769	36	8	adult	adult	NOUN
dpc-4769	36	9	patients	patient	NOUN
dpc-4769	36	10	with	with	ADP
dpc-4769	36	11	moderate	moderate	ADJ
dpc-4769	36	12	-	-	PUNCT
dpc-4769	36	13	to	to	ADP
dpc-4769	36	14	-	-	PUNCT
dpc-4769	36	15	severe	severe	ADJ
dpc-4769	36	16	plaque	plaque	NOUN
dpc-4769	36	17	psoriasis	psoriasis	NOUN
dpc-4769	36	18	treated	treat	VERB
dpc-4769	36	19	with	with	ADP
dpc-4769	36	20	tildrakizumab	tildrakizumab	NOUN
dpc-4769	36	21	200	200	NUM
dpc-4769	36	22	mg	mg	ADV
dpc-4769	36	23	from	from	ADP
dpc-4769	36	24	march	march	PROPN
dpc-4769	36	25	2023	2023	NUM
dpc-4769	36	26	to	to	ADP
dpc-4769	36	27	march	march	PROPN
dpc-4769	36	28	2024	2024	NUM
dpc-4769	36	29	across	across	ADP
dpc-4769	36	30	13	13	NUM
dpc-4769	36	31	italian	italian	ADJ
dpc-4769	36	32	dermatology	dermatology	NOUN
dpc-4769	36	33	units	unit	NOUN
dpc-4769	36	34	.	.	PUNCT
dpc-4769	37	1	data	datum	NOUN
dpc-4769	37	2	collected	collect	VERB
dpc-4769	37	3	included	include	VERB
dpc-4769	37	4	demographics	demographic	NOUN
dpc-4769	37	5	,	,	PUNCT
dpc-4769	37	6	disease	disease	NOUN
dpc-4769	37	7	duration	duration	NOUN
dpc-4769	37	8	,	,	PUNCT
dpc-4769	37	9	comorbidities	comorbiditie	NOUN
dpc-4769	37	10	,	,	PUNCT
dpc-4769	37	11	and	and	CCONJ
dpc-4769	37	12	previous	previous	ADJ
dpc-4769	37	13	treatments	treatment	NOUN
dpc-4769	37	14	.	.	PUNCT
dpc-4769	38	1	pasi	pasi	PROPN
dpc-4769	38	2	,	,	PUNCT
dpc-4769	38	3	bsa	bsa	PROPN
dpc-4769	38	4	,	,	PUNCT
dpc-4769	38	5	and	and	CCONJ
dpc-4769	38	6	dlqi	dlqi	ADJ
dpc-4769	38	7	scores	score	NOUN
dpc-4769	38	8	were	be	AUX
dpc-4769	38	9	recorded	record	VERB
dpc-4769	38	10	at	at	ADP
dpc-4769	38	11	baseline	baseline	NOUN
dpc-4769	38	12	and	and	CCONJ
dpc-4769	38	13	at	at	ADP
dpc-4769	38	14	weeks	week	NOUN
dpc-4769	38	15	4	4	NUM
dpc-4769	38	16	,	,	PUNCT
dpc-4769	38	17	16	16	NUM
dpc-4769	38	18	,	,	PUNCT
dpc-4769	38	19	and	and	CCONJ
dpc-4769	38	20	28	28	NUM
dpc-4769	38	21	.	.	PUNCT
dpc-4769	39	1	safety	safety	NOUN
dpc-4769	39	2	was	be	AUX
dpc-4769	39	3	assessed	assess	VERB
dpc-4769	39	4	through	through	ADP
dpc-4769	39	5	adverse	adverse	ADJ
dpc-4769	39	6	event	event	NOUN
dpc-4769	39	7	reporting	report	VERB
dpc-4769	39	8	.	.	PUNCT
dpc-4769	40	1	univariate	univariate	ADJ
dpc-4769	40	2	analysis	analysis	NOUN
dpc-4769	40	3	was	be	AUX
dpc-4769	40	4	performed	perform	VERB
dpc-4769	40	5	to	to	PART
dpc-4769	40	6	identify	identify	VERB
dpc-4769	40	7	baseline	baseline	ADJ
dpc-4769	40	8	characteristics	characteristic	NOUN
dpc-4769	40	9	significantly	significantly	ADV
dpc-4769	40	10	associated	associate	VERB
dpc-4769	40	11	with	with	ADP
dpc-4769	40	12	achieving	achieve	VERB
dpc-4769	40	13	pasi	pasi	NOUN
dpc-4769	40	14	≤	≤	ADV
dpc-4769	40	15	5	5	NUM
dpc-4769	40	16	at	at	ADP
dpc-4769	40	17	week	week	NOUN
dpc-4769	40	18	16	16	NUM
dpc-4769	40	19	.	.	PUNCT
dpc-4769	41	1	results	result	NOUN
dpc-4769	41	2	:	:	PUNCT
dpc-4769	41	3	significant	significant	ADJ
dpc-4769	41	4	reductions	reduction	NOUN
dpc-4769	41	5	in	in	ADP
dpc-4769	41	6	pasi	pasi	NOUN
dpc-4769	41	7	scores	score	NOUN
dpc-4769	41	8	were	be	AUX
dpc-4769	41	9	observed	observe	VERB
dpc-4769	41	10	at	at	ADP
dpc-4769	41	11	week	week	NOUN
dpc-4769	41	12	4	4	NUM
dpc-4769	41	13	(	(	PUNCT
dpc-4769	41	14	9	9	NUM
dpc-4769	41	15	±	±	NUM
dpc-4769	41	16	6.9	6.9	NUM
dpc-4769	41	17	,	,	PUNCT
dpc-4769	41	18	p	p	X
dpc-4769	41	19	<	<	X
dpc-4769	41	20	0.001	0.001	NUM
dpc-4769	41	21	)	)	PUNCT
dpc-4769	41	22	,	,	PUNCT
dpc-4769	41	23	with	with	ADP
dpc-4769	41	24	further	further	ADJ
dpc-4769	41	25	improvements	improvement	NOUN
dpc-4769	41	26	at	at	ADP
dpc-4769	41	27	weeks	week	NOUN
dpc-4769	41	28	16	16	NUM
dpc-4769	41	29	(	(	PUNCT
dpc-4769	41	30	3.9	3.9	NUM
dpc-4769	41	31	±	±	NUM
dpc-4769	41	32	4.2	4.2	NUM
dpc-4769	41	33	,	,	PUNCT
dpc-4769	41	34	p	p	X
dpc-4769	41	35	<	<	X
dpc-4769	41	36	0.001	0.001	NUM
dpc-4769	41	37	)	)	PUNCT
dpc-4769	41	38	and	and	CCONJ
dpc-4769	41	39	28	28	NUM
dpc-4769	41	40	(	(	PUNCT
dpc-4769	41	41	2.9	2.9	NUM
dpc-4769	41	42	±	±	NUM
dpc-4769	41	43	4.4	4.4	NUM
dpc-4769	41	44	,	,	PUNCT
dpc-4769	41	45	p	p	X
dpc-4769	41	46	<	<	X
dpc-4769	41	47	0.001	0.001	NUM
dpc-4769	41	48	)	)	PUNCT
dpc-4769	41	49	.	.	PUNCT
dpc-4769	42	1	univariate	univariate	ADJ
dpc-4769	42	2	analysis	analysis	NOUN
dpc-4769	42	3	showed	show	VERB
dpc-4769	42	4	that	that	SCONJ
dpc-4769	42	5	obese	obese	ADJ
dpc-4769	42	6	patients	patient	NOUN
dpc-4769	42	7	(	(	PUNCT
dpc-4769	42	8	bmi	bmi	X
dpc-4769	42	9	>	>	X
dpc-4769	42	10	30	30	NUM
dpc-4769	42	11	)	)	PUNCT
dpc-4769	42	12	had	have	VERB
dpc-4769	42	13	higher	high	ADJ
dpc-4769	42	14	odds	odd	NOUN
dpc-4769	42	15	(	(	PUNCT
dpc-4769	42	16	or	or	CCONJ
dpc-4769	42	17	=	=	SYM
dpc-4769	42	18	4.333	4.333	NUM
dpc-4769	42	19	,	,	PUNCT
dpc-4769	42	20	p	p	X
dpc-4769	42	21	<	<	X
dpc-4769	42	22	0.05	0.05	NUM
dpc-4769	42	23	)	)	PUNCT
dpc-4769	42	24	of	of	ADP
dpc-4769	42	25	achieving	achieve	VERB
dpc-4769	42	26	pasi	pasi	NOUN
dpc-4769	42	27	≤	≤	ADV
dpc-4769	42	28	5	5	NUM
dpc-4769	42	29	.	.	PUNCT
dpc-4769	42	30	longer	long	ADJ
dpc-4769	42	31	disease	disease	VERB
dpc-4769	42	32	duration	duration	NOUN
dpc-4769	42	33	and	and	CCONJ
dpc-4769	42	34	starting	start	VERB
dpc-4769	42	35	with	with	ADP
dpc-4769	42	36	a	a	DET
dpc-4769	42	37	100	100	NUM
dpc-4769	42	38	mg	mg	NOUN
dpc-4769	42	39	dosage	dosage	NOUN
dpc-4769	42	40	also	also	ADV
dpc-4769	42	41	correlated	correlate	VERB
dpc-4769	42	42	with	with	ADP
dpc-4769	42	43	better	well	ADJ
dpc-4769	42	44	outcomes	outcome	NOUN
dpc-4769	42	45	.	.	PUNCT
dpc-4769	43	1	the	the	DET
dpc-4769	43	2	safety	safety	NOUN
dpc-4769	43	3	profile	profile	NOUN
dpc-4769	43	4	was	be	AUX
dpc-4769	43	5	favorable	favorable	ADJ
dpc-4769	43	6	,	,	PUNCT
dpc-4769	43	7	with	with	ADP
dpc-4769	43	8	minimal	minimal	ADJ
dpc-4769	43	9	adverse	adverse	ADJ
dpc-4769	43	10	events	event	NOUN
dpc-4769	43	11	reported	report	VERB
dpc-4769	43	12	.	.	PUNCT
dpc-4769	44	1	conclusions	conclusion	NOUN
dpc-4769	44	2	:	:	PUNCT
dpc-4769	44	3	tildrakizumab	tildrakizumab	NOUN
dpc-4769	44	4	200	200	NUM
dpc-4769	44	5	mg	mg	NOUN
dpc-4769	44	6	is	be	AUX
dpc-4769	44	7	effective	effective	ADJ
dpc-4769	44	8	and	and	CCONJ
dpc-4769	44	9	safe	safe	ADJ
dpc-4769	44	10	for	for	ADP
dpc-4769	44	11	moderate	moderate	ADJ
dpc-4769	44	12	-	-	PUNCT
dpc-4769	44	13	to	to	ADP
dpc-4769	44	14	-	-	PUNCT
dpc-4769	44	15	severe	severe	ADJ
dpc-4769	44	16	psoriasis	psoriasis	NOUN
dpc-4769	44	17	,	,	PUNCT
dpc-4769	44	18	particularly	particularly	ADV
dpc-4769	44	19	in	in	ADP
dpc-4769	44	20	obese	obese	ADJ
dpc-4769	44	21	patients	patient	NOUN
dpc-4769	44	22	.	.	PUNCT
dpc-4769	45	1	these	these	DET
dpc-4769	45	2	findings	finding	NOUN
dpc-4769	45	3	support	support	VERB
dpc-4769	45	4	its	its	PRON
dpc-4769	45	5	use	use	NOUN
dpc-4769	45	6	as	as	ADP
dpc-4769	45	7	a	a	DET
dpc-4769	45	8	long	long	ADJ
dpc-4769	45	9	-	-	PUNCT
dpc-4769	45	10	term	term	NOUN
dpc-4769	45	11	treatment	treatment	NOUN
dpc-4769	45	12	option	option	NOUN
dpc-4769	45	13	.	.	PUNCT
dpc-4769	46	1	abstract	abstract	ADJ
dpc-4769	46	2	original	original	ADJ
dpc-4769	46	3	article	article	NOUN
dpc-4769	46	4	|	|	ADV
dpc-4769	46	5	dermatol	dermatol	ADJ
dpc-4769	46	6	pract	pract	NOUN
dpc-4769	46	7	concept	concept	NOUN
dpc-4769	46	8	.	.	PUNCT
dpc-4769	47	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	47	2	3	3	NUM
dpc-4769	47	3	plaque	plaque	NOUN
dpc-4769	47	4	psoriasis	psoriasis	NOUN
dpc-4769	47	5	and	and	CCONJ
dpc-4769	47	6	treatment	treatment	NOUN
dpc-4769	47	7	with	with	ADP
dpc-4769	47	8	tildrakizumab	tildrakizumab	NOUN
dpc-4769	47	9	200	200	NUM
dpc-4769	47	10	mg	mg	NOUN
dpc-4769	47	11	.	.	PUNCT
dpc-4769	48	1	exclusion	exclusion	NOUN
dpc-4769	48	2	criteria	criterion	NOUN
dpc-4769	48	3	were	be	AUX
dpc-4769	48	4	malignancy	malignancy	NOUN
dpc-4769	48	5	or	or	CCONJ
dpc-4769	48	6	history	history	NOUN
dpc-4769	48	7	of	of	ADP
dpc-4769	48	8	malignancy	malignancy	NOUN
dpc-4769	48	9	in	in	ADP
dpc-4769	48	10	the	the	DET
dpc-4769	48	11	last	last	ADJ
dpc-4769	48	12	five	five	NUM
dpc-4769	48	13	years	year	NOUN
dpc-4769	48	14	.	.	PUNCT
dpc-4769	49	1	each	each	DET
dpc-4769	49	2	participating	participate	VERB
dpc-4769	49	3	center	center	NOUN
dpc-4769	49	4	was	be	AUX
dpc-4769	49	5	responsible	responsible	ADJ
dpc-4769	49	6	for	for	ADP
dpc-4769	49	7	collecting	collect	VERB
dpc-4769	49	8	data	datum	NOUN
dpc-4769	49	9	,	,	PUNCT
dpc-4769	49	10	including	include	VERB
dpc-4769	49	11	demographic	demographic	ADJ
dpc-4769	49	12	information	information	NOUN
dpc-4769	49	13	(	(	PUNCT
dpc-4769	49	14	e.g.	e.g.	ADV
dpc-4769	49	15	,	,	PUNCT
dpc-4769	49	16	age	age	NOUN
dpc-4769	49	17	,	,	PUNCT
dpc-4769	49	18	sex	sex	NOUN
dpc-4769	49	19	,	,	PUNCT
dpc-4769	49	20	height	height	NOUN
dpc-4769	49	21	,	,	PUNCT
dpc-4769	49	22	weight	weight	NOUN
dpc-4769	49	23	,	,	PUNCT
dpc-4769	49	24	and	and	CCONJ
dpc-4769	49	25	body	body	NOUN
dpc-4769	49	26	mass	mass	NOUN
dpc-4769	49	27	index	index	NOUN
dpc-4769	49	28	[	[	X
dpc-4769	49	29	bmi	bmi	X
dpc-4769	49	30	]	]	X
dpc-4769	49	31	)	)	PUNCT
dpc-4769	49	32	,	,	PUNCT
dpc-4769	49	33	disease	disease	NOUN
dpc-4769	49	34	duration	duration	NOUN
dpc-4769	49	35	(	(	PUNCT
dpc-4769	49	36	defined	define	VERB
dpc-4769	49	37	as	as	ADP
dpc-4769	49	38	the	the	DET
dpc-4769	49	39	time	time	NOUN
dpc-4769	49	40	from	from	ADP
dpc-4769	49	41	diagnosis	diagnosis	NOUN
dpc-4769	49	42	to	to	ADP
dpc-4769	49	43	the	the	DET
dpc-4769	49	44	start	start	NOUN
dpc-4769	49	45	of	of	ADP
dpc-4769	49	46	tildrakizumab	tildrakizumab	NOUN
dpc-4769	49	47	treatment	treatment	NOUN
dpc-4769	49	48	)	)	PUNCT
dpc-4769	49	49	,	,	PUNCT
dpc-4769	49	50	comorbidities	comorbiditie	NOUN
dpc-4769	49	51	,	,	PUNCT
dpc-4769	49	52	and	and	CCONJ
dpc-4769	49	53	previous	previous	ADJ
dpc-4769	49	54	systemic	systemic	NOUN
dpc-4769	49	55	,	,	PUNCT
dpc-4769	49	56	including	include	VERB
dpc-4769	49	57	biological	biological	ADJ
dpc-4769	49	58	,	,	PUNCT
dpc-4769	49	59	therapies	therapy	NOUN
dpc-4769	49	60	.	.	PUNCT
dpc-4769	50	1	to	to	PART
dpc-4769	50	2	ensure	ensure	VERB
dpc-4769	50	3	patient	patient	ADJ
dpc-4769	50	4	confidentiality	confidentiality	NOUN
dpc-4769	50	5	and	and	CCONJ
dpc-4769	50	6	to	to	PART
dpc-4769	50	7	comply	comply	VERB
dpc-4769	50	8	with	with	ADP
dpc-4769	50	9	data	datum	NOUN
dpc-4769	50	10	protection	protection	NOUN
dpc-4769	50	11	regulations	regulation	NOUN
dpc-4769	50	12	,	,	PUNCT
dpc-4769	50	13	all	all	DET
dpc-4769	50	14	patient	patient	ADJ
dpc-4769	50	15	data	datum	NOUN
dpc-4769	50	16	were	be	AUX
dpc-4769	50	17	anonymized	anonymize	VERB
dpc-4769	50	18	at	at	ADP
dpc-4769	50	19	the	the	DET
dpc-4769	50	20	point	point	NOUN
dpc-4769	50	21	of	of	ADP
dpc-4769	50	22	collection	collection	NOUN
dpc-4769	50	23	.	.	PUNCT
dpc-4769	51	1	once	once	ADV
dpc-4769	51	2	anonymized	anonymize	VERB
dpc-4769	51	3	,	,	PUNCT
dpc-4769	51	4	the	the	DET
dpc-4769	51	5	data	datum	NOUN
dpc-4769	51	6	were	be	AUX
dpc-4769	51	7	securely	securely	ADV
dpc-4769	51	8	transmitted	transmit	VERB
dpc-4769	51	9	to	to	ADP
dpc-4769	51	10	the	the	DET
dpc-4769	51	11	coordinating	coordinating	NOUN
dpc-4769	51	12	center	center	NOUN
dpc-4769	51	13	,	,	PUNCT
dpc-4769	51	14	where	where	SCONJ
dpc-4769	51	15	they	they	PRON
dpc-4769	51	16	were	be	AUX
dpc-4769	51	17	aggregated	aggregate	VERB
dpc-4769	51	18	and	and	CCONJ
dpc-4769	51	19	analyzed	analyze	VERB
dpc-4769	51	20	.	.	PUNCT
dpc-4769	52	1	this	this	DET
dpc-4769	52	2	centralized	centralized	ADJ
dpc-4769	52	3	approach	approach	NOUN
dpc-4769	52	4	facilitated	facilitate	VERB
dpc-4769	52	5	a	a	DET
dpc-4769	52	6	comprehensive	comprehensive	ADJ
dpc-4769	52	7	analysis	analysis	NOUN
dpc-4769	52	8	of	of	ADP
dpc-4769	52	9	treatment	treatment	NOUN
dpc-4769	52	10	outcomes	outcome	NOUN
dpc-4769	52	11	across	across	ADP
dpc-4769	52	12	the	the	DET
dpc-4769	52	13	diverse	diverse	ADJ
dpc-4769	52	14	patient	patient	ADJ
dpc-4769	52	15	population	population	NOUN
dpc-4769	52	16	involved	involve	VERB
dpc-4769	52	17	in	in	ADP
dpc-4769	52	18	the	the	DET
dpc-4769	52	19	study	study	NOUN
dpc-4769	52	20	.	.	PUNCT
dpc-4769	53	1	the	the	DET
dpc-4769	53	2	study	study	NOUN
dpc-4769	53	3	duration	duration	NOUN
dpc-4769	53	4	was	be	AUX
dpc-4769	53	5	designed	design	VERB
dpc-4769	53	6	to	to	PART
dpc-4769	53	7	cover	cover	VERB
dpc-4769	53	8	several	several	ADJ
dpc-4769	53	9	observation	observation	NOUN
dpc-4769	53	10	periods	period	NOUN
dpc-4769	53	11	:	:	PUNCT
dpc-4769	53	12	baseline	baseline	NOUN
dpc-4769	53	13	,	,	PUNCT
dpc-4769	53	14	week	week	NOUN
dpc-4769	53	15	4	4	NUM
dpc-4769	53	16	,	,	PUNCT
dpc-4769	53	17	week	week	NOUN
dpc-4769	53	18	16	16	NUM
dpc-4769	53	19	,	,	PUNCT
dpc-4769	53	20	and	and	CCONJ
dpc-4769	53	21	week	week	NOUN
dpc-4769	53	22	28	28	NUM
dpc-4769	53	23	.	.	PUNCT
dpc-4769	54	1	these	these	DET
dpc-4769	54	2	intervals	interval	NOUN
dpc-4769	54	3	were	be	AUX
dpc-4769	54	4	chosen	choose	VERB
dpc-4769	54	5	to	to	PART
dpc-4769	54	6	effectively	effectively	ADV
dpc-4769	54	7	monitor	monitor	VERB
dpc-4769	54	8	the	the	DET
dpc-4769	54	9	progression	progression	NOUN
dpc-4769	54	10	and	and	CCONJ
dpc-4769	54	11	response	response	NOUN
dpc-4769	54	12	to	to	PART
dpc-4769	54	13	tildrakizumab	tildrakizumab	VERB
dpc-4769	54	14	treatment	treatment	NOUN
dpc-4769	54	15	over	over	ADP
dpc-4769	54	16	time	time	NOUN
dpc-4769	54	17	.	.	PUNCT
dpc-4769	55	1	the	the	DET
dpc-4769	55	2	pasi	pasi	NOUN
dpc-4769	55	3	and	and	CCONJ
dpc-4769	55	4	body	body	NOUN
dpc-4769	55	5	surface	surface	NOUN
dpc-4769	55	6	area	area	NOUN
dpc-4769	55	7	(	(	PUNCT
dpc-4769	55	8	bsa	bsa	PROPN
dpc-4769	55	9	)	)	PUNCT
dpc-4769	55	10	scores	score	NOUN
dpc-4769	55	11	at	at	ADP
dpc-4769	55	12	each	each	DET
dpc-4769	55	13	visit	visit	NOUN
dpc-4769	55	14	(	(	PUNCT
dpc-4769	55	15	baseline	baseline	NOUN
dpc-4769	55	16	,	,	PUNCT
dpc-4769	55	17	weeks	week	NOUN
dpc-4769	55	18	4	4	NUM
dpc-4769	55	19	,	,	PUNCT
dpc-4769	55	20	16	16	NUM
dpc-4769	55	21	,	,	PUNCT
dpc-4769	55	22	and	and	CCONJ
dpc-4769	55	23	28	28	NUM
dpc-4769	55	24	)	)	PUNCT
dpc-4769	55	25	were	be	AUX
dpc-4769	55	26	collected	collect	VERB
dpc-4769	55	27	from	from	ADP
dpc-4769	55	28	the	the	DET
dpc-4769	55	29	electronic	electronic	ADJ
dpc-4769	55	30	medical	medical	ADJ
dpc-4769	55	31	records	record	NOUN
dpc-4769	55	32	.	.	PUNCT
dpc-4769	56	1	the	the	DET
dpc-4769	56	2	impact	impact	NOUN
dpc-4769	56	3	on	on	ADP
dpc-4769	56	4	patients	patient	NOUN
dpc-4769	56	5	’	'	PUNCT
dpc-4769	56	6	quality	quality	NOUN
dpc-4769	56	7	of	of	ADP
dpc-4769	56	8	life	life	NOUN
dpc-4769	56	9	(	(	PUNCT
dpc-4769	56	10	qol	qol	NOUN
dpc-4769	56	11	)	)	PUNCT
dpc-4769	56	12	was	be	AUX
dpc-4769	56	13	assessed	assess	VERB
dpc-4769	56	14	through	through	ADP
dpc-4769	56	15	dlqi	dlqi	NOUN
dpc-4769	56	16	at	at	ADP
dpc-4769	56	17	each	each	DET
dpc-4769	56	18	visit	visit	NOUN
dpc-4769	56	19	(	(	PUNCT
dpc-4769	56	20	baseline	baseline	NOUN
dpc-4769	56	21	,	,	PUNCT
dpc-4769	56	22	weeks	week	NOUN
dpc-4769	56	23	4,16	4,16	NUM
dpc-4769	56	24	,	,	PUNCT
dpc-4769	56	25	and	and	CCONJ
dpc-4769	56	26	28	28	NUM
dpc-4769	56	27	)	)	PUNCT
dpc-4769	56	28	.	.	PUNCT
dpc-4769	57	1	safety	safety	NOUN
dpc-4769	57	2	was	be	AUX
dpc-4769	57	3	assessed	assess	VERB
dpc-4769	57	4	based	base	VERB
dpc-4769	57	5	on	on	ADP
dpc-4769	57	6	reported	report	VERB
dpc-4769	57	7	adverse	adverse	ADJ
dpc-4769	57	8	events	event	NOUN
dpc-4769	57	9	(	(	PUNCT
dpc-4769	57	10	aes	aes	NOUN
dpc-4769	57	11	)	)	PUNCT
dpc-4769	57	12	,	,	PUNCT
dpc-4769	57	13	encompassing	encompass	VERB
dpc-4769	57	14	serious	serious	ADJ
dpc-4769	57	15	aes	aes	PROPN
dpc-4769	57	16	,	,	PUNCT
dpc-4769	57	17	aes	aes	PROPN
dpc-4769	57	18	leading	lead	VERB
dpc-4769	57	19	to	to	ADP
dpc-4769	57	20	the	the	DET
dpc-4769	57	21	cessation	cessation	NOUN
dpc-4769	57	22	of	of	ADP
dpc-4769	57	23	the	the	DET
dpc-4769	57	24	study	study	NOUN
dpc-4769	57	25	drug	drug	NOUN
dpc-4769	57	26	,	,	PUNCT
dpc-4769	57	27	and	and	CCONJ
dpc-4769	57	28	aes	aes	NOUN
dpc-4769	57	29	necessitating	necessitate	VERB
dpc-4769	57	30	changes	change	NOUN
dpc-4769	57	31	in	in	ADP
dpc-4769	57	32	dosage	dosage	NOUN
dpc-4769	57	33	,	,	PUNCT
dpc-4769	57	34	as	as	ADV
dpc-4769	57	35	well	well	ADV
dpc-4769	57	36	as	as	ADP
dpc-4769	57	37	on	on	ADP
dpc-4769	57	38	laboratory	laboratory	NOUN
dpc-4769	57	39	findings	finding	NOUN
dpc-4769	57	40	(	(	PUNCT
dpc-4769	57	41	hematology	hematology	NOUN
dpc-4769	57	42	,	,	PUNCT
dpc-4769	57	43	clinical	clinical	ADJ
dpc-4769	57	44	chemistry	chemistry	NOUN
dpc-4769	57	45	,	,	PUNCT
dpc-4769	57	46	and	and	CCONJ
dpc-4769	57	47	urinalysis	urinalysis	NOUN
dpc-4769	57	48	)	)	PUNCT
dpc-4769	57	49	and	and	CCONJ
dpc-4769	57	50	outcomes	outcome	NOUN
dpc-4769	57	51	from	from	ADP
dpc-4769	57	52	physical	physical	ADJ
dpc-4769	57	53	examinations	examination	NOUN
dpc-4769	57	54	.	.	PUNCT
dpc-4769	58	1	serious	serious	ADJ
dpc-4769	58	2	adverse	adverse	ADJ
dpc-4769	58	3	events	event	NOUN
dpc-4769	58	4	were	be	AUX
dpc-4769	58	5	categorized	categorize	VERB
dpc-4769	58	6	as	as	ADP
dpc-4769	58	7	aes	aes	PROPN
dpc-4769	58	8	that	that	PRON
dpc-4769	58	9	led	lead	VERB
dpc-4769	58	10	to	to	ADP
dpc-4769	58	11	death	death	NOUN
dpc-4769	58	12	,	,	PUNCT
dpc-4769	58	13	required	require	VERB
dpc-4769	58	14	hospital	hospital	NOUN
dpc-4769	58	15	admission	admission	NOUN
dpc-4769	58	16	,	,	PUNCT
dpc-4769	58	17	or	or	CCONJ
dpc-4769	58	18	extended	extend	VERB
dpc-4769	58	19	a	a	DET
dpc-4769	58	20	hospital	hospital	NOUN
dpc-4769	58	21	stay	stay	NOUN
dpc-4769	58	22	.	.	PUNCT
dpc-4769	59	1	the	the	DET
dpc-4769	59	2	recording	recording	NOUN
dpc-4769	59	3	of	of	ADP
dpc-4769	59	4	aes	aes	PROPN
dpc-4769	59	5	occurred	occur	VERB
dpc-4769	59	6	at	at	ADP
dpc-4769	59	7	weeks	week	NOUN
dpc-4769	59	8	4	4	NUM
dpc-4769	59	9	,	,	PUNCT
dpc-4769	59	10	16	16	NUM
dpc-4769	59	11	,	,	PUNCT
dpc-4769	59	12	and	and	CCONJ
dpc-4769	59	13	28	28	NUM
dpc-4769	59	14	.	.	PUNCT
dpc-4769	60	1	statistical	statistical	ADJ
dpc-4769	60	2	analysis	analysis	NOUN
dpc-4769	60	3	demographic	demographic	ADJ
dpc-4769	60	4	information	information	NOUN
dpc-4769	60	5	,	,	PUNCT
dpc-4769	60	6	clinical	clinical	ADJ
dpc-4769	60	7	characteristics	characteristic	NOUN
dpc-4769	60	8	,	,	PUNCT
dpc-4769	60	9	and	and	CCONJ
dpc-4769	60	10	primary	primary	ADJ
dpc-4769	60	11	outcome	outcome	NOUN
dpc-4769	60	12	metrics	metric	NOUN
dpc-4769	60	13	at	at	ADP
dpc-4769	60	14	the	the	DET
dpc-4769	60	15	initial	initial	ADJ
dpc-4769	60	16	visit	visit	NOUN
dpc-4769	60	17	were	be	AUX
dpc-4769	60	18	compiled	compile	VERB
dpc-4769	60	19	using	use	VERB
dpc-4769	60	20	descriptive	descriptive	ADJ
dpc-4769	60	21	statistical	statistical	ADJ
dpc-4769	60	22	methods	method	NOUN
dpc-4769	60	23	.	.	PUNCT
dpc-4769	61	1	this	this	DET
dpc-4769	61	2	descriptive	descriptive	ADJ
dpc-4769	61	3	information	information	NOUN
dpc-4769	61	4	utilized	utilize	VERB
dpc-4769	61	5	frequencies	frequency	NOUN
dpc-4769	61	6	and	and	CCONJ
dpc-4769	61	7	percentages	percentage	NOUN
dpc-4769	61	8	for	for	ADP
dpc-4769	61	9	categorical	categorical	ADJ
dpc-4769	61	10	data	datum	NOUN
dpc-4769	61	11	and	and	CCONJ
dpc-4769	61	12	means	mean	NOUN
dpc-4769	61	13	plus	plus	CCONJ
dpc-4769	61	14	standard	standard	ADJ
dpc-4769	61	15	deviations	deviation	NOUN
dpc-4769	61	16	for	for	ADP
dpc-4769	61	17	continuous	continuous	ADJ
dpc-4769	61	18	data	datum	NOUN
dpc-4769	61	19	.	.	PUNCT
dpc-4769	62	1	for	for	ADP
dpc-4769	62	2	continuous	continuous	ADJ
dpc-4769	62	3	variables	variable	NOUN
dpc-4769	62	4	across	across	ADP
dpc-4769	62	5	various	various	ADJ
dpc-4769	62	6	scheduled	schedule	VERB
dpc-4769	62	7	appointments	appointment	NOUN
dpc-4769	62	8	,	,	PUNCT
dpc-4769	62	9	the	the	DET
dpc-4769	62	10	wilcoxon	wilcoxon	ADJ
dpc-4769	62	11	matched	match	VERB
dpc-4769	62	12	-	-	PUNCT
dpc-4769	62	13	pairs	pair	NOUN
dpc-4769	62	14	signed	sign	VERB
dpc-4769	62	15	-	-	PUNCT
dpc-4769	62	16	rank	rank	NOUN
dpc-4769	62	17	test	test	NOUN
dpc-4769	62	18	was	be	AUX
dpc-4769	62	19	applied	apply	VERB
dpc-4769	62	20	.	.	PUNCT
dpc-4769	63	1	to	to	PART
dpc-4769	63	2	explore	explore	VERB
dpc-4769	63	3	the	the	DET
dpc-4769	63	4	correlation	correlation	NOUN
dpc-4769	63	5	among	among	ADP
dpc-4769	63	6	variables	variable	NOUN
dpc-4769	63	7	such	such	ADJ
dpc-4769	63	8	as	as	ADP
dpc-4769	63	9	age	age	NOUN
dpc-4769	63	10	,	,	PUNCT
dpc-4769	63	11	obesity	obesity	NOUN
dpc-4769	63	12	,	,	PUNCT
dpc-4769	63	13	sex	sex	NOUN
dpc-4769	63	14	,	,	PUNCT
dpc-4769	63	15	pasi	pasi	NOUN
dpc-4769	63	16	,	,	PUNCT
dpc-4769	63	17	prior	prior	ADJ
dpc-4769	63	18	biologic	biologic	NOUN
dpc-4769	63	19	treatment	treatment	NOUN
dpc-4769	63	20	use	use	NOUN
dpc-4769	63	21	,	,	PUNCT
dpc-4769	63	22	the	the	DET
dpc-4769	63	23	presence	presence	NOUN
dpc-4769	63	24	of	of	ADP
dpc-4769	63	25	comorbidities	comorbiditie	NOUN
dpc-4769	63	26	,	,	PUNCT
dpc-4769	63	27	and	and	CCONJ
dpc-4769	63	28	the	the	DET
dpc-4769	63	29	effectiveness	effectiveness	NOUN
dpc-4769	63	30	of	of	ADP
dpc-4769	63	31	tildrakizumab	tildrakizumab	NOUN
dpc-4769	63	32	200	200	NUM
dpc-4769	63	33	mg	mg	NOUN
dpc-4769	63	34	as	as	SCONJ
dpc-4769	63	35	measured	measure	VERB
dpc-4769	63	36	by	by	ADP
dpc-4769	63	37	pasi	pasi	PROPN
dpc-4769	63	38	,	,	PUNCT
dpc-4769	63	39	bsa	bsa	PROPN
dpc-4769	63	40	,	,	PUNCT
dpc-4769	63	41	and	and	CCONJ
dpc-4769	63	42	dlqi	dlqi	ADJ
dpc-4769	63	43	scores	score	NOUN
dpc-4769	63	44	,	,	PUNCT
dpc-4769	63	45	univariate	univariate	ADJ
dpc-4769	63	46	regression	regression	NOUN
dpc-4769	63	47	analysis	analysis	NOUN
dpc-4769	63	48	was	be	AUX
dpc-4769	63	49	employed	employ	VERB
dpc-4769	63	50	.	.	PUNCT
dpc-4769	64	1	a	a	DET
dpc-4769	64	2	p	p	NOUN
dpc-4769	64	3	-	-	PUNCT
dpc-4769	64	4	value	value	NOUN
dpc-4769	64	5	of	of	ADP
dpc-4769	64	6	less	less	ADJ
dpc-4769	64	7	than	than	ADP
dpc-4769	64	8	0.05	0.05	NUM
dpc-4769	64	9	was	be	AUX
dpc-4769	64	10	deemed	deem	VERB
dpc-4769	64	11	to	to	PART
dpc-4769	64	12	indicate	indicate	VERB
dpc-4769	64	13	significant	significant	ADJ
dpc-4769	64	14	statistical	statistical	ADJ
dpc-4769	64	15	results	result	NOUN
dpc-4769	64	16	.	.	PUNCT
dpc-4769	65	1	the	the	DET
dpc-4769	65	2	statistical	statistical	ADJ
dpc-4769	65	3	computations	computation	NOUN
dpc-4769	65	4	were	be	AUX
dpc-4769	65	5	performed	perform	VERB
dpc-4769	65	6	with	with	ADP
dpc-4769	65	7	graphpad	graphpad	NOUN
dpc-4769	65	8	prism	prism	NOUN
dpc-4769	65	9	version	version	NOUN
dpc-4769	65	10	6.0	6.0	NUM
dpc-4769	65	11	(	(	PUNCT
dpc-4769	65	12	graphpad	graphpad	PROPN
dpc-4769	65	13	software	software	PROPN
dpc-4769	65	14	inc	inc	PROPN
dpc-4769	65	15	.	.	PROPN
dpc-4769	65	16	,	,	PUNCT
dpc-4769	65	17	based	base	VERB
dpc-4769	65	18	in	in	ADP
dpc-4769	65	19	la	la	PROPN
dpc-4769	65	20	jolla	jolla	PROPN
dpc-4769	65	21	,	,	PUNCT
dpc-4769	65	22	ca	ca	PROPN
dpc-4769	65	23	,	,	PUNCT
dpc-4769	65	24	usa	usa	PROPN
dpc-4769	65	25	)	)	PUNCT
dpc-4769	65	26	and	and	CCONJ
dpc-4769	65	27	sas	sa	VERB
dpc-4769	65	28	®	®	NOUN
dpc-4769	65	29	software	software	NOUN
dpc-4769	65	30	,	,	PUNCT
dpc-4769	65	31	version	version	NOUN
dpc-4769	65	32	9.3	9.3	NUM
dpc-4769	65	33	(	(	PUNCT
dpc-4769	65	34	sas	sas	PROPN
dpc-4769	65	35	institute	institute	PROPN
dpc-4769	65	36	inc	inc	PROPN
dpc-4769	65	37	.	.	PROPN
dpc-4769	65	38	,	,	PUNCT
dpc-4769	65	39	located	locate	VERB
dpc-4769	65	40	in	in	ADP
dpc-4769	65	41	cary	cary	PROPN
dpc-4769	65	42	,	,	PUNCT
dpc-4769	65	43	nc	nc	PROPN
dpc-4769	65	44	,	,	PUNCT
dpc-4769	65	45	usa	usa	PROPN
dpc-4769	65	46	)	)	PUNCT
dpc-4769	65	47	.	.	PUNCT
dpc-4769	66	1	results	result	VERB
dpc-4769	66	2	a	a	DET
dpc-4769	66	3	total	total	NOUN
dpc-4769	66	4	of	of	ADP
dpc-4769	66	5	54	54	NUM
dpc-4769	66	6	patients	patient	NOUN
dpc-4769	66	7	(	(	PUNCT
dpc-4769	66	8	36	36	NUM
dpc-4769	66	9	male	male	NOUN
dpc-4769	66	10	,	,	PUNCT
dpc-4769	66	11	66.7	66.7	NUM
dpc-4769	66	12	%	%	NOUN
dpc-4769	66	13	;	;	PUNCT
dpc-4769	66	14	mean	mean	VERB
dpc-4769	66	15	age	age	NOUN
dpc-4769	66	16	52.9	52.9	NUM
dpc-4769	66	17	±	±	NUM
dpc-4769	66	18	12.6	12.6	NUM
dpc-4769	66	19	years	year	NOUN
dpc-4769	66	20	,	,	PUNCT
dpc-4769	66	21	mean	mean	VERB
dpc-4769	66	22	psoriasis	psoriasis	NOUN
dpc-4769	66	23	duration	duration	NOUN
dpc-4769	66	24	18.3	18.3	NUM
dpc-4769	66	25	±	±	NUM
dpc-4769	66	26	10.9	10.9	NUM
dpc-4769	66	27	years	year	NOUN
dpc-4769	66	28	)	)	PUNCT
dpc-4769	66	29	were	be	AUX
dpc-4769	66	30	enrolled	enrol	VERB
dpc-4769	66	31	.	.	PUNCT
dpc-4769	67	1	of	of	ADP
dpc-4769	67	2	the	the	DET
dpc-4769	67	3	54	54	NUM
dpc-4769	67	4	patients	patient	NOUN
dpc-4769	67	5	included	include	VERB
dpc-4769	67	6	in	in	ADP
dpc-4769	67	7	this	this	DET
dpc-4769	67	8	study	study	NOUN
dpc-4769	67	9	,	,	PUNCT
dpc-4769	67	10	52	52	NUM
dpc-4769	67	11	,	,	PUNCT
dpc-4769	67	12	44	44	NUM
dpc-4769	67	13	,	,	PUNCT
dpc-4769	67	14	and	and	CCONJ
dpc-4769	67	15	32	32	NUM
dpc-4769	67	16	patients	patient	NOUN
dpc-4769	67	17	were	be	AUX
dpc-4769	67	18	treated	treat	VERB
dpc-4769	67	19	for	for	ADP
dpc-4769	67	20	at	at	ADV
dpc-4769	67	21	least	least	ADV
dpc-4769	67	22	4	4	NUM
dpc-4769	67	23	,	,	PUNCT
dpc-4769	67	24	16	16	NUM
dpc-4769	67	25	,	,	PUNCT
dpc-4769	67	26	and	and	CCONJ
dpc-4769	67	27	28	28	NUM
dpc-4769	67	28	weeks	week	NOUN
dpc-4769	67	29	,	,	PUNCT
dpc-4769	67	30	respectively	respectively	ADV
dpc-4769	67	31	(	(	PUNCT
dpc-4769	67	32	the	the	DET
dpc-4769	67	33	declining	decline	VERB
dpc-4769	67	34	number	number	NOUN
dpc-4769	67	35	of	of	ADP
dpc-4769	67	36	patients	patient	NOUN
dpc-4769	67	37	at	at	ADP
dpc-4769	67	38	each	each	DET
dpc-4769	67	39	timepoint	timepoint	NOUN
dpc-4769	67	40	does	do	AUX
dpc-4769	67	41	not	not	PART
dpc-4769	67	42	represent	represent	VERB
dpc-4769	67	43	treatment	treatment	NOUN
dpc-4769	67	44	withdrawal	withdrawal	NOUN
dpc-4769	67	45	)	)	PUNCT
dpc-4769	67	46	.	.	PUNCT
dpc-4769	68	1	dyslipidemia	dyslipidemia	NOUN
dpc-4769	68	2	was	be	AUX
dpc-4769	68	3	the	the	DET
dpc-4769	68	4	most	most	ADV
dpc-4769	68	5	common	common	ADJ
dpc-4769	68	6	comorbidity	comorbidity	NOUN
dpc-4769	68	7	assessed	assess	VERB
dpc-4769	68	8	(	(	PUNCT
dpc-4769	68	9	n=30	n=30	PROPN
dpc-4769	68	10	,	,	PUNCT
dpc-4769	68	11	55.6	55.6	NUM
dpc-4769	68	12	%	%	NOUN
dpc-4769	68	13	)	)	PUNCT
dpc-4769	68	14	,	,	PUNCT
dpc-4769	68	15	followed	follow	VERB
dpc-4769	68	16	by	by	ADP
dpc-4769	68	17	obesity	obesity	NOUN
dpc-4769	68	18	(	(	PUNCT
dpc-4769	68	19	n=28	n=28	NOUN
dpc-4769	68	20	,	,	PUNCT
dpc-4769	68	21	51.8.2	51.8.2	NUM
dpc-4769	68	22	%	%	NOUN
dpc-4769	68	23	)	)	PUNCT
dpc-4769	68	24	,	,	PUNCT
dpc-4769	68	25	hypertension	hypertension	NOUN
dpc-4769	68	26	(	(	PUNCT
dpc-4769	68	27	n=27	n=27	PROPN
dpc-4769	68	28	,	,	PUNCT
dpc-4769	68	29	50	50	NUM
dpc-4769	68	30	%	%	NOUN
dpc-4769	68	31	)	)	PUNCT
dpc-4769	68	32	,	,	PUNCT
dpc-4769	68	33	diabetes	diabetes	NOUN
dpc-4769	68	34	mellitus	mellitus	NOUN
dpc-4769	68	35	(	(	PUNCT
dpc-4769	68	36	n=8	n=8	PROPN
dpc-4769	68	37	,	,	PUNCT
dpc-4769	68	38	14.8	14.8	NUM
dpc-4769	68	39	%	%	NOUN
dpc-4769	68	40	)	)	PUNCT
dpc-4769	68	41	,	,	PUNCT
dpc-4769	68	42	psychiatric	psychiatric	ADJ
dpc-4769	68	43	disorders	disorder	NOUN
dpc-4769	68	44	(	(	PUNCT
dpc-4769	68	45	n=	n=	ADJ
dpc-4769	68	46	6;11.1	6;11.1	NUM
dpc-4769	68	47	%	%	NOUN
dpc-4769	68	48	)	)	PUNCT
dpc-4769	68	49	,	,	PUNCT
dpc-4769	68	50	atopy	atopy	NOUN
dpc-4769	68	51	(	(	PUNCT
dpc-4769	68	52	n=5	n=5	ADJ
dpc-4769	68	53	,	,	PUNCT
dpc-4769	68	54	9.3	9.3	NUM
dpc-4769	68	55	%	%	NOUN
dpc-4769	68	56	)	)	PUNCT
dpc-4769	68	57	,	,	PUNCT
dpc-4769	68	58	immune	immune	NOUN
dpc-4769	68	59	-	-	PUNCT
dpc-4769	68	60	mediate	mediate	NOUN
dpc-4769	68	61	disease	disease	NOUN
dpc-4769	68	62	(	(	PUNCT
dpc-4769	68	63	n=3,5.6	n=3,5.6	NOUN
dpc-4769	68	64	%	%	NOUN
dpc-4769	68	65	)	)	PUNCT
dpc-4769	68	66	,	,	PUNCT
dpc-4769	68	67	and	and	CCONJ
dpc-4769	68	68	cardiopathy	cardiopathy	ADJ
dpc-4769	68	69	(	(	PUNCT
dpc-4769	68	70	n=1	n=1	PROPN
dpc-4769	68	71	,	,	PUNCT
dpc-4769	68	72	1.8	1.8	NUM
dpc-4769	68	73	%	%	NOUN
dpc-4769	68	74	)	)	PUNCT
dpc-4769	68	75	.	.	PUNCT
dpc-4769	69	1	patients	patient	NOUN
dpc-4769	69	2	’	'	PUNCT
dpc-4769	69	3	clinical	clinical	ADJ
dpc-4769	69	4	features	feature	NOUN
dpc-4769	69	5	are	be	AUX
dpc-4769	69	6	reported	report	VERB
dpc-4769	69	7	in	in	ADP
dpc-4769	69	8	table	table	NOUN
dpc-4769	69	9	1	1	NUM
dpc-4769	69	10	.	.	PUNCT
dpc-4769	69	11	baseline	baseline	PROPN
dpc-4769	69	12	disease	disease	NOUN
dpc-4769	69	13	severity	severity	NOUN
dpc-4769	69	14	was	be	AUX
dpc-4769	69	15	moderate	moderate	ADJ
dpc-4769	69	16	to	to	PART
dpc-4769	69	17	severe	severe	VERB
dpc-4769	69	18	,	,	PUNCT
dpc-4769	69	19	with	with	ADP
dpc-4769	69	20	a	a	DET
dpc-4769	69	21	mean	mean	ADJ
dpc-4769	69	22	pasi	pasi	NOUN
dpc-4769	69	23	score	score	NOUN
dpc-4769	69	24	of	of	ADP
dpc-4769	69	25	15.9	15.9	NUM
dpc-4769	69	26	±	±	NUM
dpc-4769	69	27	8.9	8.9	NUM
dpc-4769	69	28	,	,	PUNCT
dpc-4769	69	29	mean	mean	PROPN
dpc-4769	69	30	bsa	bsa	NOUN
dpc-4769	69	31	of	of	ADP
dpc-4769	69	32	17.9	17.9	NUM
dpc-4769	69	33	±	±	NUM
dpc-4769	69	34	14.9	14.9	NUM
dpc-4769	69	35	,	,	PUNCT
dpc-4769	69	36	and	and	CCONJ
dpc-4769	69	37	mean	mean	VERB
dpc-4769	69	38	dlqi	dlqi	NOUN
dpc-4769	69	39	of	of	ADP
dpc-4769	69	40	15.3	15.3	NUM
dpc-4769	69	41	±	±	NUM
dpc-4769	69	42	6.2	6.2	NUM
dpc-4769	69	43	.	.	PUNCT
dpc-4769	70	1	as	as	SCONJ
dpc-4769	70	2	regards	regard	VERB
dpc-4769	70	3	difficult	difficult	ADJ
dpc-4769	70	4	-	-	PUNCT
dpc-4769	70	5	to	to	ADP
dpc-4769	70	6	-	-	PUNCT
dpc-4769	70	7	treat	treat	VERB
dpc-4769	70	8	area	area	NOUN
dpc-4769	70	9	involvement	involvement	NOUN
dpc-4769	70	10	,	,	PUNCT
dpc-4769	70	11	14	14	NUM
dpc-4769	70	12	(	(	PUNCT
dpc-4769	70	13	25.9	25.9	NUM
dpc-4769	70	14	%	%	NOUN
dpc-4769	70	15	)	)	PUNCT
dpc-4769	70	16	,	,	PUNCT
dpc-4769	70	17	11	11	NUM
dpc-4769	70	18	(	(	PUNCT
dpc-4769	70	19	20.3	20.3	NUM
dpc-4769	70	20	%	%	NOUN
dpc-4769	70	21	)	)	PUNCT
dpc-4769	70	22	,	,	PUNCT
dpc-4769	70	23	10	10	NUM
dpc-4769	70	24	(	(	PUNCT
dpc-4769	70	25	18.5	18.5	NUM
dpc-4769	70	26	%	%	NOUN
dpc-4769	70	27	)	)	PUNCT
dpc-4769	70	28	,	,	PUNCT
dpc-4769	70	29	9	9	NUM
dpc-4769	70	30	(	(	PUNCT
dpc-4769	70	31	16.7	16.7	NUM
dpc-4769	70	32	%	%	NOUN
dpc-4769	70	33	)	)	PUNCT
dpc-4769	70	34	,	,	PUNCT
dpc-4769	70	35	and	and	CCONJ
dpc-4769	70	36	3	3	NUM
dpc-4769	70	37	(	(	PUNCT
dpc-4769	70	38	5.5	5.5	NUM
dpc-4769	70	39	%	%	NOUN
dpc-4769	70	40	)	)	PUNCT
dpc-4769	70	41	patients	patient	NOUN
dpc-4769	70	42	had	have	VERB
dpc-4769	70	43	the	the	DET
dpc-4769	70	44	involvement	involvement	NOUN
dpc-4769	70	45	of	of	ADP
dpc-4769	70	46	fingernails	fingernail	NOUN
dpc-4769	70	47	,	,	PUNCT
dpc-4769	70	48	folds	fold	NOUN
dpc-4769	70	49	,	,	PUNCT
dpc-4769	70	50	genitalia	genitalia	NOUN
dpc-4769	70	51	,	,	PUNCT
dpc-4769	70	52	head	head	NOUN
dpc-4769	70	53	-	-	PUNCT
dpc-4769	70	54	neck	neck	NOUN
dpc-4769	70	55	,	,	PUNCT
dpc-4769	70	56	and	and	CCONJ
dpc-4769	70	57	palmoplantar	palmoplantar	PROPN
dpc-4769	70	58	area	area	NOUN
dpc-4769	70	59	,	,	PUNCT
dpc-4769	70	60	respectively	respectively	ADV
dpc-4769	70	61	,	,	PUNCT
dpc-4769	70	62	underlying	underlie	VERB
dpc-4769	70	63	the	the	DET
dpc-4769	70	64	complexity	complexity	NOUN
dpc-4769	70	65	of	of	ADP
dpc-4769	70	66	the	the	DET
dpc-4769	70	67	enrolled	enrol	VERB
dpc-4769	70	68	cohort	cohort	NOUN
dpc-4769	70	69	of	of	ADP
dpc-4769	70	70	subjects	subject	NOUN
dpc-4769	70	71	.	.	PUNCT
dpc-4769	71	1	moreover	moreover	ADV
dpc-4769	71	2	,	,	PUNCT
dpc-4769	71	3	psa	psa	PROPN
dpc-4769	71	4	was	be	AUX
dpc-4769	71	5	collected	collect	VERB
dpc-4769	71	6	in	in	ADP
dpc-4769	71	7	13	13	NUM
dpc-4769	71	8	(	(	PUNCT
dpc-4769	71	9	24.1	24.1	NUM
dpc-4769	71	10	%	%	NOUN
dpc-4769	71	11	)	)	PUNCT
dpc-4769	71	12	patients	patient	NOUN
dpc-4769	71	13	.	.	PUNCT
dpc-4769	72	1	the	the	DET
dpc-4769	72	2	majority	majority	NOUN
dpc-4769	72	3	of	of	ADP
dpc-4769	72	4	the	the	DET
dpc-4769	72	5	patients	patient	NOUN
dpc-4769	72	6	were	be	AUX
dpc-4769	72	7	previously	previously	ADV
dpc-4769	72	8	treated	treat	VERB
dpc-4769	72	9	with	with	ADP
dpc-4769	72	10	at	at	ADV
dpc-4769	72	11	least	least	ADV
dpc-4769	72	12	one	one	NUM
dpc-4769	72	13	conventional	conventional	ADJ
dpc-4769	72	14	systemic	systemic	ADJ
dpc-4769	72	15	treatment	treatment	NOUN
dpc-4769	72	16	(	(	PUNCT
dpc-4769	72	17	cyclosporine	cyclosporine	NOUN
dpc-4769	72	18	31	31	NUM
dpc-4769	73	1	[	[	X
dpc-4769	73	2	57.4	57.4	NUM
dpc-4769	73	3	%	%	NOUN
dpc-4769	73	4	]	]	X
dpc-4769	73	5	,	,	PUNCT
dpc-4769	73	6	nb	nb	ADJ
dpc-4769	73	7	-	-	ADJ
dpc-4769	73	8	uvb	uvb	ADJ
dpc-4769	73	9	phototherapy	phototherapy	NOUN
dpc-4769	73	10	19	19	NUM
dpc-4769	74	1	[	[	SYM
dpc-4769	74	2	35.2	35.2	NUM
dpc-4769	74	3	%	%	NOUN
dpc-4769	74	4	]	]	PUNCT
dpc-4769	74	5	,	,	PUNCT
dpc-4769	74	6	methotrexate	methotrexate	VERB
dpc-4769	74	7	16	16	NUM
dpc-4769	75	1	[	[	X
dpc-4769	75	2	29.6	29.6	NUM
dpc-4769	75	3	%	%	NOUN
dpc-4769	75	4	]	]	X
dpc-4769	75	5	,	,	PUNCT
dpc-4769	75	6	acitretin	acitretin	VERB
dpc-4769	75	7	16	16	NUM
dpc-4769	76	1	[	[	X
dpc-4769	76	2	29.6	29.6	NUM
dpc-4769	76	3	%	%	NOUN
dpc-4769	76	4	]	]	PUNCT
dpc-4769	76	5	)	)	PUNCT
dpc-4769	76	6	,	,	PUNCT
dpc-4769	76	7	and	and	CCONJ
dpc-4769	76	8	the	the	DET
dpc-4769	76	9	most	most	ADV
dpc-4769	76	10	common	common	ADJ
dpc-4769	76	11	biologic	biologic	NOUN
dpc-4769	76	12	classes	class	NOUN
dpc-4769	76	13	that	that	PRON
dpc-4769	76	14	patients	patient	NOUN
dpc-4769	76	15	had	have	AUX
dpc-4769	76	16	been	be	AUX
dpc-4769	76	17	exposed	expose	VERB
dpc-4769	76	18	to	to	AUX
dpc-4769	76	19	previously	previously	ADV
dpc-4769	76	20	were	be	AUX
dpc-4769	76	21	anti	anti	ADJ
dpc-4769	76	22	-	-	ADJ
dpc-4769	76	23	tnf	tnf	ADJ
dpc-4769	76	24	(	(	PUNCT
dpc-4769	76	25	adalimumab	adalimumab	NOUN
dpc-4769	76	26	19	19	NUM
dpc-4769	76	27	[	[	SYM
dpc-4769	76	28	35.2	35.2	NUM
dpc-4769	76	29	%	%	NOUN
dpc-4769	76	30	]	]	PUNCT
dpc-4769	76	31	,	,	PUNCT
dpc-4769	76	32	etanercept	etanercept	VERB
dpc-4769	76	33	5	5	NUM
dpc-4769	77	1	[	[	SYM
dpc-4769	77	2	9.3	9.3	NUM
dpc-4769	77	3	%	%	NOUN
dpc-4769	77	4	]	]	PUNCT
dpc-4769	77	5	,	,	PUNCT
dpc-4769	77	6	infliximab	infliximab	NOUN
dpc-4769	77	7	2	2	NUM
dpc-4769	77	8	[	[	SYM
dpc-4769	77	9	3.7	3.7	NUM
dpc-4769	77	10	%	%	NOUN
dpc-4769	77	11	]	]	PUNCT
dpc-4769	77	12	,	,	PUNCT
dpc-4769	77	13	and	and	CCONJ
dpc-4769	77	14	golimumab	golimumab	VERB
dpc-4769	77	15	2	2	NUM
dpc-4769	78	1	[	[	SYM
dpc-4769	78	2	3.7	3.7	NUM
dpc-4769	78	3	%	%	NOUN
dpc-4769	78	4	]	]	PUNCT
dpc-4769	78	5	)	)	PUNCT
dpc-4769	78	6	,	,	PUNCT
dpc-4769	78	7	anti	anti	ADJ
dpc-4769	78	8	-	-	ADJ
dpc-4769	78	9	il-12/23	il-12/23	ADJ
dpc-4769	78	10	(	(	PUNCT
dpc-4769	78	11	ustekinumab	ustekinumab	NOUN
dpc-4769	78	12	9	9	NUM
dpc-4769	78	13	[	[	SYM
dpc-4769	78	14	16.7	16.7	NUM
dpc-4769	78	15	%	%	NOUN
dpc-4769	78	16	]	]	X
dpc-4769	78	17	,	,	PUNCT
dpc-4769	78	18	anti	anti	ADJ
dpc-4769	78	19	-	-	ADJ
dpc-4769	78	20	il-17	il-17	ADP
dpc-4769	78	21	[	[	X
dpc-4769	78	22	secukinumab	secukinumab	NOUN
dpc-4769	78	23	7	7	NUM
dpc-4769	78	24	[	[	SYM
dpc-4769	78	25	12.9	12.9	NUM
dpc-4769	78	26	%	%	NOUN
dpc-4769	78	27	]	]	PUNCT
dpc-4769	78	28	,	,	PUNCT
dpc-4769	78	29	ixekizumab	ixekizumab	VERB
dpc-4769	78	30	3	3	NUM
dpc-4769	78	31	[	[	X
dpc-4769	78	32	5.6	5.6	NUM
dpc-4769	78	33	%	%	NOUN
dpc-4769	78	34	]	]	PUNCT
dpc-4769	78	35	,	,	PUNCT
dpc-4769	78	36	brodalumab	brodalumab	NOUN
dpc-4769	78	37	3	3	NUM
dpc-4769	79	1	[	[	X
dpc-4769	79	2	5.6	5.6	NUM
dpc-4769	79	3	%	%	NOUN
dpc-4769	79	4	]	]	PUNCT
dpc-4769	79	5	)	)	PUNCT
dpc-4769	79	6	,	,	PUNCT
dpc-4769	79	7	and	and	CCONJ
dpc-4769	79	8	anti	anti	ADJ
dpc-4769	79	9	-	-	NOUN
dpc-4769	79	10	il-23	il-23	NOUN
dpc-4769	79	11	(	(	PUNCT
dpc-4769	79	12	risankizumab	risankizumab	NOUN
dpc-4769	79	13	3	3	NUM
dpc-4769	79	14	[	[	X
dpc-4769	79	15	5.6	5.6	NUM
dpc-4769	79	16	%	%	NOUN
dpc-4769	79	17	]	]	PUNCT
dpc-4769	79	18	,	,	PUNCT
dpc-4769	79	19	guselkumab	guselkumab	NOUN
dpc-4769	79	20	2	2	NUM
dpc-4769	79	21	[	[	SYM
dpc-4769	79	22	3.7	3.7	NUM
dpc-4769	79	23	%	%	NOUN
dpc-4769	79	24	]	]	PUNCT
dpc-4769	79	25	)	)	PUNCT
dpc-4769	79	26	.	.	PUNCT
dpc-4769	80	1	prior	prior	ADV
dpc-4769	80	2	to	to	ADP
dpc-4769	80	3	the	the	DET
dpc-4769	80	4	start	start	NOUN
dpc-4769	80	5	of	of	ADP
dpc-4769	80	6	the	the	DET
dpc-4769	80	7	study	study	NOUN
dpc-4769	80	8	,	,	PUNCT
dpc-4769	80	9	19	19	NUM
dpc-4769	80	10	patients	patient	NOUN
dpc-4769	80	11	(	(	PUNCT
dpc-4769	80	12	35.19	35.19	NUM
dpc-4769	80	13	%	%	NOUN
dpc-4769	80	14	)	)	PUNCT
dpc-4769	80	15	had	have	AUX
dpc-4769	80	16	been	be	AUX
dpc-4769	80	17	treated	treat	VERB
dpc-4769	80	18	with	with	ADP
dpc-4769	80	19	tildrakizumab	tildrakizumab	NOUN
dpc-4769	80	20	100	100	NUM
dpc-4769	80	21	mg	mg	PROPN
dpc-4769	80	22	(	(	PUNCT
dpc-4769	80	23	before	before	ADP
dpc-4769	80	24	switching	switch	VERB
dpc-4769	80	25	to	to	ADP
dpc-4769	80	26	200	200	NUM
dpc-4769	80	27	mg	mg	NOUN
dpc-4769	80	28	)	)	PUNCT
dpc-4769	80	29	.	.	PUNCT
dpc-4769	81	1	only	only	ADV
dpc-4769	81	2	13	13	NUM
dpc-4769	81	3	(	(	PUNCT
dpc-4769	81	4	24.1	24.1	NUM
dpc-4769	81	5	%	%	NOUN
dpc-4769	81	6	)	)	PUNCT
dpc-4769	81	7	patients	patient	NOUN
dpc-4769	81	8	were	be	AUX
dpc-4769	81	9	bio	bio	ADJ
dpc-4769	81	10	-	-	ADJ
dpc-4769	81	11	naïve	naïve	ADJ
dpc-4769	81	12	(	(	PUNCT
dpc-4769	81	13	table	table	NOUN
dpc-4769	81	14	1	1	NUM
dpc-4769	81	15	)	)	PUNCT
dpc-4769	81	16	.	.	PUNCT
dpc-4769	82	1	patients	patient	NOUN
dpc-4769	82	2	withdrawing	withdraw	VERB
dpc-4769	82	3	from	from	ADP
dpc-4769	82	4	the	the	DET
dpc-4769	82	5	study	study	NOUN
dpc-4769	82	6	were	be	AUX
dpc-4769	82	7	defined	define	VERB
dpc-4769	82	8	as	as	ADP
dpc-4769	82	9	non	non	NOUN
dpc-4769	82	10	-	-	NOUN
dpc-4769	82	11	responders	responder	NOUN
dpc-4769	82	12	according	accord	VERB
dpc-4769	82	13	to	to	ADP
dpc-4769	82	14	the	the	DET
dpc-4769	82	15	non	non	ADJ
dpc-4769	82	16	responder	responder	NOUN
dpc-4769	82	17	imputation	imputation	NOUN
dpc-4769	82	18	method	method	NOUN
dpc-4769	82	19	.	.	PUNCT
dpc-4769	83	1	no	no	DET
dpc-4769	83	2	treatment	treatment	NOUN
dpc-4769	83	3	withdrawal	withdrawal	NOUN
dpc-4769	83	4	was	be	AUX
dpc-4769	83	5	observed	observe	VERB
dpc-4769	83	6	due	due	ADJ
dpc-4769	83	7	to	to	ADP
dpc-4769	83	8	aes	aes	PROPN
dpc-4769	83	9	.	.	PUNCT
dpc-4769	84	1	aes	aes	PROPN
dpc-4769	84	2	that	that	PRON
dpc-4769	84	3	did	do	AUX
dpc-4769	84	4	not	not	PART
dpc-4769	84	5	require	require	VERB
dpc-4769	84	6	tildrakizumab	tildrakizumab	ADJ
dpc-4769	84	7	discontinuation	discontinuation	NOUN
dpc-4769	84	8	were	be	AUX
dpc-4769	84	9	reported	report	VERB
dpc-4769	84	10	in	in	ADP
dpc-4769	84	11	1.8%%	1.8%%	NUM
dpc-4769	84	12	(	(	PUNCT
dpc-4769	84	13	1/54	1/54	NUM
dpc-4769	84	14	)	)	PUNCT
dpc-4769	84	15	of	of	ADP
dpc-4769	84	16	patients	patient	NOUN
dpc-4769	84	17	and	and	CCONJ
dpc-4769	84	18	were	be	AUX
dpc-4769	84	19	represented	represent	VERB
dpc-4769	84	20	by	by	ADP
dpc-4769	84	21	injection	injection	NOUN
dpc-4769	84	22	-	-	PUNCT
dpc-4769	84	23	site	site	NOUN
dpc-4769	84	24	reactions	reaction	NOUN
dpc-4769	84	25	,	,	PUNCT
dpc-4769	84	26	headache	headache	NOUN
dpc-4769	84	27	,	,	PUNCT
dpc-4769	84	28	and	and	CCONJ
dpc-4769	84	29	nausea	nausea	NOUN
dpc-4769	84	30	/	/	SYM
dpc-4769	84	31	fatigue	fatigue	NOUN
dpc-4769	84	32	the	the	DET
dpc-4769	84	33	day	day	NOUN
dpc-4769	84	34	after	after	ADP
dpc-4769	84	35	injection	injection	NOUN
dpc-4769	84	36	.	.	PUNCT
dpc-4769	85	1	a	a	DET
dpc-4769	85	2	significant	significant	ADJ
dpc-4769	85	3	reduction	reduction	NOUN
dpc-4769	85	4	in	in	ADP
dpc-4769	85	5	the	the	DET
dpc-4769	85	6	mean	mean	ADJ
dpc-4769	85	7	baseline	baseline	NOUN
dpc-4769	85	8	pasi	pasi	PROPN
dpc-4769	85	9	score	score	NOUN
dpc-4769	85	10	(	(	PUNCT
dpc-4769	85	11	9	9	NUM
dpc-4769	85	12	±	±	NUM
dpc-4769	85	13	6.9	6.9	NUM
dpc-4769	85	14	,	,	PUNCT
dpc-4769	85	15	p	p	X
dpc-4769	85	16	<	<	X
dpc-4769	85	17	0.001	0.001	NUM
dpc-4769	85	18	)	)	PUNCT
dpc-4769	85	19	was	be	AUX
dpc-4769	85	20	detected	detect	VERB
dpc-4769	85	21	at	at	ADP
dpc-4769	85	22	week	week	NOUN
dpc-4769	85	23	4	4	NUM
dpc-4769	85	24	of	of	ADP
dpc-4769	85	25	tildrakizumab	tildrakizumab	NOUN
dpc-4769	85	26	200	200	NUM
dpc-4769	85	27	mg	mg	PROPN
dpc-4769	85	28	therapy	therapy	NOUN
dpc-4769	85	29	,	,	PUNCT
dpc-4769	85	30	with	with	ADP
dpc-4769	85	31	a	a	DET
dpc-4769	85	32	further	further	ADJ
dpc-4769	85	33	improvement	improvement	NOUN
dpc-4769	85	34	at	at	ADP
dpc-4769	85	35	weeks	week	NOUN
dpc-4769	85	36	16	16	NUM
dpc-4769	85	37	(	(	PUNCT
dpc-4769	85	38	3.9	3.9	NUM
dpc-4769	85	39	±	±	NUM
dpc-4769	85	40	4.2	4.2	NUM
dpc-4769	85	41	,	,	PUNCT
dpc-4769	85	42	p	p	X
dpc-4769	85	43	<	<	X
dpc-4769	85	44	0.001	0.001	NUM
dpc-4769	85	45	)	)	PUNCT
dpc-4769	85	46	and	and	CCONJ
dpc-4769	85	47	28	28	NUM
dpc-4769	85	48	(	(	PUNCT
dpc-4769	85	49	2.9	2.9	NUM
dpc-4769	85	50	±4.4	±4.4	PROPN
dpc-4769	85	51	,	,	PUNCT
dpc-4769	85	52	p	p	X
dpc-4769	85	53	<	<	X
dpc-4769	85	54	0.001	0.001	NUM
dpc-4769	85	55	)	)	PUNCT
dpc-4769	85	56	(	(	PUNCT
dpc-4769	85	57	table	table	NOUN
dpc-4769	85	58	1	1	NUM
dpc-4769	85	59	)	)	PUNCT
dpc-4769	85	60	.	.	PUNCT
dpc-4769	86	1	the	the	DET
dpc-4769	86	2	pasi	pasi	PROPN
dpc-4769	86	3	score	score	NOUN
dpc-4769	86	4	reduction	reduction	NOUN
dpc-4769	86	5	was	be	AUX
dpc-4769	86	6	associated	associate	VERB
dpc-4769	86	7	with	with	ADP
dpc-4769	86	8	a	a	DET
dpc-4769	86	9	significant	significant	ADJ
dpc-4769	86	10	decrease	decrease	NOUN
dpc-4769	86	11	in	in	ADP
dpc-4769	86	12	both	both	DET
dpc-4769	86	13	baseline	baseline	PROPN
dpc-4769	86	14	bsa	bsa	PROPN
dpc-4769	86	15	and	and	CCONJ
dpc-4769	86	16	dlqi	dlqi	ADJ
dpc-4769	86	17	scores	score	NOUN
dpc-4769	86	18	.	.	PUNCT
dpc-4769	87	1	data	datum	NOUN
dpc-4769	87	2	were	be	AUX
dpc-4769	87	3	analyzed	analyze	VERB
dpc-4769	87	4	according	accord	VERB
dpc-4769	87	5	to	to	ADP
dpc-4769	87	6	the	the	DET
dpc-4769	87	7	non	non	ADJ
dpc-4769	87	8	-	-	ADJ
dpc-4769	87	9	responder	responder	ADJ
dpc-4769	87	10	imputation	imputation	NOUN
dpc-4769	87	11	analysis	analysis	NOUN
dpc-4769	87	12	and	and	CCONJ
dpc-4769	87	13	are	be	AUX
dpc-4769	87	14	shown	show	VERB
dpc-4769	87	15	in	in	ADP
dpc-4769	87	16	figure	figure	NOUN
dpc-4769	87	17	1	1	NUM
dpc-4769	87	18	.	.	PUNCT
dpc-4769	88	1	our	our	PRON
dpc-4769	88	2	analysis	analysis	NOUN
dpc-4769	88	3	focused	focus	VERB
dpc-4769	88	4	on	on	ADP
dpc-4769	88	5	24	24	NUM
dpc-4769	88	6	patients	patient	NOUN
dpc-4769	88	7	who	who	PRON
dpc-4769	88	8	started	start	VERB
dpc-4769	88	9	tildrakizumab	tildrakizumab	NOUN
dpc-4769	88	10	200	200	NUM
dpc-4769	88	11	mg	mg	NOUN
dpc-4769	88	12	and	and	CCONJ
dpc-4769	88	13	had	have	AUX
dpc-4769	88	14	completed	complete	VERB
dpc-4769	88	15	up	up	ADP
dpc-4769	88	16	to	to	PART
dpc-4769	88	17	16	16	NUM
dpc-4769	88	18	weeks	week	NOUN
dpc-4769	88	19	of	of	ADP
dpc-4769	88	20	4	4	NUM
dpc-4769	88	21	original	original	ADJ
dpc-4769	88	22	article	article	NOUN
dpc-4769	88	23	|	|	ADV
dpc-4769	88	24	dermatol	dermatol	ADJ
dpc-4769	88	25	pract	pract	NOUN
dpc-4769	88	26	concept	concept	NOUN
dpc-4769	88	27	.	.	PUNCT
dpc-4769	89	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	89	2	characteristics	characteristic	NOUN
dpc-4769	89	3	significantly	significantly	ADV
dpc-4769	89	4	associated	associate	VERB
dpc-4769	89	5	with	with	ADP
dpc-4769	89	6	achieving	achieve	VERB
dpc-4769	89	7	a	a	DET
dpc-4769	89	8	pasi	pasi	NOUN
dpc-4769	89	9	≤	≤	ADV
dpc-4769	89	10	5	5	NUM
dpc-4769	89	11	at	at	ADP
dpc-4769	89	12	week	week	NOUN
dpc-4769	89	13	16	16	NUM
dpc-4769	89	14	.	.	PUNCT
dpc-4769	90	1	patients	patient	NOUN
dpc-4769	90	2	with	with	ADP
dpc-4769	90	3	a	a	DET
dpc-4769	90	4	bmi	bmi	NOUN
dpc-4769	90	5	over	over	ADP
dpc-4769	90	6	30	30	NUM
dpc-4769	90	7	had	have	VERB
dpc-4769	90	8	significantly	significantly	ADV
dpc-4769	90	9	higher	high	ADJ
dpc-4769	90	10	odds	odd	NOUN
dpc-4769	90	11	of	of	ADP
dpc-4769	90	12	achieving	achieve	VERB
dpc-4769	90	13	a	a	DET
dpc-4769	90	14	pasi	pasi	NOUN
dpc-4769	90	15	≤	≤	ADV
dpc-4769	90	16	5	5	NUM
dpc-4769	90	17	(	(	PUNCT
dpc-4769	90	18	or	or	CCONJ
dpc-4769	90	19	=	=	SYM
dpc-4769	90	20	4.333	4.333	NUM
dpc-4769	90	21	;	;	PUNCT
dpc-4769	90	22	95	95	NUM
dpc-4769	90	23	%	%	NOUN
dpc-4769	90	24	ci	ci	NOUN
dpc-4769	90	25	:	:	PUNCT
dpc-4769	90	26	1.435	1.435	NUM
dpc-4769	90	27	–	–	PUNCT
dpc-4769	90	28	6.00	6.00	NUM
dpc-4769	90	29	,	,	PUNCT
dpc-4769	90	30	p	p	X
dpc-4769	90	31	<	<	X
dpc-4769	90	32	0.05	0.05	NUM
dpc-4769	90	33	)	)	PUNCT
dpc-4769	90	34	.	.	PUNCT
dpc-4769	91	1	additionally	additionally	ADV
dpc-4769	91	2	,	,	PUNCT
dpc-4769	91	3	patients	patient	NOUN
dpc-4769	91	4	with	with	ADP
dpc-4769	91	5	a	a	DET
dpc-4769	91	6	disease	disease	NOUN
dpc-4769	91	7	duration	duration	NOUN
dpc-4769	91	8	greater	great	ADJ
dpc-4769	91	9	than	than	ADP
dpc-4769	91	10	two	two	NUM
dpc-4769	91	11	years	year	NOUN
dpc-4769	91	12	at	at	ADP
dpc-4769	91	13	baseline	baseline	PROPN
dpc-4769	91	14	were	be	AUX
dpc-4769	91	15	significantly	significantly	ADV
dpc-4769	91	16	associated	associate	VERB
dpc-4769	91	17	with	with	ADP
dpc-4769	91	18	achieving	achieve	VERB
dpc-4769	91	19	a	a	DET
dpc-4769	91	20	pasi	pasi	NOUN
dpc-4769	91	21	≤	≤	ADV
dpc-4769	91	22	5	5	NUM
dpc-4769	91	23	at	at	ADP
dpc-4769	91	24	week	week	NOUN
dpc-4769	91	25	16	16	NUM
dpc-4769	91	26	(	(	PUNCT
dpc-4769	91	27	or	or	CCONJ
dpc-4769	91	28	=	=	SYM
dpc-4769	91	29	4.51	4.51	NUM
dpc-4769	91	30	;	;	PUNCT
dpc-4769	91	31	95	95	NUM
dpc-4769	91	32	%	%	NOUN
dpc-4769	91	33	ci	ci	NOUN
dpc-4769	91	34	:	:	PUNCT
dpc-4769	91	35	2.891–5.923	2.891–5.923	NUM
dpc-4769	91	36	,	,	PUNCT
dpc-4769	91	37	p	p	X
dpc-4769	91	38	<	<	X
dpc-4769	91	39	0.001	0.001	NUM
dpc-4769	91	40	)	)	PUNCT
dpc-4769	91	41	.	.	PUNCT
dpc-4769	92	1	patients	patient	NOUN
dpc-4769	92	2	without	without	ADP
dpc-4769	92	3	psa	psa	NOUN
dpc-4769	92	4	at	at	ADP
dpc-4769	92	5	baseline	baseline	PROPN
dpc-4769	92	6	had	have	VERB
dpc-4769	92	7	higher	high	ADJ
dpc-4769	92	8	odds	odd	NOUN
dpc-4769	92	9	of	of	ADP
dpc-4769	92	10	achieving	achieve	VERB
dpc-4769	92	11	a	a	DET
dpc-4769	92	12	pasi	pasi	NOUN
dpc-4769	92	13	≤	≤	ADV
dpc-4769	92	14	5	5	NUM
dpc-4769	92	15	compared	compare	VERB
dpc-4769	92	16	to	to	ADP
dpc-4769	92	17	those	those	PRON
dpc-4769	92	18	with	with	ADP
dpc-4769	92	19	psa	psa	NOUN
dpc-4769	92	20	(	(	PUNCT
dpc-4769	92	21	or	or	CCONJ
dpc-4769	92	22	=	=	SYM
dpc-4769	92	23	3.8	3.8	NUM
dpc-4769	92	24	;	;	PUNCT
dpc-4769	92	25	95	95	NUM
dpc-4769	92	26	%	%	NOUN
dpc-4769	92	27	ci	ci	NOUN
dpc-4769	92	28	:	:	PUNCT
dpc-4769	92	29	1.193–5.530	1.193–5.530	NUM
dpc-4769	92	30	,	,	PUNCT
dpc-4769	92	31	p	p	X
dpc-4769	92	32	<	<	X
dpc-4769	92	33	0.05	0.05	NUM
dpc-4769	92	34	)	)	PUNCT
dpc-4769	92	35	.	.	PUNCT
dpc-4769	93	1	lastly	lastly	ADV
dpc-4769	93	2	,	,	PUNCT
dpc-4769	93	3	patients	patient	NOUN
dpc-4769	93	4	starting	start	VERB
dpc-4769	93	5	with	with	ADP
dpc-4769	93	6	tildrakizumab	tildrakizumab	NOUN
dpc-4769	93	7	100	100	NUM
dpc-4769	93	8	had	have	VERB
dpc-4769	93	9	significantly	significantly	ADV
dpc-4769	93	10	higher	high	ADJ
dpc-4769	93	11	odds	odd	NOUN
dpc-4769	93	12	of	of	ADP
dpc-4769	93	13	achieving	achieve	VERB
dpc-4769	93	14	a	a	DET
dpc-4769	93	15	pasi	pasi	NOUN
dpc-4769	93	16	≤	≤	ADV
dpc-4769	93	17	5	5	NUM
dpc-4769	93	18	at	at	ADP
dpc-4769	93	19	week	week	NOUN
dpc-4769	93	20	16	16	NUM
dpc-4769	93	21	compared	compare	VERB
dpc-4769	93	22	to	to	ADP
dpc-4769	93	23	naïve	naïve	ADJ
dpc-4769	93	24	patients	patient	NOUN
dpc-4769	93	25	(	(	PUNCT
dpc-4769	93	26	or	or	CCONJ
dpc-4769	93	27	=	=	SYM
dpc-4769	93	28	3.00	3.00	NUM
dpc-4769	93	29	;	;	PUNCT
dpc-4769	93	30	95	95	NUM
dpc-4769	93	31	%	%	NOUN
dpc-4769	93	32	ci	ci	NOUN
dpc-4769	93	33	:	:	PUNCT
dpc-4769	93	34	0.8482	0.8482	NUM
dpc-4769	93	35	–	–	PUNCT
dpc-4769	93	36	5.305	5.305	NUM
dpc-4769	93	37	,	,	PUNCT
dpc-4769	93	38	p	p	X
dpc-4769	93	39	<	<	X
dpc-4769	93	40	0.05	0.05	NUM
dpc-4769	93	41	)	)	PUNCT
dpc-4769	93	42	.	.	PUNCT
dpc-4769	94	1	other	other	ADJ
dpc-4769	94	2	variables	variable	NOUN
dpc-4769	94	3	showed	show	VERB
dpc-4769	94	4	associations	association	NOUN
dpc-4769	94	5	with	with	ADP
dpc-4769	94	6	no	no	DET
dpc-4769	94	7	statistical	statistical	ADJ
dpc-4769	94	8	significance	significance	NOUN
dpc-4769	94	9	.	.	PUNCT
dpc-4769	95	1	males	male	NOUN
dpc-4769	95	2	had	have	VERB
dpc-4769	95	3	higher	high	ADJ
dpc-4769	95	4	odds	odd	NOUN
dpc-4769	95	5	of	of	ADP
dpc-4769	95	6	achieving	achieve	VERB
dpc-4769	95	7	a	a	DET
dpc-4769	95	8	pasi	pasi	NOUN
dpc-4769	95	9	≤	≤	ADV
dpc-4769	95	10	5	5	NUM
dpc-4769	95	11	compared	compare	VERB
dpc-4769	95	12	to	to	ADP
dpc-4769	95	13	females	female	NOUN
dpc-4769	95	14	.	.	PUNCT
dpc-4769	96	1	patients	patient	NOUN
dpc-4769	96	2	aged	age	VERB
dpc-4769	96	3	45	45	NUM
dpc-4769	96	4	-	-	SYM
dpc-4769	96	5	65	65	NUM
dpc-4769	96	6	had	have	VERB
dpc-4769	96	7	higher	high	ADJ
dpc-4769	96	8	odds	odd	NOUN
dpc-4769	96	9	of	of	ADP
dpc-4769	96	10	achieving	achieve	VERB
dpc-4769	96	11	a	a	DET
dpc-4769	96	12	pasi	pasi	NOUN
dpc-4769	96	13	≤	≤	ADV
dpc-4769	96	14	5	5	NUM
dpc-4769	96	15	compared	compare	VERB
dpc-4769	96	16	to	to	ADP
dpc-4769	96	17	those	those	PRON
dpc-4769	96	18	under	under	ADP
dpc-4769	96	19	45	45	NUM
dpc-4769	96	20	,	,	PUNCT
dpc-4769	96	21	while	while	SCONJ
dpc-4769	96	22	patients	patient	NOUN
dpc-4769	96	23	over	over	ADP
dpc-4769	96	24	65	65	NUM
dpc-4769	96	25	had	have	VERB
dpc-4769	96	26	lower	low	ADJ
dpc-4769	96	27	odds	odd	NOUN
dpc-4769	96	28	compared	compare	VERB
dpc-4769	96	29	to	to	ADP
dpc-4769	96	30	those	those	PRON
dpc-4769	96	31	under	under	ADP
dpc-4769	96	32	45	45	NUM
dpc-4769	96	33	.	.	PUNCT
dpc-4769	97	1	patients	patient	NOUN
dpc-4769	97	2	with	with	ADP
dpc-4769	97	3	a	a	DET
dpc-4769	97	4	bmi	bmi	NOUN
dpc-4769	97	5	between	between	ADP
dpc-4769	97	6	25	25	NUM
dpc-4769	97	7	and	and	CCONJ
dpc-4769	97	8	30	30	NUM
dpc-4769	97	9	also	also	ADV
dpc-4769	97	10	had	have	VERB
dpc-4769	97	11	higher	high	ADJ
dpc-4769	97	12	odds	odd	NOUN
dpc-4769	97	13	of	of	ADP
dpc-4769	97	14	achieving	achieve	VERB
dpc-4769	97	15	a	a	DET
dpc-4769	97	16	pasi	pasi	NOUN
dpc-4769	97	17	≤	≤	ADV
dpc-4769	97	18	5	5	NUM
dpc-4769	97	19	.	.	PUNCT
dpc-4769	98	1	patients	patient	NOUN
dpc-4769	98	2	with	with	ADP
dpc-4769	98	3	more	more	ADJ
dpc-4769	98	4	than	than	ADP
dpc-4769	98	5	two	two	NUM
dpc-4769	98	6	comorbidities	comorbiditie	NOUN
dpc-4769	98	7	had	have	VERB
dpc-4769	98	8	higher	high	ADJ
dpc-4769	98	9	odds	odd	NOUN
dpc-4769	98	10	of	of	ADP
dpc-4769	98	11	achieving	achieve	VERB
dpc-4769	98	12	a	a	DET
dpc-4769	98	13	pasi	pasi	NOUN
dpc-4769	98	14	<	<	X
dpc-4769	98	15	5	5	NUM
dpc-4769	98	16	compared	compare	VERB
dpc-4769	98	17	to	to	ADP
dpc-4769	98	18	those	those	PRON
dpc-4769	98	19	with	with	ADP
dpc-4769	98	20	fewer	few	ADJ
dpc-4769	98	21	than	than	ADP
dpc-4769	98	22	two	two	NUM
dpc-4769	98	23	comorbidities	comorbiditie	NOUN
dpc-4769	98	24	.	.	PUNCT
dpc-4769	99	1	patients	patient	NOUN
dpc-4769	99	2	with	with	ADP
dpc-4769	99	3	nail	nail	NOUN
dpc-4769	99	4	psoriasis	psoriasis	NOUN
dpc-4769	99	5	and	and	CCONJ
dpc-4769	99	6	genital	genital	ADJ
dpc-4769	99	7	psoriasis	psoriasis	NOUN
dpc-4769	99	8	had	have	VERB
dpc-4769	99	9	lower	low	ADJ
dpc-4769	99	10	odds	odd	NOUN
dpc-4769	99	11	of	of	ADP
dpc-4769	99	12	achieving	achieve	VERB
dpc-4769	99	13	a	a	DET
dpc-4769	99	14	pasi	pasi	NOUN
dpc-4769	99	15	≤	≤	ADV
dpc-4769	99	16	5	5	NUM
dpc-4769	99	17	compared	compare	VERB
dpc-4769	99	18	to	to	ADP
dpc-4769	99	19	those	those	PRON
dpc-4769	99	20	with	with	ADP
dpc-4769	99	21	trunk	trunk	NOUN
dpc-4769	99	22	psoriasis	psoriasis	NOUN
dpc-4769	99	23	.	.	PUNCT
dpc-4769	100	1	those	those	PRON
dpc-4769	100	2	with	with	ADP
dpc-4769	100	3	a	a	DET
dpc-4769	100	4	baseline	baseline	ADJ
dpc-4769	100	5	pasi	pasi	NOUN
dpc-4769	100	6	score	score	VERB
dpc-4769	100	7	greater	great	ADJ
dpc-4769	100	8	than	than	ADP
dpc-4769	100	9	10	10	NUM
dpc-4769	100	10	had	have	VERB
dpc-4769	100	11	higher	high	ADJ
dpc-4769	100	12	odds	odd	NOUN
dpc-4769	100	13	of	of	ADP
dpc-4769	100	14	achieving	achieve	VERB
dpc-4769	100	15	a	a	DET
dpc-4769	100	16	pasi	pasi	NOUN
dpc-4769	100	17	≤	≤	ADV
dpc-4769	100	18	5	5	NUM
dpc-4769	100	19	compared	compare	VERB
dpc-4769	100	20	to	to	ADP
dpc-4769	100	21	those	those	PRON
dpc-4769	100	22	with	with	ADP
dpc-4769	100	23	a	a	DET
dpc-4769	100	24	pasi	pasi	NOUN
dpc-4769	100	25	score	score	VERB
dpc-4769	100	26	less	less	ADJ
dpc-4769	100	27	than	than	ADP
dpc-4769	100	28	10	10	NUM
dpc-4769	100	29	.	.	PUNCT
dpc-4769	101	1	regarding	regard	VERB
dpc-4769	101	2	previous	previous	ADJ
dpc-4769	101	3	treatments	treatment	NOUN
dpc-4769	101	4	,	,	PUNCT
dpc-4769	101	5	patients	patient	NOUN
dpc-4769	101	6	who	who	PRON
dpc-4769	101	7	had	have	AUX
dpc-4769	101	8	been	be	AUX
dpc-4769	101	9	treated	treat	VERB
dpc-4769	101	10	with	with	ADP
dpc-4769	101	11	ciclosporin	ciclosporin	NOUN
dpc-4769	101	12	had	have	VERB
dpc-4769	101	13	higher	high	ADJ
dpc-4769	101	14	odds	odd	NOUN
dpc-4769	101	15	of	of	ADP
dpc-4769	101	16	achieving	achieve	VERB
dpc-4769	101	17	a	a	DET
dpc-4769	101	18	pasi	pasi	NOUN
dpc-4769	101	19	≤	≤	ADV
dpc-4769	101	20	5	5	NUM
dpc-4769	101	21	compared	compare	VERB
dpc-4769	101	22	to	to	ADP
dpc-4769	101	23	those	those	PRON
dpc-4769	101	24	treated	treat	VERB
dpc-4769	101	25	with	with	ADP
dpc-4769	101	26	methotrexate	methotrexate	NOUN
dpc-4769	101	27	,	,	PUNCT
dpc-4769	101	28	and	and	CCONJ
dpc-4769	101	29	those	those	PRON
dpc-4769	101	30	treated	treat	VERB
dpc-4769	101	31	with	with	ADP
dpc-4769	101	32	acitretin	acitretin	NOUN
dpc-4769	101	33	had	have	VERB
dpc-4769	101	34	similar	similar	ADJ
dpc-4769	101	35	odds	odd	NOUN
dpc-4769	101	36	.	.	PUNCT
dpc-4769	102	1	patients	patient	NOUN
dpc-4769	102	2	who	who	PRON
dpc-4769	102	3	had	have	AUX
dpc-4769	102	4	received	receive	VERB
dpc-4769	102	5	fewer	few	ADJ
dpc-4769	102	6	than	than	ADP
dpc-4769	102	7	two	two	NUM
dpc-4769	102	8	previous	previous	ADJ
dpc-4769	102	9	systemic	systemic	ADJ
dpc-4769	102	10	treatments	treatment	NOUN
dpc-4769	102	11	had	have	VERB
dpc-4769	102	12	higher	high	ADJ
dpc-4769	102	13	odds	odd	NOUN
dpc-4769	102	14	of	of	ADP
dpc-4769	102	15	achieving	achieve	VERB
dpc-4769	102	16	a	a	DET
dpc-4769	102	17	pasi	pasi	NOUN
dpc-4769	102	18	≤	≤	ADV
dpc-4769	102	19	5	5	NUM
dpc-4769	102	20	compared	compare	VERB
dpc-4769	102	21	to	to	ADP
dpc-4769	102	22	naïve	naïve	ADJ
dpc-4769	102	23	patients	patient	NOUN
dpc-4769	102	24	,	,	PUNCT
dpc-4769	102	25	true	true	ADJ
dpc-4769	102	26	also	also	ADV
dpc-4769	102	27	for	for	ADP
dpc-4769	102	28	those	those	PRON
dpc-4769	102	29	with	with	ADP
dpc-4769	102	30	more	more	ADJ
dpc-4769	102	31	than	than	ADP
dpc-4769	102	32	two	two	NUM
dpc-4769	102	33	previous	previous	ADJ
dpc-4769	102	34	treatments	treatment	NOUN
dpc-4769	102	35	(	(	PUNCT
dpc-4769	102	36	figure	figure	NOUN
dpc-4769	102	37	2	2	NUM
dpc-4769	102	38	)	)	PUNCT
dpc-4769	102	39	.	.	PUNCT
dpc-4769	103	1	discussion	discussion	NOUN
dpc-4769	103	2	this	this	DET
dpc-4769	103	3	study	study	NOUN
dpc-4769	103	4	undertook	undertake	VERB
dpc-4769	103	5	a	a	DET
dpc-4769	103	6	detailed	detailed	ADJ
dpc-4769	103	7	evaluation	evaluation	NOUN
dpc-4769	103	8	of	of	ADP
dpc-4769	103	9	patient	patient	ADJ
dpc-4769	103	10	characteristics	characteristic	NOUN
dpc-4769	103	11	to	to	PART
dpc-4769	103	12	determine	determine	VERB
dpc-4769	103	13	the	the	DET
dpc-4769	103	14	most	most	ADV
dpc-4769	103	15	suitable	suitable	ADJ
dpc-4769	103	16	candidates	candidate	NOUN
dpc-4769	103	17	for	for	ADP
dpc-4769	103	18	the	the	DET
dpc-4769	103	19	200	200	NUM
dpc-4769	103	20	mg	mg	ADJ
dpc-4769	103	21	dosage	dosage	NOUN
dpc-4769	103	22	of	of	ADP
dpc-4769	103	23	tildrakizumab	tildrakizumab	NOUN
dpc-4769	103	24	,	,	PUNCT
dpc-4769	103	25	a	a	DET
dpc-4769	103	26	drug	drug	NOUN
dpc-4769	103	27	used	use	VERB
dpc-4769	103	28	in	in	ADP
dpc-4769	103	29	the	the	DET
dpc-4769	103	30	treatment	treatment	NOUN
dpc-4769	103	31	of	of	ADP
dpc-4769	103	32	moderate	moderate	ADJ
dpc-4769	103	33	-	-	PUNCT
dpc-4769	103	34	to	to	ADP
dpc-4769	103	35	-	-	PUNCT
dpc-4769	103	36	severe	severe	ADJ
dpc-4769	103	37	psoriasis	psoriasis	NOUN
dpc-4769	103	38	.	.	PUNCT
dpc-4769	104	1	the	the	DET
dpc-4769	104	2	objective	objective	NOUN
dpc-4769	104	3	was	be	AUX
dpc-4769	104	4	to	to	PART
dpc-4769	104	5	identify	identify	VERB
dpc-4769	104	6	specific	specific	ADJ
dpc-4769	104	7	factors	factor	NOUN
dpc-4769	104	8	that	that	PRON
dpc-4769	104	9	enhance	enhance	VERB
dpc-4769	104	10	treatment	treatment	NOUN
dpc-4769	104	11	effectiveness	effectiveness	NOUN
dpc-4769	104	12	and	and	CCONJ
dpc-4769	104	13	safety	safety	NOUN
dpc-4769	104	14	,	,	PUNCT
dpc-4769	104	15	thereby	thereby	ADV
dpc-4769	104	16	optimizing	optimize	VERB
dpc-4769	104	17	patient	patient	ADJ
dpc-4769	104	18	outcomes	outcome	NOUN
dpc-4769	104	19	.	.	PUNCT
dpc-4769	105	1	comprehensive	comprehensive	ADJ
dpc-4769	105	2	data	datum	NOUN
dpc-4769	105	3	gathered	gather	VERB
dpc-4769	105	4	from	from	ADP
dpc-4769	105	5	multiple	multiple	ADJ
dpc-4769	105	6	clinical	clinical	ADJ
dpc-4769	105	7	sites	site	NOUN
dpc-4769	105	8	included	include	VERB
dpc-4769	105	9	patient	patient	ADJ
dpc-4769	105	10	demographics	demographic	NOUN
dpc-4769	105	11	,	,	PUNCT
dpc-4769	105	12	disease	disease	NOUN
dpc-4769	105	13	severity	severity	NOUN
dpc-4769	105	14	,	,	PUNCT
dpc-4769	105	15	previous	previous	ADJ
dpc-4769	105	16	treatment	treatment	NOUN
dpc-4769	105	17	histories	history	NOUN
dpc-4769	105	18	,	,	PUNCT
dpc-4769	105	19	and	and	CCONJ
dpc-4769	105	20	specific	specific	ADJ
dpc-4769	105	21	comorbidities	comorbiditie	NOUN
dpc-4769	105	22	including	include	VERB
dpc-4769	105	23	obesity	obesity	NOUN
dpc-4769	105	24	.	.	PUNCT
dpc-4769	106	1	our	our	PRON
dpc-4769	106	2	findings	finding	NOUN
dpc-4769	106	3	demonstrate	demonstrate	VERB
dpc-4769	106	4	a	a	DET
dpc-4769	106	5	significant	significant	ADJ
dpc-4769	106	6	reduction	reduction	NOUN
dpc-4769	106	7	in	in	ADP
dpc-4769	106	8	pasi	pasi	NOUN
dpc-4769	106	9	scores	score	NOUN
dpc-4769	106	10	as	as	ADV
dpc-4769	106	11	early	early	ADV
dpc-4769	106	12	as	as	ADP
dpc-4769	106	13	four	four	NUM
dpc-4769	106	14	weeks	week	NOUN
dpc-4769	106	15	after	after	ADP
dpc-4769	106	16	initiation	initiation	NOUN
dpc-4769	106	17	of	of	ADP
dpc-4769	106	18	tildrakizumab	tildrakizumab	NOUN
dpc-4769	106	19	200	200	NUM
dpc-4769	106	20	mg	mg	PROPN
dpc-4769	106	21	treatment	treatment	NOUN
dpc-4769	106	22	,	,	PUNCT
dpc-4769	106	23	with	with	ADP
dpc-4769	106	24	continued	continue	VERB
dpc-4769	106	25	improvement	improvement	NOUN
dpc-4769	106	26	observed	observe	VERB
dpc-4769	106	27	up	up	ADP
dpc-4769	106	28	to	to	PART
dpc-4769	106	29	28	28	NUM
dpc-4769	106	30	weeks	week	NOUN
dpc-4769	106	31	.	.	PUNCT
dpc-4769	107	1	these	these	DET
dpc-4769	107	2	results	result	NOUN
dpc-4769	107	3	are	be	AUX
dpc-4769	107	4	in	in	ADP
dpc-4769	107	5	line	line	NOUN
dpc-4769	107	6	with	with	ADP
dpc-4769	107	7	a	a	DET
dpc-4769	107	8	previous	previous	ADJ
dpc-4769	107	9	randomized	randomized	ADJ
dpc-4769	107	10	controlled	control	VERB
dpc-4769	107	11	trial	trial	NOUN
dpc-4769	107	12	[	[	X
dpc-4769	107	13	13	13	NUM
dpc-4769	107	14	]	]	PUNCT
dpc-4769	107	15	.	.	PUNCT
dpc-4769	108	1	this	this	PRON
dpc-4769	108	2	corroborates	corroborate	VERB
dpc-4769	108	3	with	with	ADP
dpc-4769	108	4	the	the	DET
dpc-4769	108	5	treatment	treatment	NOUN
dpc-4769	108	6	at	at	ADP
dpc-4769	108	7	the	the	DET
dpc-4769	108	8	time	time	NOUN
dpc-4769	108	9	of	of	ADP
dpc-4769	108	10	analysis	analysis	NOUN
dpc-4769	108	11	.	.	PUNCT
dpc-4769	109	1	at	at	ADP
dpc-4769	109	2	week	week	NOUN
dpc-4769	109	3	16	16	NUM
dpc-4769	109	4	,	,	PUNCT
dpc-4769	109	5	44	44	NUM
dpc-4769	109	6	patients	patient	NOUN
dpc-4769	109	7	had	have	AUX
dpc-4769	109	8	completed	complete	VERB
dpc-4769	109	9	the	the	DET
dpc-4769	109	10	treatment	treatment	NOUN
dpc-4769	109	11	.	.	PUNCT
dpc-4769	110	1	however	however	ADV
dpc-4769	110	2	,	,	PUNCT
dpc-4769	110	3	only	only	ADV
dpc-4769	110	4	24	24	NUM
dpc-4769	110	5	of	of	ADP
dpc-4769	110	6	these	these	DET
dpc-4769	110	7	44	44	NUM
dpc-4769	110	8	patients	patient	NOUN
dpc-4769	110	9	achieved	achieve	VERB
dpc-4769	110	10	a	a	DET
dpc-4769	110	11	pasi	pasi	NOUN
dpc-4769	110	12	score	score	VERB
dpc-4769	110	13	≤	≤	NUM
dpc-4769	110	14	5	5	NUM
dpc-4769	110	15	,	,	PUNCT
dpc-4769	110	16	which	which	PRON
dpc-4769	110	17	represents	represent	VERB
dpc-4769	110	18	the	the	DET
dpc-4769	110	19	subset	subset	NOUN
dpc-4769	110	20	of	of	ADP
dpc-4769	110	21	patients	patient	NOUN
dpc-4769	110	22	analyzed	analyze	VERB
dpc-4769	110	23	for	for	ADP
dpc-4769	110	24	effectiveness	effectiveness	NOUN
dpc-4769	110	25	at	at	ADP
dpc-4769	110	26	week	week	NOUN
dpc-4769	110	27	16	16	NUM
dpc-4769	110	28	.	.	PUNCT
dpc-4769	111	1	univariate	univariate	ADJ
dpc-4769	111	2	analysis	analysis	NOUN
dpc-4769	111	3	revealed	reveal	VERB
dpc-4769	111	4	several	several	ADJ
dpc-4769	111	5	baseline	baseline	ADJ
dpc-4769	111	6	patient	patient	ADJ
dpc-4769	111	7	table	table	NOUN
dpc-4769	111	8	1	1	NUM
dpc-4769	111	9	.	.	PUNCT
dpc-4769	111	10	patient	patient	ADJ
dpc-4769	111	11	features	feature	NOUN
dpc-4769	111	12	at	at	ADP
dpc-4769	111	13	baseline	baseline	NOUN
dpc-4769	111	14	(	(	PUNCT
dpc-4769	111	15	week	week	NOUN
dpc-4769	111	16	0	0	NUM
dpc-4769	111	17	)	)	PUNCT
dpc-4769	111	18	nb	nb	NOUN
dpc-4769	111	19	-	-	ADJ
dpc-4769	111	20	uvb	uvb	ADJ
dpc-4769	111	21	(	(	PUNCT
dpc-4769	111	22	narrow	narrow	ADJ
dpc-4769	111	23	band	band	NOUN
dpc-4769	111	24	–	–	PUNCT
dpc-4769	111	25	ultraviolet	ultraviolet	NOUN
dpc-4769	111	26	b	b	NOUN
dpc-4769	111	27	)	)	PUNCT
dpc-4769	111	28	.	.	PUNCT
dpc-4769	112	1	number	number	NOUN
dpc-4769	112	2	of	of	ADP
dpc-4769	112	3	patients	patient	NOUN
dpc-4769	112	4	54	54	NUM
dpc-4769	112	5	sex	sex	NOUN
dpc-4769	112	6	:	:	PUNCT
dpc-4769	112	7	male	male	ADJ
dpc-4769	112	8	female	female	NOUN
dpc-4769	112	9	36	36	NUM
dpc-4769	112	10	(	(	PUNCT
dpc-4769	112	11	66.7	66.7	NUM
dpc-4769	112	12	%	%	NOUN
dpc-4769	112	13	)	)	PUNCT
dpc-4769	112	14	18	18	NUM
dpc-4769	112	15	(	(	PUNCT
dpc-4769	112	16	33.3	33.3	NUM
dpc-4769	112	17	%	%	NOUN
dpc-4769	112	18	)	)	PUNCT
dpc-4769	112	19	mean	mean	NOUN
dpc-4769	112	20	age	age	NOUN
dpc-4769	112	21	(	(	PUNCT
dpc-4769	112	22	years	year	NOUN
dpc-4769	112	23	)	)	PUNCT
dpc-4769	112	24	52.9	52.9	NUM
dpc-4769	112	25	±	±	NUM
dpc-4769	112	26	12.6	12.6	NUM
dpc-4769	112	27	mean	mean	NOUN
dpc-4769	112	28	duration	duration	NOUN
dpc-4769	112	29	of	of	ADP
dpc-4769	112	30	psoriasis	psoriasis	NOUN
dpc-4769	112	31	(	(	PUNCT
dpc-4769	112	32	years	year	NOUN
dpc-4769	112	33	)	)	PUNCT
dpc-4769	112	34	18.3	18.3	NUM
dpc-4769	112	35	±	±	NUM
dpc-4769	112	36	10.9	10.9	NUM
dpc-4769	112	37	psoriatic	psoriatic	ADJ
dpc-4769	112	38	arthritis	arthritis	NOUN
dpc-4769	112	39	13	13	NUM
dpc-4769	112	40	(	(	PUNCT
dpc-4769	112	41	24	24	NUM
dpc-4769	112	42	%	%	NOUN
dpc-4769	112	43	)	)	PUNCT
dpc-4769	112	44	difficult	difficult	ADJ
dpc-4769	112	45	-	-	PUNCT
dpc-4769	112	46	to	to	ADP
dpc-4769	112	47	-	-	PUNCT
dpc-4769	112	48	treat	treat	VERB
dpc-4769	112	49	area	area	NOUN
dpc-4769	112	50	involvement	involvement	NOUN
dpc-4769	112	51	head	head	NOUN
dpc-4769	112	52	-	-	PUNCT
dpc-4769	112	53	neck	neck	NOUN
dpc-4769	112	54	palms	palm	NOUN
dpc-4769	112	55	or	or	CCONJ
dpc-4769	112	56	soles	sol	NOUN
dpc-4769	112	57	genital	genital	ADJ
dpc-4769	112	58	fingernails	fingernail	NOUN
dpc-4769	112	59	folds	fold	NOUN
dpc-4769	112	60	9	9	NUM
dpc-4769	112	61	(	(	PUNCT
dpc-4769	112	62	16.7	16.7	NUM
dpc-4769	112	63	%	%	NOUN
dpc-4769	112	64	)	)	PUNCT
dpc-4769	112	65	3	3	NUM
dpc-4769	112	66	(	(	PUNCT
dpc-4769	112	67	5.5	5.5	NUM
dpc-4769	112	68	%	%	NOUN
dpc-4769	112	69	)	)	PUNCT
dpc-4769	112	70	10	10	NUM
dpc-4769	112	71	(	(	PUNCT
dpc-4769	112	72	18.5	18.5	NUM
dpc-4769	112	73	%	%	NOUN
dpc-4769	112	74	)	)	PUNCT
dpc-4769	112	75	14	14	NUM
dpc-4769	112	76	(	(	PUNCT
dpc-4769	112	77	25.9	25.9	NUM
dpc-4769	112	78	%	%	NOUN
dpc-4769	112	79	)	)	PUNCT
dpc-4769	112	80	11	11	NUM
dpc-4769	112	81	(	(	PUNCT
dpc-4769	112	82	20.3	20.3	NUM
dpc-4769	112	83	%	%	NOUN
dpc-4769	112	84	)	)	PUNCT
dpc-4769	112	85	comorbidities	comorbiditie	NOUN
dpc-4769	112	86	:	:	PUNCT
dpc-4769	112	87	hypertension	hypertension	NOUN
dpc-4769	112	88	dyslipidemia	dyslipidemia	NOUN
dpc-4769	112	89	obesity	obesity	NOUN
dpc-4769	112	90	diabetes	diabetes	NOUN
dpc-4769	112	91	cardiopathy	cardiopathy	ADJ
dpc-4769	112	92	psychiatric	psychiatric	ADJ
dpc-4769	112	93	disorders	disorder	NOUN
dpc-4769	112	94	immune	immune	NOUN
dpc-4769	112	95	-	-	PUNCT
dpc-4769	112	96	mediated	mediate	VERB
dpc-4769	112	97	diseases	disease	NOUN
dpc-4769	112	98	atopy	atopy	VERB
dpc-4769	112	99	27	27	NUM
dpc-4769	112	100	(	(	PUNCT
dpc-4769	112	101	50	50	NUM
dpc-4769	112	102	%	%	NOUN
dpc-4769	112	103	)	)	PUNCT
dpc-4769	112	104	30	30	NUM
dpc-4769	112	105	(	(	PUNCT
dpc-4769	112	106	55.6	55.6	NUM
dpc-4769	112	107	%	%	NOUN
dpc-4769	112	108	)	)	PUNCT
dpc-4769	112	109	28	28	NUM
dpc-4769	112	110	(	(	PUNCT
dpc-4769	112	111	51.8	51.8	NUM
dpc-4769	112	112	%	%	NOUN
dpc-4769	112	113	)	)	PUNCT
dpc-4769	112	114	8	8	NUM
dpc-4769	112	115	(	(	PUNCT
dpc-4769	112	116	14.8	14.8	NUM
dpc-4769	112	117	%	%	NOUN
dpc-4769	112	118	)	)	PUNCT
dpc-4769	112	119	1	1	NUM
dpc-4769	112	120	(	(	PUNCT
dpc-4769	112	121	1.8	1.8	NUM
dpc-4769	112	122	%	%	NOUN
dpc-4769	112	123	)	)	PUNCT
dpc-4769	112	124	6	6	NUM
dpc-4769	112	125	(	(	PUNCT
dpc-4769	112	126	11.1	11.1	NUM
dpc-4769	112	127	%	%	NOUN
dpc-4769	112	128	)	)	PUNCT
dpc-4769	112	129	3	3	NUM
dpc-4769	112	130	(	(	PUNCT
dpc-4769	112	131	5.6	5.6	NUM
dpc-4769	112	132	%	%	NOUN
dpc-4769	112	133	)	)	PUNCT
dpc-4769	112	134	5	5	NUM
dpc-4769	112	135	(	(	PUNCT
dpc-4769	112	136	9.3	9.3	NUM
dpc-4769	112	137	%	%	NOUN
dpc-4769	112	138	)	)	PUNCT
dpc-4769	112	139	previous	previous	ADJ
dpc-4769	112	140	systemic	systemic	ADJ
dpc-4769	112	141	treatments	treatment	NOUN
dpc-4769	112	142	(	(	PUNCT
dpc-4769	112	143	conventional	conventional	ADJ
dpc-4769	112	144	):	):	PUNCT
dpc-4769	112	145	methotrexate	methotrexate	NOUN
dpc-4769	112	146	cyclosporine	cyclosporine	PROPN
dpc-4769	112	147	nb	nb	PROPN
dpc-4769	112	148	-	-	PUNCT
dpc-4769	112	149	uvb	uvb	ADJ
dpc-4769	112	150	phototherapy	phototherapy	NOUN
dpc-4769	112	151	acitretin	acitretin	VERB
dpc-4769	112	152	16	16	NUM
dpc-4769	112	153	(	(	PUNCT
dpc-4769	112	154	29.6	29.6	NUM
dpc-4769	112	155	%	%	NOUN
dpc-4769	112	156	)	)	PUNCT
dpc-4769	112	157	31	31	NUM
dpc-4769	112	158	(	(	PUNCT
dpc-4769	112	159	57.4	57.4	NUM
dpc-4769	112	160	%	%	NOUN
dpc-4769	112	161	)	)	PUNCT
dpc-4769	112	162	19	19	NUM
dpc-4769	112	163	(	(	PUNCT
dpc-4769	112	164	35.2	35.2	NUM
dpc-4769	112	165	%	%	NOUN
dpc-4769	112	166	)	)	PUNCT
dpc-4769	112	167	16	16	NUM
dpc-4769	112	168	(	(	PUNCT
dpc-4769	112	169	29.6	29.6	NUM
dpc-4769	112	170	%	%	NOUN
dpc-4769	112	171	)	)	PUNCT
dpc-4769	112	172	bionaïve	bionaïve	NOUN
dpc-4769	112	173	13	13	NUM
dpc-4769	112	174	(	(	PUNCT
dpc-4769	112	175	24.1	24.1	NUM
dpc-4769	112	176	%	%	NOUN
dpc-4769	112	177	)	)	PUNCT
dpc-4769	112	178	previous	previous	ADJ
dpc-4769	112	179	biologic	biologic	NOUN
dpc-4769	112	180	treatments	treatment	NOUN
dpc-4769	112	181	:	:	PUNCT
dpc-4769	112	182	anti	anti	ADJ
dpc-4769	112	183	-	-	ADJ
dpc-4769	112	184	tnfα	tnfα	ADJ
dpc-4769	112	185	adalimumab	adalimumab	NOUN
dpc-4769	112	186	etanercept	etanercept	NOUN
dpc-4769	112	187	infliximab	infliximab	PROPN
dpc-4769	112	188	golimumab	golimumab	PROPN
dpc-4769	112	189	certolizumab	certolizumab	PROPN
dpc-4769	112	190	anti	anti	ADJ
dpc-4769	112	191	-	-	ADJ
dpc-4769	112	192	il-12/23	il-12/23	ADJ
dpc-4769	112	193	ustekinumab	ustekinumab	NOUN
dpc-4769	112	194	anti	anti	ADJ
dpc-4769	112	195	-	-	ADJ
dpc-4769	112	196	il-17	il-17	ADV
dpc-4769	112	197	secukinumab	secukinumab	NOUN
dpc-4769	112	198	ixekizumab	ixekizumab	PROPN
dpc-4769	112	199	brodalumab	brodalumab	PROPN
dpc-4769	112	200	bimekizumab	bimekizumab	ADP
dpc-4769	112	201	anti	anti	ADJ
dpc-4769	112	202	-	-	ADJ
dpc-4769	112	203	il-23	il-23	ADJ
dpc-4769	112	204	risankizumab	risankizumab	NOUN
dpc-4769	112	205	guselkumab	guselkumab	NOUN
dpc-4769	112	206	19	19	NUM
dpc-4769	112	207	(	(	PUNCT
dpc-4769	112	208	35.2	35.2	NUM
dpc-4769	112	209	%	%	NOUN
dpc-4769	112	210	)	)	PUNCT
dpc-4769	112	211	5	5	NUM
dpc-4769	112	212	(	(	PUNCT
dpc-4769	112	213	9.3	9.3	NUM
dpc-4769	112	214	%	%	NOUN
dpc-4769	112	215	)	)	PUNCT
dpc-4769	112	216	2	2	NUM
dpc-4769	112	217	(	(	PUNCT
dpc-4769	112	218	3.7	3.7	NUM
dpc-4769	112	219	%	%	NOUN
dpc-4769	112	220	)	)	PUNCT
dpc-4769	112	221	2	2	NUM
dpc-4769	112	222	(	(	PUNCT
dpc-4769	112	223	3.7	3.7	NUM
dpc-4769	112	224	%	%	NOUN
dpc-4769	112	225	)	)	PUNCT
dpc-4769	112	226	0	0	NUM
dpc-4769	112	227	9	9	NUM
dpc-4769	112	228	(	(	PUNCT
dpc-4769	112	229	16.7	16.7	NUM
dpc-4769	112	230	%	%	NOUN
dpc-4769	112	231	)	)	PUNCT
dpc-4769	112	232	7	7	NUM
dpc-4769	112	233	(	(	PUNCT
dpc-4769	112	234	12.9	12.9	NUM
dpc-4769	112	235	%	%	NOUN
dpc-4769	112	236	)	)	PUNCT
dpc-4769	112	237	3	3	NUM
dpc-4769	112	238	(	(	PUNCT
dpc-4769	112	239	5.6	5.6	NUM
dpc-4769	112	240	%	%	NOUN
dpc-4769	112	241	)	)	PUNCT
dpc-4769	112	242	3	3	NUM
dpc-4769	112	243	(	(	PUNCT
dpc-4769	112	244	5.6	5.6	NUM
dpc-4769	112	245	%	%	NOUN
dpc-4769	112	246	)	)	PUNCT
dpc-4769	112	247	0	0	NUM
dpc-4769	112	248	3	3	NUM
dpc-4769	112	249	(	(	PUNCT
dpc-4769	112	250	5.6	5.6	NUM
dpc-4769	112	251	%	%	NOUN
dpc-4769	112	252	)	)	PUNCT
dpc-4769	112	253	2	2	NUM
dpc-4769	112	254	(	(	PUNCT
dpc-4769	112	255	3.7	3.7	NUM
dpc-4769	112	256	%	%	NOUN
dpc-4769	112	257	)	)	PUNCT
dpc-4769	112	258	previous	previous	ADJ
dpc-4769	112	259	tildrakizumab	tildrakizumab	NOUN
dpc-4769	112	260	100	100	NUM
dpc-4769	112	261	mg	mg	PROPN
dpc-4769	112	262	treatments	treatment	NOUN
dpc-4769	112	263	:	:	PUNCT
dpc-4769	112	264	19	19	NUM
dpc-4769	112	265	(	(	PUNCT
dpc-4769	112	266	35.19	35.19	NUM
dpc-4769	112	267	%	%	NOUN
dpc-4769	112	268	)	)	PUNCT
dpc-4769	112	269	original	original	ADJ
dpc-4769	112	270	article	article	NOUN
dpc-4769	112	271	|	|	ADV
dpc-4769	112	272	dermatol	dermatol	ADJ
dpc-4769	112	273	pract	pract	NOUN
dpc-4769	112	274	concept	concept	NOUN
dpc-4769	112	275	.	.	PUNCT
dpc-4769	113	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	113	2	5	5	NUM
dpc-4769	113	3	figure	figure	NOUN
dpc-4769	113	4	1	1	NUM
dpc-4769	113	5	.	.	PUNCT
dpc-4769	114	1	mean	mean	VERB
dpc-4769	114	2	psoriasis	psoriasis	NOUN
dpc-4769	114	3	area	area	NOUN
dpc-4769	114	4	severity	severity	NOUN
dpc-4769	114	5	index	index	NOUN
dpc-4769	114	6	(	(	PUNCT
dpc-4769	114	7	pasi	pasi	NOUN
dpc-4769	114	8	)	)	PUNCT
dpc-4769	114	9	,	,	PUNCT
dpc-4769	114	10	body	body	NOUN
dpc-4769	114	11	surface	surface	NOUN
dpc-4769	114	12	area	area	NOUN
dpc-4769	114	13	(	(	PUNCT
dpc-4769	114	14	bsa	bsa	PROPN
dpc-4769	114	15	)	)	PUNCT
dpc-4769	114	16	,	,	PUNCT
dpc-4769	114	17	and	and	CCONJ
dpc-4769	114	18	dermatology	dermatology	NOUN
dpc-4769	114	19	life	life	NOUN
dpc-4769	114	20	quality	quality	NOUN
dpc-4769	114	21	index	index	NOUN
dpc-4769	114	22	(	(	PUNCT
dpc-4769	114	23	dlqi	dlqi	ADJ
dpc-4769	114	24	)	)	PUNCT
dpc-4769	114	25	score	score	NOUN
dpc-4769	114	26	values	value	NOUN
dpc-4769	114	27	.	.	PUNCT
dpc-4769	115	1	figure	figure	NOUN
dpc-4769	115	2	2	2	NUM
dpc-4769	115	3	.	.	PUNCT
dpc-4769	115	4	forest	forest	NOUN
dpc-4769	115	5	plot	plot	NOUN
dpc-4769	115	6	of	of	ADP
dpc-4769	115	7	the	the	DET
dpc-4769	115	8	fully	fully	ADV
dpc-4769	115	9	adjusted	adjust	VERB
dpc-4769	115	10	logistic	logistic	ADJ
dpc-4769	115	11	regression	regression	NOUN
dpc-4769	115	12	model	model	NOUN
dpc-4769	115	13	to	to	PART
dpc-4769	115	14	assess	assess	VERB
dpc-4769	115	15	the	the	DET
dpc-4769	115	16	association	association	NOUN
dpc-4769	115	17	between	between	ADP
dpc-4769	115	18	patients	patient	NOUN
dpc-4769	115	19	’	'	PUNCT
dpc-4769	115	20	baseline	baseline	PROPN
dpc-4769	115	21	characteristics	characteristic	NOUN
dpc-4769	115	22	and	and	CCONJ
dpc-4769	115	23	achieving	achieve	VERB
dpc-4769	115	24	a	a	DET
dpc-4769	115	25	pasi	pasi	NOUN
dpc-4769	115	26	≤	≤	ADV
dpc-4769	115	27	5	5	NUM
dpc-4769	115	28	at	at	ADP
dpc-4769	115	29	week	week	NOUN
dpc-4769	115	30	16	16	NUM
dpc-4769	115	31	.	.	PUNCT
dpc-4769	116	1	odds	odd	NOUN
dpc-4769	116	2	ratios	ratio	NOUN
dpc-4769	116	3	(	(	PUNCT
dpc-4769	116	4	or	or	CCONJ
dpc-4769	116	5	)	)	PUNCT
dpc-4769	116	6	and	and	CCONJ
dpc-4769	116	7	95	95	NUM
dpc-4769	116	8	%	%	NOUN
dpc-4769	116	9	confidence	confidence	NOUN
dpc-4769	116	10	intervals	interval	NOUN
dpc-4769	116	11	(	(	PUNCT
dpc-4769	116	12	ci	ci	NOUN
dpc-4769	116	13	)	)	PUNCT
dpc-4769	116	14	are	be	AUX
dpc-4769	116	15	depicted	depict	VERB
dpc-4769	116	16	.	.	PUNCT
dpc-4769	117	1	bmi	bmi	PROPN
dpc-4769	117	2	,	,	PUNCT
dpc-4769	117	3	body	body	NOUN
dpc-4769	117	4	mass	mass	PROPN
dpc-4769	117	5	index	index	NOUN
dpc-4769	117	6	;	;	PUNCT
dpc-4769	117	7	pasi	pasi	NOUN
dpc-4769	117	8	,	,	PUNCT
dpc-4769	117	9	psoriasis	psoriasis	NOUN
dpc-4769	117	10	area	area	NOUN
dpc-4769	117	11	severity	severity	NOUN
dpc-4769	117	12	index	index	NOUN
dpc-4769	117	13	;	;	PUNCT
dpc-4769	117	14	psa	psa	NOUN
dpc-4769	117	15	,	,	PUNCT
dpc-4769	117	16	psoriatic	psoriatic	ADJ
dpc-4769	117	17	arthritis	arthritis	NOUN
dpc-4769	117	18	.	.	PUNCT
dpc-4769	118	1	6	6	NUM
dpc-4769	118	2	original	original	ADJ
dpc-4769	118	3	article	article	NOUN
dpc-4769	118	4	|	|	ADV
dpc-4769	118	5	dermatol	dermatol	ADJ
dpc-4769	118	6	pract	pract	NOUN
dpc-4769	118	7	concept	concept	NOUN
dpc-4769	118	8	.	.	PUNCT
dpc-4769	119	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	119	2	psoriasis	psoriasis	NOUN
dpc-4769	119	3	,	,	PUNCT
dpc-4769	119	4	particularly	particularly	ADV
dpc-4769	119	5	in	in	ADP
dpc-4769	119	6	obese	obese	ADJ
dpc-4769	119	7	patients	patient	NOUN
dpc-4769	119	8	,	,	PUNCT
dpc-4769	119	9	suggests	suggest	VERB
dpc-4769	119	10	that	that	SCONJ
dpc-4769	119	11	treatment	treatment	NOUN
dpc-4769	119	12	strategies	strategy	NOUN
dpc-4769	119	13	should	should	AUX
dpc-4769	119	14	consider	consider	VERB
dpc-4769	119	15	patient	patient	NOUN
dpc-4769	119	16	-	-	PUNCT
dpc-4769	119	17	specific	specific	ADJ
dpc-4769	119	18	factors	factor	NOUN
dpc-4769	119	19	such	such	ADJ
dpc-4769	119	20	as	as	ADP
dpc-4769	119	21	bmi	bmi	NOUN
dpc-4769	119	22	to	to	PART
dpc-4769	119	23	optimize	optimize	VERB
dpc-4769	119	24	therapeutic	therapeutic	ADJ
dpc-4769	119	25	outcomes	outcome	NOUN
dpc-4769	119	26	.	.	PUNCT
dpc-4769	120	1	furthermore	furthermore	ADV
dpc-4769	120	2	,	,	PUNCT
dpc-4769	120	3	the	the	DET
dpc-4769	120	4	favorable	favorable	ADJ
dpc-4769	120	5	safety	safety	NOUN
dpc-4769	120	6	profile	profile	NOUN
dpc-4769	120	7	of	of	ADP
dpc-4769	120	8	tildrakizumab	tildrakizumab	NOUN
dpc-4769	120	9	200	200	NUM
dpc-4769	120	10	mg	mg	NOUN
dpc-4769	120	11	observed	observe	VERB
dpc-4769	120	12	in	in	ADP
dpc-4769	120	13	this	this	DET
dpc-4769	120	14	study	study	NOUN
dpc-4769	120	15	supports	support	VERB
dpc-4769	120	16	its	its	PRON
dpc-4769	120	17	use	use	NOUN
dpc-4769	120	18	as	as	ADP
dpc-4769	120	19	a	a	DET
dpc-4769	120	20	long	long	ADJ
dpc-4769	120	21	-	-	PUNCT
dpc-4769	120	22	term	term	NOUN
dpc-4769	120	23	treatment	treatment	NOUN
dpc-4769	120	24	option	option	NOUN
dpc-4769	120	25	for	for	ADP
dpc-4769	120	26	psoriasis	psoriasis	NOUN
dpc-4769	120	27	.	.	PUNCT
dpc-4769	121	1	this	this	DET
dpc-4769	121	2	study	study	NOUN
dpc-4769	121	3	highlighted	highlight	VERB
dpc-4769	121	4	several	several	ADJ
dpc-4769	121	5	baseline	baseline	ADJ
dpc-4769	121	6	patient	patient	ADJ
dpc-4769	121	7	characteristics	characteristic	NOUN
dpc-4769	121	8	that	that	PRON
dpc-4769	121	9	influence	influence	VERB
dpc-4769	121	10	the	the	DET
dpc-4769	121	11	effectiveness	effectiveness	NOUN
dpc-4769	121	12	of	of	ADP
dpc-4769	121	13	tildrakizumab	tildrakizumab	NOUN
dpc-4769	121	14	200	200	NUM
dpc-4769	121	15	mg	mg	ADJ
dpc-4769	121	16	treatment	treatment	NOUN
dpc-4769	121	17	in	in	ADP
dpc-4769	121	18	a	a	DET
dpc-4769	121	19	real	real	ADJ
dpc-4769	121	20	-	-	PUNCT
dpc-4769	121	21	world	world	NOUN
dpc-4769	121	22	population	population	NOUN
dpc-4769	121	23	with	with	ADP
dpc-4769	121	24	moderate	moderate	ADJ
dpc-4769	121	25	-	-	PUNCT
dpc-4769	121	26	to	to	ADP
dpc-4769	121	27	-	-	PUNCT
dpc-4769	121	28	severe	severe	ADJ
dpc-4769	121	29	plaque	plaque	NOUN
dpc-4769	121	30	psoriasis	psoriasis	NOUN
dpc-4769	121	31	.	.	PUNCT
dpc-4769	122	1	the	the	DET
dpc-4769	122	2	results	result	NOUN
dpc-4769	122	3	emphasize	emphasize	VERB
dpc-4769	122	4	the	the	DET
dpc-4769	122	5	importance	importance	NOUN
dpc-4769	122	6	of	of	ADP
dpc-4769	122	7	considering	consider	VERB
dpc-4769	122	8	specific	specific	ADJ
dpc-4769	122	9	demographic	demographic	ADJ
dpc-4769	122	10	and	and	CCONJ
dpc-4769	122	11	clinical	clinical	ADJ
dpc-4769	122	12	factors	factor	NOUN
dpc-4769	122	13	when	when	SCONJ
dpc-4769	122	14	predicting	predict	VERB
dpc-4769	122	15	treatment	treatment	NOUN
dpc-4769	122	16	response	response	NOUN
dpc-4769	122	17	.	.	PUNCT
dpc-4769	123	1	univariate	univariate	ADJ
dpc-4769	123	2	analysis	analysis	NOUN
dpc-4769	123	3	revealed	reveal	VERB
dpc-4769	123	4	several	several	ADJ
dpc-4769	123	5	baseline	baseline	ADJ
dpc-4769	123	6	patient	patient	ADJ
dpc-4769	123	7	characteristics	characteristic	NOUN
dpc-4769	123	8	significantly	significantly	ADV
dpc-4769	123	9	associated	associate	VERB
dpc-4769	123	10	with	with	ADP
dpc-4769	123	11	achieving	achieve	VERB
dpc-4769	123	12	a	a	DET
dpc-4769	123	13	pasi	pasi	NOUN
dpc-4769	123	14	≤	≤	ADV
dpc-4769	123	15	5	5	NUM
dpc-4769	123	16	at	at	ADP
dpc-4769	123	17	week	week	NOUN
dpc-4769	123	18	16	16	NUM
dpc-4769	123	19	.	.	PUNCT
dpc-4769	124	1	firstly	firstly	ADV
dpc-4769	124	2	,	,	PUNCT
dpc-4769	124	3	patients	patient	NOUN
dpc-4769	124	4	with	with	ADP
dpc-4769	124	5	a	a	DET
dpc-4769	124	6	bmi	bmi	NOUN
dpc-4769	124	7	over	over	ADP
dpc-4769	124	8	30	30	NUM
dpc-4769	124	9	showed	show	VERB
dpc-4769	124	10	significantly	significantly	ADV
dpc-4769	124	11	higher	high	ADJ
dpc-4769	124	12	odds	odd	NOUN
dpc-4769	124	13	of	of	ADP
dpc-4769	124	14	achieving	achieve	VERB
dpc-4769	124	15	a	a	DET
dpc-4769	124	16	pasi	pasi	NOUN
dpc-4769	124	17	≤	≤	ADV
dpc-4769	124	18	5	5	NUM
dpc-4769	124	19	at	at	ADP
dpc-4769	124	20	week	week	NOUN
dpc-4769	124	21	16	16	NUM
dpc-4769	124	22	.	.	PUNCT
dpc-4769	125	1	this	this	DET
dpc-4769	125	2	finding	finding	NOUN
dpc-4769	125	3	suggests	suggest	VERB
dpc-4769	125	4	that	that	SCONJ
dpc-4769	125	5	tildrakizumab	tildrakizumab	NOUN
dpc-4769	125	6	is	be	AUX
dpc-4769	125	7	particularly	particularly	ADV
dpc-4769	125	8	effective	effective	ADJ
dpc-4769	125	9	in	in	ADP
dpc-4769	125	10	obese	obese	ADJ
dpc-4769	125	11	patients	patient	NOUN
dpc-4769	125	12	.	.	PUNCT
dpc-4769	126	1	the	the	DET
dpc-4769	126	2	pasi	pasi	NOUN
dpc-4769	126	3	reduction	reduction	NOUN
dpc-4769	126	4	in	in	ADP
dpc-4769	126	5	these	these	DET
dpc-4769	126	6	patients	patient	NOUN
dpc-4769	126	7	could	could	AUX
dpc-4769	126	8	be	be	AUX
dpc-4769	126	9	attributed	attribute	VERB
dpc-4769	126	10	to	to	ADP
dpc-4769	126	11	tildrakizumab	tildrakizumab	NOUN
dpc-4769	126	12	’s	’s	PART
dpc-4769	126	13	ability	ability	NOUN
dpc-4769	126	14	to	to	PART
dpc-4769	126	15	effectively	effectively	ADV
dpc-4769	126	16	modulate	modulate	VERB
dpc-4769	126	17	inflammatory	inflammatory	ADJ
dpc-4769	126	18	pathways	pathway	NOUN
dpc-4769	126	19	that	that	PRON
dpc-4769	126	20	are	be	AUX
dpc-4769	126	21	upregulated	upregulate	VERB
dpc-4769	126	22	in	in	ADP
dpc-4769	126	23	obesity	obesity	NOUN
dpc-4769	126	24	[	[	X
dpc-4769	126	25	27	27	NUM
dpc-4769	126	26	]	]	PUNCT
dpc-4769	126	27	.	.	PUNCT
dpc-4769	127	1	a	a	DET
dpc-4769	127	2	recent	recent	ADJ
dpc-4769	127	3	study	study	NOUN
dpc-4769	127	4	evaluated	evaluate	VERB
dpc-4769	127	5	the	the	DET
dpc-4769	127	6	effectiveness	effectiveness	NOUN
dpc-4769	127	7	and	and	CCONJ
dpc-4769	127	8	safety	safety	NOUN
dpc-4769	127	9	of	of	ADP
dpc-4769	127	10	tildrakizumab	tildrakizumab	NOUN
dpc-4769	127	11	200	200	NUM
dpc-4769	127	12	mg	mg	NOUN
dpc-4769	127	13	in	in	ADP
dpc-4769	127	14	obese	obese	ADJ
dpc-4769	127	15	patients	patient	NOUN
dpc-4769	127	16	with	with	ADP
dpc-4769	127	17	moderate	moderate	ADJ
dpc-4769	127	18	-	-	PUNCT
dpc-4769	127	19	to	to	ADP
dpc-4769	127	20	severe	severe	ADJ
dpc-4769	127	21	psoriasis	psoriasis	NOUN
dpc-4769	127	22	,	,	PUNCT
dpc-4769	127	23	suggesting	suggest	VERB
dpc-4769	127	24	that	that	SCONJ
dpc-4769	127	25	this	this	DET
dpc-4769	127	26	higher	high	ADJ
dpc-4769	127	27	dose	dose	NOUN
dpc-4769	127	28	may	may	AUX
dpc-4769	127	29	be	be	AUX
dpc-4769	127	30	more	more	ADV
dpc-4769	127	31	effective	effective	ADJ
dpc-4769	127	32	than	than	ADP
dpc-4769	127	33	the	the	DET
dpc-4769	127	34	100	100	NUM
dpc-4769	127	35	mg	mg	NOUN
dpc-4769	127	36	dose	dose	NOUN
dpc-4769	127	37	in	in	ADP
dpc-4769	127	38	patients	patient	NOUN
dpc-4769	127	39	weighing	weigh	VERB
dpc-4769	127	40	≥	≥	NOUN
dpc-4769	127	41	90	90	NUM
dpc-4769	127	42	kg	kg	NOUN
dpc-4769	127	43	with	with	ADP
dpc-4769	127	44	high	high	ADJ
dpc-4769	127	45	disease	disease	NOUN
dpc-4769	127	46	burden	burden	NOUN
dpc-4769	127	47	[	[	X
dpc-4769	127	48	14	14	NUM
dpc-4769	127	49	]	]	PUNCT
dpc-4769	127	50	.	.	PUNCT
dpc-4769	128	1	second	second	ADJ
dpc-4769	128	2	,	,	PUNCT
dpc-4769	128	3	a	a	DET
dpc-4769	128	4	disease	disease	NOUN
dpc-4769	128	5	duration	duration	NOUN
dpc-4769	128	6	of	of	ADP
dpc-4769	128	7	greater	great	ADJ
dpc-4769	128	8	than	than	ADP
dpc-4769	128	9	two	two	NUM
dpc-4769	128	10	years	year	NOUN
dpc-4769	128	11	was	be	AUX
dpc-4769	128	12	associated	associate	VERB
dpc-4769	128	13	with	with	ADP
dpc-4769	128	14	a	a	DET
dpc-4769	128	15	significant	significant	ADJ
dpc-4769	128	16	improvement	improvement	NOUN
dpc-4769	128	17	in	in	ADP
dpc-4769	128	18	pasi	pasi	NOUN
dpc-4769	128	19	.	.	PUNCT
dpc-4769	129	1	our	our	PRON
dpc-4769	129	2	findings	finding	NOUN
dpc-4769	129	3	suggest	suggest	VERB
dpc-4769	129	4	that	that	SCONJ
dpc-4769	129	5	tildrakizumab	tildrakizumab	NOUN
dpc-4769	129	6	may	may	AUX
dpc-4769	129	7	be	be	AUX
dpc-4769	129	8	particularly	particularly	ADV
dpc-4769	129	9	effective	effective	ADJ
dpc-4769	129	10	in	in	ADP
dpc-4769	129	11	patients	patient	NOUN
dpc-4769	129	12	with	with	ADP
dpc-4769	129	13	a	a	DET
dpc-4769	129	14	longer	long	ADJ
dpc-4769	129	15	disease	disease	NOUN
dpc-4769	129	16	duration	duration	NOUN
dpc-4769	129	17	.	.	PUNCT
dpc-4769	130	1	however	however	ADV
dpc-4769	130	2	,	,	PUNCT
dpc-4769	130	3	it	it	PRON
dpc-4769	130	4	is	be	AUX
dpc-4769	130	5	worth	worth	ADJ
dpc-4769	130	6	noting	note	VERB
dpc-4769	130	7	that	that	SCONJ
dpc-4769	130	8	other	other	ADJ
dpc-4769	130	9	studies	study	NOUN
dpc-4769	130	10	on	on	ADP
dpc-4769	130	11	il-23	il-23	NOUN
dpc-4769	130	12	inhibitors	inhibitor	NOUN
dpc-4769	130	13	,	,	PUNCT
dpc-4769	130	14	such	such	ADJ
dpc-4769	130	15	as	as	ADP
dpc-4769	130	16	risankizumab	risankizumab	NOUN
dpc-4769	130	17	and	and	CCONJ
dpc-4769	130	18	guselkumab	guselkumab	NOUN
dpc-4769	130	19	,	,	PUNCT
dpc-4769	130	20	have	have	AUX
dpc-4769	130	21	reported	report	VERB
dpc-4769	130	22	different	different	ADJ
dpc-4769	130	23	outcomes	outcome	NOUN
dpc-4769	130	24	regarding	regard	VERB
dpc-4769	130	25	disease	disease	NOUN
dpc-4769	130	26	duration	duration	NOUN
dpc-4769	130	27	[	[	X
dpc-4769	130	28	28,29	28,29	X
dpc-4769	130	29	]	]	X
dpc-4769	130	30	.	.	PUNCT
dpc-4769	131	1	for	for	ADP
dpc-4769	131	2	instance	instance	NOUN
dpc-4769	131	3	,	,	PUNCT
dpc-4769	131	4	schäkel	schäkel	ADV
dpc-4769	131	5	et	et	PROPN
dpc-4769	131	6	al	al	PROPN
dpc-4769	131	7	.	.	PUNCT
dpc-4769	132	1	[	[	X
dpc-4769	132	2	29	29	NUM
dpc-4769	132	3	]	]	PUNCT
dpc-4769	132	4	observed	observe	VERB
dpc-4769	132	5	that	that	SCONJ
dpc-4769	132	6	patients	patient	NOUN
dpc-4769	132	7	with	with	ADP
dpc-4769	132	8	a	a	DET
dpc-4769	132	9	shorter	short	ADJ
dpc-4769	132	10	disease	disease	NOUN
dpc-4769	132	11	duration	duration	NOUN
dpc-4769	132	12	(	(	PUNCT
dpc-4769	132	13	≤2	≤2	NOUN
dpc-4769	132	14	years	year	NOUN
dpc-4769	132	15	)	)	PUNCT
dpc-4769	132	16	experienced	experience	VERB
dpc-4769	132	17	higher	high	ADJ
dpc-4769	132	18	rates	rate	NOUN
dpc-4769	132	19	of	of	ADP
dpc-4769	132	20	complete	complete	ADJ
dpc-4769	132	21	skin	skin	NOUN
dpc-4769	132	22	clearance	clearance	NOUN
dpc-4769	132	23	and	and	CCONJ
dpc-4769	132	24	faster	fast	ADJ
dpc-4769	132	25	responses	response	NOUN
dpc-4769	132	26	compared	compare	VERB
dpc-4769	132	27	to	to	ADP
dpc-4769	132	28	those	those	PRON
dpc-4769	132	29	with	with	ADP
dpc-4769	132	30	longer	long	ADJ
dpc-4769	132	31	disease	disease	NOUN
dpc-4769	132	32	duration	duration	NOUN
dpc-4769	132	33	.	.	PUNCT
dpc-4769	133	1	these	these	DET
dpc-4769	133	2	contrasting	contrast	VERB
dpc-4769	133	3	results	result	NOUN
dpc-4769	133	4	indicate	indicate	VERB
dpc-4769	133	5	that	that	SCONJ
dpc-4769	133	6	the	the	DET
dpc-4769	133	7	impact	impact	NOUN
dpc-4769	133	8	of	of	ADP
dpc-4769	133	9	disease	disease	NOUN
dpc-4769	133	10	duration	duration	NOUN
dpc-4769	133	11	on	on	ADP
dpc-4769	133	12	treatment	treatment	NOUN
dpc-4769	133	13	outcomes	outcome	NOUN
dpc-4769	133	14	may	may	AUX
dpc-4769	133	15	vary	vary	VERB
dpc-4769	133	16	depending	depend	VERB
dpc-4769	133	17	on	on	ADP
dpc-4769	133	18	the	the	DET
dpc-4769	133	19	specific	specific	ADJ
dpc-4769	133	20	il-23	il-23	NOUN
dpc-4769	133	21	inhibitor	inhibitor	NOUN
dpc-4769	133	22	used	use	VERB
dpc-4769	133	23	.	.	PUNCT
dpc-4769	134	1	another	another	DET
dpc-4769	134	2	important	important	ADJ
dpc-4769	134	3	factor	factor	NOUN
dpc-4769	134	4	is	be	AUX
dpc-4769	134	5	the	the	DET
dpc-4769	134	6	absence	absence	NOUN
dpc-4769	134	7	of	of	ADP
dpc-4769	134	8	psa	psa	NOUN
dpc-4769	134	9	at	at	ADP
dpc-4769	134	10	baseline	baseline	NOUN
dpc-4769	134	11	,	,	PUNCT
dpc-4769	134	12	which	which	PRON
dpc-4769	134	13	was	be	AUX
dpc-4769	134	14	associated	associate	VERB
dpc-4769	134	15	with	with	ADP
dpc-4769	134	16	better	well	ADJ
dpc-4769	134	17	treatment	treatment	NOUN
dpc-4769	134	18	outcomes	outcome	NOUN
dpc-4769	134	19	.	.	PUNCT
dpc-4769	135	1	this	this	PRON
dpc-4769	135	2	suggests	suggest	VERB
dpc-4769	135	3	that	that	SCONJ
dpc-4769	135	4	the	the	DET
dpc-4769	135	5	presence	presence	NOUN
dpc-4769	135	6	of	of	ADP
dpc-4769	135	7	joint	joint	ADJ
dpc-4769	135	8	comorbidities	comorbiditie	NOUN
dpc-4769	135	9	might	might	AUX
dpc-4769	135	10	negatively	negatively	ADV
dpc-4769	135	11	influence	influence	VERB
dpc-4769	135	12	the	the	DET
dpc-4769	135	13	response	response	NOUN
dpc-4769	135	14	to	to	ADP
dpc-4769	135	15	tildrakizumab	tildrakizumab	NOUN
dpc-4769	135	16	,	,	PUNCT
dpc-4769	135	17	possibly	possibly	ADV
dpc-4769	135	18	due	due	ADP
dpc-4769	135	19	to	to	ADP
dpc-4769	135	20	the	the	DET
dpc-4769	135	21	increased	increase	VERB
dpc-4769	135	22	complexity	complexity	NOUN
dpc-4769	135	23	of	of	ADP
dpc-4769	135	24	disease	disease	NOUN
dpc-4769	135	25	management	management	NOUN
dpc-4769	135	26	in	in	ADP
dpc-4769	135	27	these	these	DET
dpc-4769	135	28	patients	patient	NOUN
dpc-4769	135	29	.	.	PUNCT
dpc-4769	136	1	finally	finally	ADV
dpc-4769	136	2	,	,	PUNCT
dpc-4769	136	3	patients	patient	NOUN
dpc-4769	136	4	who	who	PRON
dpc-4769	136	5	started	start	VERB
dpc-4769	136	6	with	with	ADP
dpc-4769	136	7	a	a	DET
dpc-4769	136	8	100	100	NUM
dpc-4769	136	9	mg	mg	NOUN
dpc-4769	136	10	dose	dose	NOUN
dpc-4769	136	11	of	of	ADP
dpc-4769	136	12	tildrakizumab	tildrakizumab	NOUN
dpc-4769	136	13	before	before	ADP
dpc-4769	136	14	switching	switch	VERB
dpc-4769	136	15	to	to	ADP
dpc-4769	136	16	200	200	NUM
dpc-4769	136	17	mg	mg	NOUN
dpc-4769	136	18	showed	show	VERB
dpc-4769	136	19	significantly	significantly	ADV
dpc-4769	136	20	higher	high	ADJ
dpc-4769	136	21	odds	odd	NOUN
dpc-4769	136	22	of	of	ADP
dpc-4769	136	23	achieving	achieve	VERB
dpc-4769	136	24	a	a	DET
dpc-4769	136	25	pasi	pasi	NOUN
dpc-4769	136	26	≤	≤	ADV
dpc-4769	136	27	5	5	NUM
dpc-4769	136	28	compared	compare	VERB
dpc-4769	136	29	to	to	ADP
dpc-4769	136	30	naive	naive	ADJ
dpc-4769	136	31	patients	patient	NOUN
dpc-4769	136	32	.	.	PUNCT
dpc-4769	137	1	this	this	PRON
dpc-4769	137	2	might	might	AUX
dpc-4769	137	3	reflect	reflect	VERB
dpc-4769	137	4	an	an	DET
dpc-4769	137	5	initial	initial	ADJ
dpc-4769	137	6	dosage	dosage	NOUN
dpc-4769	137	7	adjustment	adjustment	NOUN
dpc-4769	137	8	that	that	PRON
dpc-4769	137	9	allows	allow	VERB
dpc-4769	137	10	for	for	ADP
dpc-4769	137	11	optimizing	optimize	VERB
dpc-4769	137	12	treatment	treatment	NOUN
dpc-4769	137	13	effectivenesswithout	effectivenesswithout	NOUN
dpc-4769	137	14	significantly	significantly	ADV
dpc-4769	137	15	increasing	increase	VERB
dpc-4769	137	16	the	the	DET
dpc-4769	137	17	risk	risk	NOUN
dpc-4769	137	18	of	of	ADP
dpc-4769	137	19	adverse	adverse	ADJ
dpc-4769	137	20	events	event	NOUN
dpc-4769	137	21	.	.	PUNCT
dpc-4769	138	1	other	other	ADJ
dpc-4769	138	2	variables	variable	NOUN
dpc-4769	138	3	that	that	PRON
dpc-4769	138	4	showed	show	VERB
dpc-4769	138	5	associations	association	NOUN
dpc-4769	138	6	,	,	PUNCT
dpc-4769	138	7	though	though	SCONJ
dpc-4769	138	8	not	not	PART
dpc-4769	138	9	statistically	statistically	ADV
dpc-4769	138	10	significant	significant	ADJ
dpc-4769	138	11	,	,	PUNCT
dpc-4769	138	12	still	still	ADV
dpc-4769	138	13	provide	provide	VERB
dpc-4769	138	14	useful	useful	ADJ
dpc-4769	138	15	insights	insight	NOUN
dpc-4769	138	16	for	for	ADP
dpc-4769	138	17	clinical	clinical	ADJ
dpc-4769	138	18	practice	practice	NOUN
dpc-4769	138	19	,	,	PUNCT
dpc-4769	138	20	as	as	SCONJ
dpc-4769	138	21	shown	show	VERB
dpc-4769	138	22	in	in	ADP
dpc-4769	138	23	figure	figure	NOUN
dpc-4769	138	24	2	2	NUM
dpc-4769	138	25	.	.	PUNCT
dpc-4769	139	1	meta	meta	VERB
dpc-4769	139	2	-	-	PUNCT
dpc-4769	139	3	analysis	analysis	NOUN
dpc-4769	139	4	conducted	conduct	VERB
dpc-4769	139	5	by	by	ADP
dpc-4769	139	6	bilal	bilal	PROPN
dpc-4769	139	7	j	j	PROPN
dpc-4769	139	8	et	et	PROPN
dpc-4769	139	9	al	al	PROPN
dpc-4769	139	10	.	.	PROPN
dpc-4769	139	11	which	which	PRON
dpc-4769	139	12	highlighted	highlight	VERB
dpc-4769	139	13	the	the	DET
dpc-4769	139	14	drug	drug	NOUN
dpc-4769	139	15	’s	’s	PART
dpc-4769	139	16	robust	robust	ADJ
dpc-4769	139	17	efficacy	efficacy	NOUN
dpc-4769	139	18	profile	profile	NOUN
dpc-4769	139	19	[	[	X
dpc-4769	139	20	17	17	NUM
dpc-4769	139	21	]	]	PUNCT
dpc-4769	139	22	.	.	PUNCT
dpc-4769	140	1	the	the	DET
dpc-4769	140	2	study	study	NOUN
dpc-4769	140	3	cohort	cohort	NOUN
dpc-4769	140	4	exhibited	exhibit	VERB
dpc-4769	140	5	a	a	DET
dpc-4769	140	6	variety	variety	NOUN
dpc-4769	140	7	of	of	ADP
dpc-4769	140	8	comorbid	comorbid	NOUN
dpc-4769	140	9	conditions	condition	NOUN
dpc-4769	140	10	,	,	PUNCT
dpc-4769	140	11	with	with	ADP
dpc-4769	140	12	dyslipidemia	dyslipidemia	NOUN
dpc-4769	140	13	,	,	PUNCT
dpc-4769	140	14	hypertension	hypertension	NOUN
dpc-4769	140	15	,	,	PUNCT
dpc-4769	140	16	and	and	CCONJ
dpc-4769	140	17	obesity	obesity	NOUN
dpc-4769	140	18	being	be	AUX
dpc-4769	140	19	the	the	DET
dpc-4769	140	20	most	most	ADV
dpc-4769	140	21	common	common	ADJ
dpc-4769	140	22	.	.	PUNCT
dpc-4769	141	1	notably	notably	ADV
dpc-4769	141	2	,	,	PUNCT
dpc-4769	141	3	a	a	DET
dpc-4769	141	4	substantial	substantial	ADJ
dpc-4769	141	5	proportion	proportion	NOUN
dpc-4769	141	6	of	of	ADP
dpc-4769	141	7	patients	patient	NOUN
dpc-4769	141	8	(	(	PUNCT
dpc-4769	141	9	51.8	51.8	NUM
dpc-4769	141	10	%	%	NOUN
dpc-4769	141	11	)	)	PUNCT
dpc-4769	141	12	were	be	AUX
dpc-4769	141	13	obese	obese	ADJ
dpc-4769	141	14	,	,	PUNCT
dpc-4769	141	15	presenting	present	VERB
dpc-4769	141	16	a	a	DET
dpc-4769	141	17	unique	unique	ADJ
dpc-4769	141	18	opportunity	opportunity	NOUN
dpc-4769	141	19	to	to	PART
dpc-4769	141	20	examine	examine	VERB
dpc-4769	141	21	the	the	DET
dpc-4769	141	22	efficacy	efficacy	NOUN
dpc-4769	141	23	of	of	ADP
dpc-4769	141	24	tildrakizumab	tildrakizumab	NOUN
dpc-4769	141	25	in	in	ADP
dpc-4769	141	26	this	this	DET
dpc-4769	141	27	subgroup	subgroup	NOUN
dpc-4769	141	28	.	.	PUNCT
dpc-4769	142	1	obesity	obesity	NOUN
dpc-4769	142	2	is	be	AUX
dpc-4769	142	3	recognized	recognize	VERB
dpc-4769	142	4	as	as	ADP
dpc-4769	142	5	a	a	DET
dpc-4769	142	6	factor	factor	NOUN
dpc-4769	142	7	that	that	PRON
dpc-4769	142	8	can	can	AUX
dpc-4769	142	9	potentially	potentially	ADV
dpc-4769	142	10	influence	influence	VERB
dpc-4769	142	11	the	the	DET
dpc-4769	142	12	pharmacokinetics	pharmacokinetic	NOUN
dpc-4769	142	13	and	and	CCONJ
dpc-4769	142	14	pharmacodynamics	pharmacodynamic	NOUN
dpc-4769	142	15	of	of	ADP
dpc-4769	142	16	biologic	biologic	NOUN
dpc-4769	142	17	therapies	therapy	NOUN
dpc-4769	142	18	,	,	PUNCT
dpc-4769	142	19	possibly	possibly	ADV
dpc-4769	142	20	necessitating	necessitate	VERB
dpc-4769	142	21	adjustments	adjustment	NOUN
dpc-4769	142	22	in	in	ADP
dpc-4769	142	23	dosing	dose	VERB
dpc-4769	142	24	strategies	strategy	NOUN
dpc-4769	142	25	to	to	PART
dpc-4769	142	26	achieve	achieve	VERB
dpc-4769	142	27	optimal	optimal	ADJ
dpc-4769	142	28	therapeutic	therapeutic	ADJ
dpc-4769	142	29	outcomes	outcome	NOUN
dpc-4769	143	1	[	[	X
dpc-4769	143	2	18	18	NUM
dpc-4769	143	3	-	-	SYM
dpc-4769	143	4	20	20	NUM
dpc-4769	143	5	]	]	PUNCT
dpc-4769	143	6	.	.	PUNCT
dpc-4769	144	1	the	the	DET
dpc-4769	144	2	administration	administration	NOUN
dpc-4769	144	3	of	of	ADP
dpc-4769	144	4	increased	increase	VERB
dpc-4769	144	5	dosages	dosage	NOUN
dpc-4769	144	6	of	of	ADP
dpc-4769	144	7	biologic	biologic	NOUN
dpc-4769	144	8	therapies	therapy	NOUN
dpc-4769	144	9	in	in	ADP
dpc-4769	144	10	obese	obese	ADJ
dpc-4769	144	11	patients	patient	NOUN
dpc-4769	144	12	with	with	ADP
dpc-4769	144	13	psoriasis	psoriasis	NOUN
dpc-4769	144	14	is	be	AUX
dpc-4769	144	15	a	a	DET
dpc-4769	144	16	subject	subject	NOUN
dpc-4769	144	17	of	of	ADP
dpc-4769	144	18	considerable	considerable	ADJ
dpc-4769	144	19	clinical	clinical	ADJ
dpc-4769	144	20	interest	interest	NOUN
dpc-4769	144	21	,	,	PUNCT
dpc-4769	144	22	reflecting	reflect	VERB
dpc-4769	144	23	the	the	DET
dpc-4769	144	24	broader	broad	ADJ
dpc-4769	144	25	shift	shift	NOUN
dpc-4769	144	26	towards	towards	ADP
dpc-4769	144	27	personalized	personalized	ADJ
dpc-4769	144	28	medicine	medicine	NOUN
dpc-4769	144	29	in	in	ADP
dpc-4769	144	30	dermatology	dermatology	NOUN
dpc-4769	144	31	.	.	PUNCT
dpc-4769	145	1	obesity	obesity	NOUN
dpc-4769	145	2	,	,	PUNCT
dpc-4769	145	3	a	a	DET
dpc-4769	145	4	common	common	ADJ
dpc-4769	145	5	comorbidity	comorbidity	NOUN
dpc-4769	145	6	in	in	ADP
dpc-4769	145	7	psoriasis	psoriasis	NOUN
dpc-4769	145	8	,	,	PUNCT
dpc-4769	145	9	not	not	PART
dpc-4769	145	10	only	only	ADV
dpc-4769	145	11	exacerbates	exacerbate	VERB
dpc-4769	145	12	the	the	DET
dpc-4769	145	13	severity	severity	NOUN
dpc-4769	145	14	and	and	CCONJ
dpc-4769	145	15	progression	progression	NOUN
dpc-4769	145	16	of	of	ADP
dpc-4769	145	17	the	the	DET
dpc-4769	145	18	disease	disease	NOUN
dpc-4769	145	19	but	but	CCONJ
dpc-4769	145	20	also	also	ADV
dpc-4769	145	21	influences	influence	VERB
dpc-4769	145	22	the	the	DET
dpc-4769	145	23	pharmacokinetic	pharmacokinetic	ADJ
dpc-4769	145	24	profiles	profile	NOUN
dpc-4769	145	25	of	of	ADP
dpc-4769	145	26	biologic	biologic	NOUN
dpc-4769	145	27	treatments	treatment	NOUN
dpc-4769	145	28	,	,	PUNCT
dpc-4769	145	29	necessitating	necessitate	VERB
dpc-4769	145	30	a	a	DET
dpc-4769	145	31	nuanced	nuanced	ADJ
dpc-4769	145	32	approach	approach	NOUN
dpc-4769	145	33	to	to	PART
dpc-4769	145	34	dosage	dosage	VERB
dpc-4769	145	35	optimization	optimization	NOUN
dpc-4769	145	36	[	[	X
dpc-4769	145	37	21,22	21,22	NOUN
dpc-4769	145	38	]	]	X
dpc-4769	145	39	.	.	PUNCT
dpc-4769	146	1	obesity	obesity	NOUN
dpc-4769	146	2	alters	alter	VERB
dpc-4769	146	3	the	the	DET
dpc-4769	146	4	volume	volume	NOUN
dpc-4769	146	5	of	of	ADP
dpc-4769	146	6	distribution	distribution	NOUN
dpc-4769	146	7	and	and	CCONJ
dpc-4769	146	8	clearance	clearance	NOUN
dpc-4769	146	9	rates	rate	NOUN
dpc-4769	146	10	for	for	ADP
dpc-4769	146	11	biologics	biologic	NOUN
dpc-4769	146	12	,	,	PUNCT
dpc-4769	146	13	which	which	PRON
dpc-4769	146	14	are	be	AUX
dpc-4769	146	15	primarily	primarily	ADV
dpc-4769	146	16	distributed	distribute	VERB
dpc-4769	146	17	in	in	ADP
dpc-4769	146	18	the	the	DET
dpc-4769	146	19	vascular	vascular	ADJ
dpc-4769	146	20	compartment	compartment	NOUN
dpc-4769	146	21	and	and	CCONJ
dpc-4769	146	22	,	,	PUNCT
dpc-4769	146	23	to	to	ADP
dpc-4769	146	24	a	a	DET
dpc-4769	146	25	lesser	less	ADJ
dpc-4769	146	26	extent	extent	NOUN
dpc-4769	146	27	,	,	PUNCT
dpc-4769	146	28	in	in	ADP
dpc-4769	146	29	adipose	adipose	ADJ
dpc-4769	146	30	tissue	tissue	NOUN
dpc-4769	146	31	.	.	PUNCT
dpc-4769	147	1	this	this	DET
dpc-4769	147	2	altered	alter	VERB
dpc-4769	147	3	distribution	distribution	NOUN
dpc-4769	147	4	can	can	AUX
dpc-4769	147	5	lead	lead	VERB
dpc-4769	147	6	to	to	ADP
dpc-4769	147	7	lower	low	ADJ
dpc-4769	147	8	drug	drug	NOUN
dpc-4769	147	9	concentrations	concentration	NOUN
dpc-4769	147	10	at	at	ADP
dpc-4769	147	11	the	the	DET
dpc-4769	147	12	site	site	NOUN
dpc-4769	147	13	of	of	ADP
dpc-4769	147	14	action	action	NOUN
dpc-4769	147	15	,	,	PUNCT
dpc-4769	147	16	potentially	potentially	ADV
dpc-4769	147	17	reducing	reduce	VERB
dpc-4769	147	18	efficacy	efficacy	NOUN
dpc-4769	147	19	.	.	PUNCT
dpc-4769	148	1	as	as	SCONJ
dpc-4769	148	2	such	such	ADJ
dpc-4769	148	3	,	,	PUNCT
dpc-4769	148	4	increased	increase	VERB
dpc-4769	148	5	dosages	dosage	NOUN
dpc-4769	148	6	may	may	AUX
dpc-4769	148	7	be	be	AUX
dpc-4769	148	8	required	require	VERB
dpc-4769	148	9	to	to	PART
dpc-4769	148	10	achieve	achieve	VERB
dpc-4769	148	11	therapeutic	therapeutic	ADJ
dpc-4769	148	12	drug	drug	NOUN
dpc-4769	148	13	levels	level	NOUN
dpc-4769	148	14	,	,	PUNCT
dpc-4769	148	15	a	a	DET
dpc-4769	148	16	concept	concept	NOUN
dpc-4769	148	17	supported	support	VERB
dpc-4769	148	18	by	by	ADP
dpc-4769	148	19	pharmacokinetic	pharmacokinetic	ADJ
dpc-4769	148	20	modeling	modeling	NOUN
dpc-4769	148	21	studies	study	NOUN
dpc-4769	148	22	[	[	X
dpc-4769	148	23	23,24	23,24	ADP
dpc-4769	148	24	]	]	PUNCT
dpc-4769	148	25	.	.	PUNCT
dpc-4769	149	1	evidence	evidence	NOUN
dpc-4769	149	2	suggests	suggest	VERB
dpc-4769	149	3	that	that	SCONJ
dpc-4769	149	4	higher	high	ADJ
dpc-4769	149	5	doses	dose	NOUN
dpc-4769	149	6	of	of	ADP
dpc-4769	149	7	biologics	biologic	NOUN
dpc-4769	149	8	may	may	AUX
dpc-4769	149	9	significantly	significantly	ADV
dpc-4769	149	10	enhance	enhance	VERB
dpc-4769	149	11	treatment	treatment	NOUN
dpc-4769	149	12	outcomes	outcome	NOUN
dpc-4769	149	13	in	in	ADP
dpc-4769	149	14	obese	obese	ADJ
dpc-4769	149	15	patients	patient	NOUN
dpc-4769	149	16	with	with	ADP
dpc-4769	149	17	psoriasis	psoriasis	NOUN
dpc-4769	149	18	.	.	PUNCT
dpc-4769	150	1	for	for	ADP
dpc-4769	150	2	example	example	NOUN
dpc-4769	150	3	,	,	PUNCT
dpc-4769	150	4	studies	study	NOUN
dpc-4769	150	5	have	have	AUX
dpc-4769	150	6	shown	show	VERB
dpc-4769	150	7	that	that	SCONJ
dpc-4769	150	8	obese	obese	ADJ
dpc-4769	150	9	patients	patient	NOUN
dpc-4769	150	10	receiving	receive	VERB
dpc-4769	150	11	standard	standard	ADJ
dpc-4769	150	12	doses	dose	NOUN
dpc-4769	150	13	of	of	ADP
dpc-4769	150	14	tnf	tnf	PROPN
dpc-4769	150	15	inhibitors	inhibitor	NOUN
dpc-4769	150	16	or	or	CCONJ
dpc-4769	150	17	il-17	il-17	ADV
dpc-4769	150	18	and	and	CCONJ
dpc-4769	150	19	il-23	il-23	NOUN
dpc-4769	150	20	blockers	blocker	NOUN
dpc-4769	150	21	exhibit	exhibit	VERB
dpc-4769	150	22	lower	low	ADJ
dpc-4769	150	23	response	response	NOUN
dpc-4769	150	24	rates	rate	NOUN
dpc-4769	150	25	compared	compare	VERB
dpc-4769	150	26	to	to	ADP
dpc-4769	150	27	their	their	PRON
dpc-4769	150	28	non	non	ADJ
dpc-4769	150	29	-	-	ADJ
dpc-4769	150	30	obese	obese	ADJ
dpc-4769	150	31	counterparts	counterpart	NOUN
dpc-4769	150	32	.	.	PUNCT
dpc-4769	151	1	in	in	ADP
dpc-4769	151	2	contrast	contrast	NOUN
dpc-4769	151	3	,	,	PUNCT
dpc-4769	151	4	dose	dose	NOUN
dpc-4769	151	5	escalation	escalation	NOUN
dpc-4769	151	6	has	have	AUX
dpc-4769	151	7	been	be	AUX
dpc-4769	151	8	associated	associate	VERB
dpc-4769	151	9	with	with	ADP
dpc-4769	151	10	improved	improve	VERB
dpc-4769	151	11	clinical	clinical	ADJ
dpc-4769	151	12	responses	response	NOUN
dpc-4769	151	13	,	,	PUNCT
dpc-4769	151	14	as	as	SCONJ
dpc-4769	151	15	measured	measure	VERB
dpc-4769	151	16	by	by	ADP
dpc-4769	151	17	pasi	pasi	NOUN
dpc-4769	151	18	score	score	NOUN
dpc-4769	151	19	reductions	reduction	NOUN
dpc-4769	151	20	and	and	CCONJ
dpc-4769	151	21	quality	quality	NOUN
dpc-4769	151	22	of	of	ADP
dpc-4769	151	23	life	life	NOUN
dpc-4769	151	24	improvements	improvement	NOUN
dpc-4769	151	25	[	[	X
dpc-4769	151	26	25	25	NUM
dpc-4769	151	27	-	-	SYM
dpc-4769	151	28	26	26	NUM
dpc-4769	151	29	]	]	PUNCT
dpc-4769	151	30	.	.	PUNCT
dpc-4769	152	1	the	the	DET
dpc-4769	152	2	safety	safety	NOUN
dpc-4769	152	3	profile	profile	NOUN
dpc-4769	152	4	of	of	ADP
dpc-4769	152	5	tildrakizumab	tildrakizumab	NOUN
dpc-4769	152	6	200	200	NUM
dpc-4769	152	7	mg	mg	NOUN
dpc-4769	152	8	observed	observe	VERB
dpc-4769	152	9	in	in	ADP
dpc-4769	152	10	our	our	PRON
dpc-4769	152	11	study	study	NOUN
dpc-4769	152	12	was	be	AUX
dpc-4769	152	13	favorable	favorable	ADJ
dpc-4769	152	14	,	,	PUNCT
dpc-4769	152	15	with	with	ADP
dpc-4769	152	16	only	only	ADV
dpc-4769	152	17	a	a	DET
dpc-4769	152	18	minimal	minimal	ADJ
dpc-4769	152	19	incidence	incidence	NOUN
dpc-4769	152	20	of	of	ADP
dpc-4769	152	21	adverse	adverse	ADJ
dpc-4769	152	22	events	event	NOUN
dpc-4769	152	23	reported	report	VERB
dpc-4769	152	24	,	,	PUNCT
dpc-4769	152	25	none	none	NOUN
dpc-4769	152	26	of	of	ADP
dpc-4769	152	27	which	which	PRON
dpc-4769	152	28	necessitated	necessitate	VERB
dpc-4769	152	29	discontinuation	discontinuation	NOUN
dpc-4769	152	30	of	of	ADP
dpc-4769	152	31	therapy	therapy	NOUN
dpc-4769	152	32	.	.	PUNCT
dpc-4769	153	1	this	this	PRON
dpc-4769	153	2	is	be	AUX
dpc-4769	153	3	in	in	ADP
dpc-4769	153	4	alignment	alignment	NOUN
dpc-4769	153	5	with	with	ADP
dpc-4769	153	6	the	the	DET
dpc-4769	153	7	safety	safety	NOUN
dpc-4769	153	8	data	datum	NOUN
dpc-4769	153	9	from	from	ADP
dpc-4769	153	10	rcts	rct	NOUN
dpc-4769	153	11	,	,	PUNCT
dpc-4769	153	12	further	far	ADV
dpc-4769	153	13	validating	validate	VERB
dpc-4769	153	14	the	the	DET
dpc-4769	153	15	tolerability	tolerability	NOUN
dpc-4769	153	16	of	of	ADP
dpc-4769	153	17	tildrakizumab	tildrakizumab	NOUN
dpc-4769	153	18	in	in	ADP
dpc-4769	153	19	a	a	DET
dpc-4769	153	20	real	real	ADJ
dpc-4769	153	21	-	-	PUNCT
dpc-4769	153	22	world	world	NOUN
dpc-4769	153	23	setting	setting	NOUN
dpc-4769	153	24	[	[	X
dpc-4769	153	25	9,13	9,13	NUM
dpc-4769	153	26	]	]	PUNCT
dpc-4769	153	27	.	.	PUNCT
dpc-4769	154	1	the	the	DET
dpc-4769	154	2	absence	absence	NOUN
dpc-4769	154	3	of	of	ADP
dpc-4769	154	4	treatment	treatment	NOUN
dpc-4769	154	5	withdrawal	withdrawal	NOUN
dpc-4769	154	6	due	due	ADP
dpc-4769	154	7	to	to	ADP
dpc-4769	154	8	aes	aes	VERB
dpc-4769	154	9	in	in	ADP
dpc-4769	154	10	our	our	PRON
dpc-4769	154	11	study	study	NOUN
dpc-4769	154	12	is	be	AUX
dpc-4769	154	13	particularly	particularly	ADV
dpc-4769	154	14	noteworthy	noteworthy	ADJ
dpc-4769	154	15	,	,	PUNCT
dpc-4769	154	16	indicating	indicate	VERB
dpc-4769	154	17	that	that	SCONJ
dpc-4769	154	18	tildrakizumab	tildrakizumab	NOUN
dpc-4769	154	19	200	200	NUM
dpc-4769	154	20	mg	mg	NOUN
dpc-4769	154	21	is	be	AUX
dpc-4769	154	22	well	well	ADV
dpc-4769	154	23	-	-	PUNCT
dpc-4769	154	24	tolerated	tolerate	VERB
dpc-4769	154	25	among	among	ADP
dpc-4769	154	26	patients	patient	NOUN
dpc-4769	154	27	with	with	ADP
dpc-4769	154	28	moderate	moderate	ADJ
dpc-4769	154	29	-	-	PUNCT
dpc-4769	154	30	to	to	ADP
dpc-4769	154	31	-	-	PUNCT
dpc-4769	154	32	severe	severe	ADJ
dpc-4769	154	33	psoriasis	psoriasis	NOUN
dpc-4769	154	34	,	,	PUNCT
dpc-4769	154	35	including	include	VERB
dpc-4769	154	36	those	those	PRON
dpc-4769	154	37	with	with	ADP
dpc-4769	154	38	comorbid	comorbid	NOUN
dpc-4769	154	39	conditions	condition	NOUN
dpc-4769	154	40	.	.	PUNCT
dpc-4769	155	1	the	the	DET
dpc-4769	155	2	significant	significant	ADJ
dpc-4769	155	3	improvements	improvement	NOUN
dpc-4769	155	4	in	in	ADP
dpc-4769	155	5	pasi	pasi	PROPN
dpc-4769	155	6	,	,	PUNCT
dpc-4769	155	7	bsa	bsa	PROPN
dpc-4769	155	8	,	,	PUNCT
dpc-4769	155	9	and	and	CCONJ
dpc-4769	155	10	dlqi	dlqi	ADJ
dpc-4769	155	11	scores	score	NOUN
dpc-4769	155	12	observed	observe	VERB
dpc-4769	155	13	in	in	ADP
dpc-4769	155	14	our	our	PRON
dpc-4769	155	15	study	study	NOUN
dpc-4769	155	16	not	not	PART
dpc-4769	155	17	only	only	ADV
dpc-4769	155	18	reflect	reflect	VERB
dpc-4769	155	19	the	the	DET
dpc-4769	155	20	clinical	clinical	ADJ
dpc-4769	155	21	effectiveness	effectiveness	NOUN
dpc-4769	155	22	of	of	ADP
dpc-4769	155	23	tildrakizumab	tildrakizumab	NOUN
dpc-4769	155	24	but	but	CCONJ
dpc-4769	155	25	also	also	ADV
dpc-4769	155	26	highlight	highlight	VERB
dpc-4769	155	27	its	its	PRON
dpc-4769	155	28	positive	positive	ADJ
dpc-4769	155	29	impact	impact	NOUN
dpc-4769	155	30	on	on	ADP
dpc-4769	155	31	patients	patient	NOUN
dpc-4769	155	32	’	'	PUNCT
dpc-4769	155	33	quality	quality	NOUN
dpc-4769	155	34	of	of	ADP
dpc-4769	155	35	life	life	NOUN
dpc-4769	155	36	.	.	PUNCT
dpc-4769	156	1	our	our	PRON
dpc-4769	156	2	findings	finding	NOUN
dpc-4769	156	3	reinforce	reinforce	VERB
dpc-4769	156	4	the	the	DET
dpc-4769	156	5	importance	importance	NOUN
dpc-4769	156	6	of	of	ADP
dpc-4769	156	7	personalized	personalized	ADJ
dpc-4769	156	8	medicine	medicine	NOUN
dpc-4769	156	9	in	in	ADP
dpc-4769	156	10	the	the	DET
dpc-4769	156	11	management	management	NOUN
dpc-4769	156	12	of	of	ADP
dpc-4769	156	13	psoriasis	psoriasis	NOUN
dpc-4769	156	14	.	.	PUNCT
dpc-4769	157	1	the	the	DET
dpc-4769	157	2	effectivenessof	effectivenessof	NOUN
dpc-4769	157	3	tildrakizumab	tildrakizumab	VERB
dpc-4769	157	4	200	200	NUM
dpc-4769	157	5	mg	mg	NOUN
dpc-4769	157	6	in	in	ADP
dpc-4769	157	7	patients	patient	NOUN
dpc-4769	157	8	with	with	ADP
dpc-4769	157	9	moderate	moderate	ADJ
dpc-4769	157	10	-	-	PUNCT
dpc-4769	157	11	to	to	ADP
dpc-4769	157	12	-	-	PUNCT
dpc-4769	157	13	severe	severe	ADJ
dpc-4769	157	14	original	original	ADJ
dpc-4769	157	15	article	article	NOUN
dpc-4769	157	16	|	|	ADV
dpc-4769	157	17	dermatol	dermatol	ADJ
dpc-4769	157	18	pract	pract	NOUN
dpc-4769	157	19	concept	concept	NOUN
dpc-4769	157	20	.	.	PUNCT
dpc-4769	158	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	158	2	7	7	NUM
dpc-4769	158	3	18;10(11):2968	18;10(11):2968	NUM
dpc-4769	158	4	.	.	PUNCT
dpc-4769	159	1	doi	doi	NOUN
dpc-4769	159	2	:	:	PUNCT
dpc-4769	159	3	10.3390	10.3390	NUM
dpc-4769	159	4	/	/	SYM
dpc-4769	159	5	biomedicines10112968	biomedicines10112968	PROPN
dpc-4769	159	6	.	.	PUNCT
dpc-4769	160	1	pmid	pmid	NOUN
dpc-4769	160	2	:	:	PUNCT
dpc-4769	160	3	36428539	36428539	NUM
dpc-4769	160	4	;	;	PUNCT
dpc-4769	160	5	pmcid	pmcid	PROPN
dpc-4769	160	6	:	:	PUNCT
dpc-4769	160	7	pmc9687727	pmc9687727	PROPN
dpc-4769	160	8	.	.	PUNCT
dpc-4769	161	1	6	6	NUM
dpc-4769	161	2	.	.	X
dpc-4769	161	3	visconti	visconti	PROPN
dpc-4769	161	4	mj	mj	PROPN
dpc-4769	161	5	,	,	PUNCT
dpc-4769	161	6	bashyam	bashyam	PROPN
dpc-4769	161	7	am	be	AUX
dpc-4769	161	8	,	,	PUNCT
dpc-4769	161	9	feldman	feldman	PROPN
dpc-4769	161	10	sr	sr	PROPN
dpc-4769	161	11	.	.	PUNCT
dpc-4769	162	1	treatment	treatment	NOUN
dpc-4769	162	2	decisions	decision	NOUN
dpc-4769	162	3	in	in	ADP
dpc-4769	162	4	psoriasis	psoriasis	NOUN
dpc-4769	162	5	.	.	PUNCT
dpc-4769	163	1	j	j	PROPN
dpc-4769	163	2	comp	comp	PROPN
dpc-4769	163	3	eff	eff	PROPN
dpc-4769	163	4	res	res	PROPN
dpc-4769	163	5	.	.	PUNCT
dpc-4769	164	1	2019	2019	NUM
dpc-4769	164	2	sep;8(12):947	sep;8(12):947	PROPN
dpc-4769	164	3	-	-	PUNCT
dpc-4769	164	4	949	949	NUM
dpc-4769	164	5	.	.	PUNCT
dpc-4769	165	1	doi	doi	NOUN
dpc-4769	165	2	:	:	PUNCT
dpc-4769	165	3	10.2217	10.2217	NUM
dpc-4769	165	4	/	/	SYM
dpc-4769	165	5	cer-2019	cer-2019	NOUN
dpc-4769	165	6	-	-	PUNCT
dpc-4769	165	7	0090	0090	NUM
dpc-4769	165	8	.	.	PUNCT
dpc-4769	166	1	epub	epub	NOUN
dpc-4769	166	2	2019	2019	NUM
dpc-4769	166	3	sep	sep	NOUN
dpc-4769	166	4	12	12	NUM
dpc-4769	166	5	.	.	PUNCT
dpc-4769	167	1	pmid	pmid	NOUN
dpc-4769	167	2	:	:	PUNCT
dpc-4769	167	3	31512930	31512930	NUM
dpc-4769	167	4	.	.	PUNCT
dpc-4769	168	1	7	7	X
dpc-4769	168	2	.	.	X
dpc-4769	168	3	ahmad	ahmad	PROPN
dpc-4769	168	4	fadzil	fadzil	PROPN
dpc-4769	168	5	mh	mh	PROPN
dpc-4769	168	6	,	,	PUNCT
dpc-4769	168	7	ihtatho	ihtatho	PROPN
dpc-4769	168	8	d	d	PROPN
dpc-4769	168	9	,	,	PUNCT
dpc-4769	168	10	mohd	mohd	PROPN
dpc-4769	168	11	affandi	affandi	VERB
dpc-4769	168	12	a	a	PRON
dpc-4769	168	13	,	,	PUNCT
dpc-4769	168	14	hussein	hussein	PROPN
dpc-4769	168	15	sh	sh	PROPN
dpc-4769	168	16	.	.	PROPN
dpc-4769	168	17	objective	objective	ADJ
dpc-4769	168	18	assessment	assessment	NOUN
dpc-4769	168	19	of	of	ADP
dpc-4769	168	20	psoriasis	psoriasis	NOUN
dpc-4769	168	21	erythema	erythema	ADJ
dpc-4769	168	22	for	for	ADP
dpc-4769	168	23	pasi	pasi	NOUN
dpc-4769	168	24	scoring	scoring	NOUN
dpc-4769	168	25	.	.	PUNCT
dpc-4769	169	1	j	j	PROPN
dpc-4769	169	2	med	med	PROPN
dpc-4769	169	3	eng	eng	PROPN
dpc-4769	169	4	technol	technol	NOUN
dpc-4769	169	5	.	.	PUNCT
dpc-4769	170	1	2009;33(7):516	2009;33(7):516	NUM
dpc-4769	170	2	-	-	SYM
dpc-4769	170	3	24	24	NUM
dpc-4769	170	4	.	.	PUNCT
dpc-4769	170	5	doi	doi	NOUN
dpc-4769	170	6	:	:	PUNCT
dpc-4769	170	7	10.1080/07434610902744074	10.1080/07434610902744074	NUM
dpc-4769	170	8	.	.	PUNCT
dpc-4769	171	1	pmid	pmid	NOUN
dpc-4769	171	2	:	:	PUNCT
dpc-4769	171	3	19639508	19639508	NUM
dpc-4769	171	4	.	.	PUNCT
dpc-4769	172	1	8	8	X
dpc-4769	172	2	.	.	X
dpc-4769	173	1	mahil	mahil	NOUN
dpc-4769	173	2	sk	sk	PROPN
dpc-4769	173	3	,	,	PUNCT
dpc-4769	173	4	capon	capon	NOUN
dpc-4769	173	5	f	f	PROPN
dpc-4769	173	6	,	,	PUNCT
dpc-4769	173	7	barker	barker	PROPN
dpc-4769	174	1	jn	jn	PROPN
dpc-4769	174	2	.	.	PROPN
dpc-4769	174	3	update	update	NOUN
dpc-4769	174	4	on	on	ADP
dpc-4769	174	5	psoriasis	psoriasis	NOUN
dpc-4769	174	6	immunopathogenesis	immunopathogenesis	NOUN
dpc-4769	174	7	and	and	CCONJ
dpc-4769	174	8	targeted	target	VERB
dpc-4769	174	9	immunotherapy	immunotherapy	NOUN
dpc-4769	174	10	.	.	PUNCT
dpc-4769	175	1	semin	semin	PROPN
dpc-4769	175	2	immunopathol	immunopathol	PROPN
dpc-4769	175	3	.	.	PUNCT
dpc-4769	176	1	2016	2016	NUM
dpc-4769	176	2	jan;38(1):11	jan;38(1):11	PROPN
dpc-4769	176	3	-	-	PUNCT
dpc-4769	176	4	27	27	NUM
dpc-4769	176	5	.	.	PUNCT
dpc-4769	177	1	doi	doi	NOUN
dpc-4769	177	2	:	:	PUNCT
dpc-4769	177	3	10.1007	10.1007	NUM
dpc-4769	177	4	/	/	SYM
dpc-4769	177	5	s00281015	s00281015	NOUN
dpc-4769	177	6	-	-	PUNCT
dpc-4769	177	7	0539	0539	NUM
dpc-4769	177	8	-	-	SYM
dpc-4769	177	9	8	8	NUM
dpc-4769	177	10	.	.	PUNCT
dpc-4769	178	1	epub	epub	NOUN
dpc-4769	178	2	2015	2015	NUM
dpc-4769	178	3	nov	nov	PROPN
dpc-4769	178	4	16	16	NUM
dpc-4769	178	5	.	.	PUNCT
dpc-4769	179	1	pmid	pmid	NOUN
dpc-4769	179	2	:	:	PUNCT
dpc-4769	179	3	26573299	26573299	NUM
dpc-4769	179	4	;	;	PUNCT
dpc-4769	179	5	pmcid	pmcid	ADJ
dpc-4769	179	6	:	:	PUNCT
dpc-4769	179	7	pmc4706579	pmc4706579	NOUN
dpc-4769	179	8	.	.	PUNCT
dpc-4769	180	1	9	9	X
dpc-4769	180	2	.	.	X
dpc-4769	180	3	reich	reich	PROPN
dpc-4769	180	4	k	k	PROPN
dpc-4769	180	5	,	,	PUNCT
dpc-4769	180	6	papp	papp	PROPN
dpc-4769	180	7	ka	ka	PROPN
dpc-4769	180	8	,	,	PUNCT
dpc-4769	180	9	blauvelt	blauvelt	VERB
dpc-4769	180	10	a	a	PRON
dpc-4769	180	11	,	,	PUNCT
dpc-4769	180	12	et	et	PROPN
dpc-4769	180	13	al	al	PROPN
dpc-4769	180	14	.	.	PROPN
dpc-4769	180	15	tildrakizumab	tildrakizumab	NOUN
dpc-4769	180	16	versus	versus	ADP
dpc-4769	180	17	placebo	placebo	NOUN
dpc-4769	180	18	or	or	CCONJ
dpc-4769	180	19	etanercept	etanercept	NOUN
dpc-4769	180	20	for	for	ADP
dpc-4769	180	21	chronic	chronic	ADJ
dpc-4769	180	22	plaque	plaque	NOUN
dpc-4769	180	23	psoriasis	psoriasis	NOUN
dpc-4769	180	24	(	(	PUNCT
dpc-4769	180	25	resurface	resurface	NOUN
dpc-4769	180	26	1	1	NUM
dpc-4769	180	27	and	and	CCONJ
dpc-4769	180	28	resurface	resurface	NOUN
dpc-4769	180	29	2	2	NUM
dpc-4769	180	30	):	):	PUNCT
dpc-4769	180	31	results	result	NOUN
dpc-4769	180	32	from	from	ADP
dpc-4769	180	33	two	two	NUM
dpc-4769	180	34	randomised	randomise	VERB
dpc-4769	180	35	controlled	control	VERB
dpc-4769	180	36	,	,	PUNCT
dpc-4769	180	37	phase	phase	NOUN
dpc-4769	180	38	3	3	NUM
dpc-4769	180	39	trials	trial	NOUN
dpc-4769	180	40	.	.	PUNCT
dpc-4769	181	1	lancet	lancet	NOUN
dpc-4769	181	2	.	.	PUNCT
dpc-4769	182	1	2017;390(10091):276	2017;390(10091):276	NUM
dpc-4769	182	2	-	-	SYM
dpc-4769	182	3	288	288	NUM
dpc-4769	182	4	.	.	PUNCT
dpc-4769	183	1	doi	doi	NOUN
dpc-4769	183	2	:	:	PUNCT
dpc-4769	183	3	10.1016	10.1016	NUM
dpc-4769	183	4	/s0140	/s0140	PROPN
dpc-4769	183	5	-	-	PUNCT
dpc-4769	183	6	6736(17)31279	6736(17)31279	NUM
dpc-4769	183	7	-	-	SYM
dpc-4769	183	8	5	5	NUM
dpc-4769	183	9	.	.	PUNCT
dpc-4769	184	1	pmid	pmid	NOUN
dpc-4769	184	2	:	:	PUNCT
dpc-4769	184	3	28596043	28596043	NUM
dpc-4769	184	4	.	.	PUNCT
dpc-4769	185	1	10	10	NUM
dpc-4769	185	2	.	.	X
dpc-4769	185	3	di	di	PROPN
dpc-4769	185	4	brizzi	brizzi	PROPN
dpc-4769	185	5	ev	ev	PROPN
dpc-4769	185	6	,	,	PUNCT
dpc-4769	185	7	buononato	buononato	PROPN
dpc-4769	185	8	d	d	PROPN
dpc-4769	185	9	,	,	PUNCT
dpc-4769	185	10	benvenuto	benvenuto	NOUN
dpc-4769	185	11	p	p	PROPN
dpc-4769	185	12	,	,	PUNCT
dpc-4769	185	13	et	et	PROPN
dpc-4769	185	14	al	al	PROPN
dpc-4769	185	15	.	.	PROPN
dpc-4769	185	16	effectiveness	effectiveness	NOUN
dpc-4769	185	17	and	and	CCONJ
dpc-4769	185	18	safety	safety	NOUN
dpc-4769	185	19	after	after	ADP
dpc-4769	185	20	a	a	DET
dpc-4769	185	21	switch	switch	NOUN
dpc-4769	185	22	to	to	PART
dpc-4769	185	23	tildrakizumab	tildrakizumab	VERB
dpc-4769	185	24	:	:	PUNCT
dpc-4769	185	25	a	a	DET
dpc-4769	185	26	real	real	ADJ
dpc-4769	185	27	world	world	NOUN
dpc-4769	185	28	multicenter	multicenter	NOUN
dpc-4769	185	29	italian	italian	ADJ
dpc-4769	185	30	study	study	NOUN
dpc-4769	185	31	in	in	ADP
dpc-4769	185	32	psoriasis	psoriasis	NOUN
dpc-4769	185	33	.	.	PUNCT
dpc-4769	186	1	dermatol	dermatol	NOUN
dpc-4769	186	2	pract	pract	PROPN
dpc-4769	186	3	concept	concept	NOUN
dpc-4769	186	4	.	.	PUNCT
dpc-4769	187	1	2023	2023	NUM
dpc-4769	187	2	oct	oct	NOUN
dpc-4769	187	3	1;13(4):e2023215	1;13(4):e2023215	PROPN
dpc-4769	187	4	.	.	PUNCT
dpc-4769	188	1	doi	doi	NOUN
dpc-4769	188	2	:	:	PUNCT
dpc-4769	188	3	10.5826	10.5826	NUM
dpc-4769	188	4	/	/	SYM
dpc-4769	188	5	dpc.1304a215	dpc.1304a215	NOUN
dpc-4769	188	6	.	.	PUNCT
dpc-4769	189	1	pmid	pmid	NOUN
dpc-4769	189	2	:	:	PUNCT
dpc-4769	189	3	37992389	37992389	NUM
dpc-4769	189	4	;	;	PUNCT
dpc-4769	189	5	pmcid	pmcid	NOUN
dpc-4769	189	6	:	:	PUNCT
dpc-4769	189	7	pmc10656146	pmc10656146	NOUN
dpc-4769	189	8	.	.	PUNCT
dpc-4769	190	1	11	11	NUM
dpc-4769	190	2	.	.	PUNCT
dpc-4769	191	1	ema	ema	PROPN
dpc-4769	191	2	.	.	PUNCT
dpc-4769	192	1	ilumetri	ilumetri	ADJ
dpc-4769	192	2	[	[	X
dpc-4769	192	3	internet	internet	NOUN
dpc-4769	192	4	]	]	PUNCT
dpc-4769	192	5	.	.	PUNCT
dpc-4769	193	1	european	european	PROPN
dpc-4769	193	2	medicines	medicine	NOUN
dpc-4769	193	3	agency	agency	NOUN
dpc-4769	193	4	.	.	PUNCT
dpc-4769	194	1	2018	2018	NUM
dpc-4769	194	2	.	.	PUNCT
dpc-4769	195	1	https://www.ema.europa.eu/en/medicines/human/epar/ilumetri	https://www.ema.europa.eu/en/medicines/human/epar/ilumetri	PROPN
dpc-4769	195	2	.	.	PROPN
dpc-4769	196	1	accessed	access	VERB
dpc-4769	196	2	10	10	NUM
dpc-4769	196	3	dec	dec	PROPN
dpc-4769	196	4	2021	2021	NUM
dpc-4769	196	5	.	.	PUNCT
dpc-4769	197	1	12	12	NUM
dpc-4769	197	2	.	.	PUNCT
dpc-4769	198	1	papp	papp	PROPN
dpc-4769	198	2	k	k	PROPN
dpc-4769	198	3	,	,	PUNCT
dpc-4769	198	4	thaçi	thaçi	PROPN
dpc-4769	198	5	d	d	PROPN
dpc-4769	198	6	,	,	PUNCT
dpc-4769	198	7	reich	reich	PROPN
dpc-4769	198	8	k	k	PROPN
dpc-4769	198	9	,	,	PUNCT
dpc-4769	198	10	et	et	PROPN
dpc-4769	198	11	al	al	PROPN
dpc-4769	198	12	.	.	PROPN
dpc-4769	198	13	tildrakizumab	tildrakizumab	NOUN
dpc-4769	198	14	(	(	PUNCT
dpc-4769	198	15	mk-3222	mk-3222	NOUN
dpc-4769	198	16	)	)	PUNCT
dpc-4769	198	17	,	,	PUNCT
dpc-4769	198	18	an	an	DET
dpc-4769	198	19	anti	anti	ADJ
dpc-4769	198	20	-	-	ADJ
dpc-4769	198	21	interleukin-23p19	interleukin-23p19	ADJ
dpc-4769	198	22	monoclonal	monoclonal	NOUN
dpc-4769	198	23	antibody	antibody	NOUN
dpc-4769	198	24	,	,	PUNCT
dpc-4769	198	25	improves	improve	VERB
dpc-4769	198	26	psoriasis	psoriasis	NOUN
dpc-4769	198	27	in	in	ADP
dpc-4769	198	28	a	a	DET
dpc-4769	198	29	phase	phase	NOUN
dpc-4769	198	30	iib	iib	NOUN
dpc-4769	198	31	randomized	randomize	VERB
dpc-4769	198	32	placebo	placebo	NOUN
dpc-4769	198	33	-	-	PUNCT
dpc-4769	198	34	controlled	control	VERB
dpc-4769	198	35	trial	trial	NOUN
dpc-4769	198	36	.	.	PUNCT
dpc-4769	199	1	br	br	PROPN
dpc-4769	199	2	j	j	PROPN
dpc-4769	199	3	derma	derma	NOUN
dpc-4769	199	4	tol	tol	NOUN
dpc-4769	199	5	.	.	PUNCT
dpc-4769	200	1	2015;173(4):930–939	2015;173(4):930–939	NUM
dpc-4769	200	2	.	.	PUNCT
dpc-4769	200	3	doi	doi	NOUN
dpc-4769	200	4	:	:	PUNCT
dpc-4769	200	5	10.1111	10.1111	NUM
dpc-4769	200	6	/	/	SYM
dpc-4769	200	7	bjd.13932	bjd.13932	NUM
dpc-4769	200	8	.	.	PUNCT
dpc-4769	201	1	pmid	pmid	NOUN
dpc-4769	201	2	:	:	PUNCT
dpc-4769	201	3	26042589	26042589	NUM
dpc-4769	201	4	.	.	PUNCT
dpc-4769	202	1	13	13	NUM
dpc-4769	202	2	.	.	PUNCT
dpc-4769	203	1	kokolakis	kokolakis	PROPN
dpc-4769	203	2	g	g	PROPN
dpc-4769	203	3	,	,	PUNCT
dpc-4769	203	4	kreis	kreis	PROPN
dpc-4769	203	5	g	g	PROPN
dpc-4769	203	6	,	,	PUNCT
dpc-4769	203	7	falqués	falqués	PROPN
dpc-4769	203	8	m	m	PRON
dpc-4769	203	9	,	,	PUNCT
dpc-4769	203	10	et	et	PROPN
dpc-4769	203	11	al	al	PROPN
dpc-4769	203	12	.	.	PROPN
dpc-4769	204	1	high	high	ADJ
dpc-4769	204	2	tolerability	tolerability	NOUN
dpc-4769	204	3	,	,	PUNCT
dpc-4769	204	4	favorable	favorable	ADJ
dpc-4769	204	5	safety	safety	NOUN
dpc-4769	204	6	,	,	PUNCT
dpc-4769	204	7	and	and	CCONJ
dpc-4769	204	8	subjects	subject	NOUN
dpc-4769	204	9	'	'	PART
dpc-4769	204	10	preference	preference	NOUN
dpc-4769	204	11	for	for	ADP
dpc-4769	204	12	a	a	DET
dpc-4769	204	13	single	single	ADJ
dpc-4769	204	14	200	200	NUM
dpc-4769	204	15	mg/2	mg/2	NOUN
dpc-4769	204	16	ml	ml	AUX
dpc-4769	204	17	tildrakizumab	tildrakizumab	VERB
dpc-4769	204	18	injection	injection	NOUN
dpc-4769	204	19	:	:	PUNCT
dpc-4769	204	20	a	a	DET
dpc-4769	204	21	phase	phase	NOUN
dpc-4769	204	22	i	i	PRON
dpc-4769	204	23	,	,	PUNCT
dpc-4769	204	24	open	open	ADJ
dpc-4769	204	25	-	-	PUNCT
dpc-4769	204	26	label	label	NOUN
dpc-4769	204	27	,	,	PUNCT
dpc-4769	204	28	randomized	randomize	VERB
dpc-4769	204	29	crossover	crossover	ADP
dpc-4769	204	30	trial	trial	NOUN
dpc-4769	204	31	in	in	ADP
dpc-4769	204	32	healthy	healthy	ADJ
dpc-4769	204	33	volunteers	volunteer	NOUN
dpc-4769	204	34	.	.	PUNCT
dpc-4769	205	1	dermatol	dermatol	NOUN
dpc-4769	205	2	ther	ther	ADV
dpc-4769	205	3	(	(	PUNCT
dpc-4769	205	4	heidelb	heidelb	NOUN
dpc-4769	205	5	)	)	PUNCT
dpc-4769	205	6	.	.	PUNCT
dpc-4769	206	1	2022	2022	NUM
dpc-4769	206	2	sep;12(9):2135	sep;12(9):2135	NOUN
dpc-4769	206	3	-	-	PUNCT
dpc-4769	206	4	2144	2144	NUM
dpc-4769	206	5	.	.	PUNCT
dpc-4769	207	1	doi	doi	NOUN
dpc-4769	207	2	:	:	PUNCT
dpc-4769	207	3	10.1007	10.1007	NUM
dpc-4769	207	4	/	/	SYM
dpc-4769	207	5	s13555022	s13555022	NOUN
dpc-4769	207	6	-	-	PUNCT
dpc-4769	207	7	00789	00789	NUM
dpc-4769	207	8	-	-	SYM
dpc-4769	207	9	9	9	NUM
dpc-4769	207	10	.	.	PUNCT
dpc-4769	208	1	epub	epub	NOUN
dpc-4769	208	2	2022	2022	NUM
dpc-4769	208	3	aug	aug	PROPN
dpc-4769	208	4	19	19	NUM
dpc-4769	208	5	.	.	PUNCT
dpc-4769	209	1	pmid	pmid	NOUN
dpc-4769	209	2	:	:	PUNCT
dpc-4769	209	3	35984626	35984626	NUM
dpc-4769	209	4	;	;	PUNCT
dpc-4769	209	5	pmcid	pmcid	ADJ
dpc-4769	209	6	:	:	PUNCT
dpc-4769	209	7	pmc9388364	pmc9388364	NOUN
dpc-4769	209	8	.	.	PUNCT
dpc-4769	210	1	14	14	NUM
dpc-4769	210	2	.	.	PUNCT
dpc-4769	211	1	gargiulo	gargiulo	PROPN
dpc-4769	211	2	l	l	NOUN
dpc-4769	211	3	,	,	PUNCT
dpc-4769	211	4	ibba	ibba	ADJ
dpc-4769	211	5	l	l	NOUN
dpc-4769	211	6	,	,	PUNCT
dpc-4769	211	7	cascio	cascio	NOUN
dpc-4769	211	8	ingurgio	ingurgio	PROPN
dpc-4769	211	9	r	r	PROPN
dpc-4769	211	10	,	,	PUNCT
dpc-4769	211	11	et	et	PROPN
dpc-4769	211	12	al	al	PROPN
dpc-4769	211	13	.	.	PROPN
dpc-4769	211	14	comparative	comparative	ADJ
dpc-4769	211	15	effectiveness	effectiveness	NOUN
dpc-4769	211	16	of	of	ADP
dpc-4769	211	17	tildrakizumab	tildrakizumab	NOUN
dpc-4769	211	18	200	200	NUM
dpc-4769	211	19	mg	mg	NOUN
dpc-4769	211	20	versus	versus	ADP
dpc-4769	211	21	tildrakizumab	tildrakizumab	NOUN
dpc-4769	211	22	100	100	NUM
dpc-4769	211	23	 	 	SPACE
dpc-4769	211	24	mg	mg	PROPN
dpc-4769	211	25	in	in	ADP
dpc-4769	211	26	psoriatic	psoriatic	ADJ
dpc-4769	211	27	patients	patient	NOUN
dpc-4769	211	28	with	with	ADP
dpc-4769	211	29	high	high	ADJ
dpc-4769	211	30	disease	disease	NOUN
dpc-4769	211	31	burden	burden	NOUN
dpc-4769	211	32	or	or	CCONJ
dpc-4769	211	33	above	above	ADP
dpc-4769	211	34	90	90	NUM
dpc-4769	211	35	  	  	SPACE
dpc-4769	211	36	kg	kg	NOUN
dpc-4769	211	37	of	of	ADP
dpc-4769	211	38	body	body	NOUN
dpc-4769	211	39	weight	weight	NOUN
dpc-4769	211	40	:	:	PUNCT
dpc-4769	211	41	a	a	DET
dpc-4769	211	42	16	16	NUM
dpc-4769	211	43	-	-	PUNCT
dpc-4769	211	44	week	week	NOUN
dpc-4769	211	45	multicenter	multicenter	NOUN
dpc-4769	211	46	retrospective	retrospective	ADJ
dpc-4769	211	47	study	study	NOUN
dpc-4769	211	48	il	il	PROPN
dpc-4769	211	49	pso	pso	PROPN
dpc-4769	211	50	(	(	PUNCT
dpc-4769	211	51	italian	italian	ADJ
dpc-4769	211	52	landscape	landscape	NOUN
dpc-4769	211	53	psoriasis	psoriasis	NOUN
dpc-4769	211	54	)	)	PUNCT
dpc-4769	211	55	.	.	PUNCT
dpc-4769	212	1	j	j	PROPN
dpc-4769	212	2	dermatolog	dermatolog	PROPN
dpc-4769	212	3	treat	treat	NOUN
dpc-4769	212	4	.	.	PUNCT
dpc-4769	213	1	2024	2024	NUM
dpc-4769	213	2	dec;35(1):2350760	dec;35(1):2350760	PROPN
dpc-4769	213	3	.	.	PUNCT
dpc-4769	213	4	doi	doi	PROPN
dpc-4769	213	5	:	:	PUNCT
dpc-4769	213	6	10.1080/09546634.2024.2350760	10.1080/09546634.2024.2350760	NUM
dpc-4769	213	7	.	.	PUNCT
dpc-4769	214	1	epub	epub	NOUN
dpc-4769	214	2	2024	2024	NUM
dpc-4769	214	3	may	may	PROPN
dpc-4769	214	4	7	7	NUM
dpc-4769	214	5	.	.	PUNCT
dpc-4769	215	1	pmid	pmid	NOUN
dpc-4769	215	2	:	:	PUNCT
dpc-4769	215	3	38714323	38714323	NUM
dpc-4769	215	4	.	.	PUNCT
dpc-4769	216	1	15	15	NUM
dpc-4769	216	2	.	.	X
dpc-4769	216	3	narcisi	narcisi	PROPN
dpc-4769	216	4	a	a	X
dpc-4769	216	5	,	,	PUNCT
dpc-4769	216	6	valenti	valenti	PROPN
dpc-4769	216	7	m	m	PROPN
dpc-4769	216	8	,	,	PUNCT
dpc-4769	216	9	gargiulo	gargiulo	PROPN
dpc-4769	216	10	l	l	NOUN
dpc-4769	216	11	,	,	PUNCT
dpc-4769	216	12	et	et	PROPN
dpc-4769	216	13	al	al	PROPN
dpc-4769	216	14	.	.	PUNCT
dpc-4769	217	1	real	real	ADJ
dpc-4769	217	2	-	-	PUNCT
dpc-4769	217	3	life	life	NOUN
dpc-4769	217	4	effectiveness	effectiveness	NOUN
dpc-4769	217	5	of	of	ADP
dpc-4769	217	6	tildrakizumab	tildrakizumab	NOUN
dpc-4769	217	7	in	in	ADP
dpc-4769	217	8	chronic	chronic	ADJ
dpc-4769	217	9	plaque	plaque	NOUN
dpc-4769	217	10	psoriasis	psoriasis	NOUN
dpc-4769	217	11	:	:	PUNCT
dpc-4769	217	12	a	a	DET
dpc-4769	217	13	52	52	NUM
dpc-4769	217	14	-	-	PUNCT
dpc-4769	217	15	week	week	NOUN
dpc-4769	217	16	multicentre	multicentre	NOUN
dpc-4769	217	17	retrospective	retrospective	ADJ
dpc-4769	217	18	study	study	NOUN
dpc-4769	217	19	-	-	PUNCT
dpc-4769	217	20	il	il	PROPN
dpc-4769	217	21	pso	pso	PROPN
dpc-4769	217	22	(	(	PUNCT
dpc-4769	217	23	italian	italian	ADJ
dpc-4769	217	24	landscape	landscape	NOUN
dpc-4769	217	25	psoriasis	psoriasis	NOUN
dpc-4769	217	26	)	)	PUNCT
dpc-4769	217	27	.	.	PUNCT
dpc-4769	218	1	j	j	PROPN
dpc-4769	218	2	eur	eur	PROPN
dpc-4769	218	3	acad	acad	PROPN
dpc-4769	218	4	dermatol	dermatol	NOUN
dpc-4769	218	5	venereol	venereol	NOUN
dpc-4769	218	6	.	.	PUNCT
dpc-4769	219	1	2023	2023	NUM
dpc-4769	219	2	jan;37(1):93	jan;37(1):93	ADP
dpc-4769	219	3	-	-	PUNCT
dpc-4769	219	4	103	103	NUM
dpc-4769	219	5	.	.	PUNCT
dpc-4769	220	1	doi	doi	NOUN
dpc-4769	220	2	:	:	PUNCT
dpc-4769	220	3	10.1111	10.1111	NUM
dpc-4769	220	4	/	/	SYM
dpc-4769	220	5	jdv.18594	jdv.18594	PROPN
dpc-4769	220	6	.	.	PUNCT
dpc-4769	221	1	epub	epub	PROPN
dpc-4769	221	2	2022	2022	NUM
dpc-4769	221	3	oct	oct	PROPN
dpc-4769	221	4	5	5	NUM
dpc-4769	221	5	.	.	PUNCT
dpc-4769	222	1	pmid	pmid	NOUN
dpc-4769	222	2	:	:	PUNCT
dpc-4769	222	3	36156312	36156312	NUM
dpc-4769	222	4	;	;	PUNCT
dpc-4769	222	5	pmcid	pmcid	ADJ
dpc-4769	222	6	:	:	PUNCT
dpc-4769	222	7	pmc10092064	pmc10092064	NOUN
dpc-4769	222	8	.	.	PUNCT
dpc-4769	223	1	16	16	NUM
dpc-4769	223	2	.	.	PUNCT
dpc-4769	224	1	ruggiero	ruggiero	PROPN
dpc-4769	224	2	a	a	DET
dpc-4769	224	3	,	,	PUNCT
dpc-4769	224	4	camela	camela	ADP
dpc-4769	224	5	e	e	NOUN
dpc-4769	224	6	,	,	PUNCT
dpc-4769	224	7	potestio	potestio	NOUN
dpc-4769	224	8	l	l	NOUN
dpc-4769	224	9	,	,	PUNCT
dpc-4769	224	10	et	et	PROPN
dpc-4769	224	11	al	al	PROPN
dpc-4769	224	12	.	.	PROPN
dpc-4769	224	13	drug	drug	PROPN
dpc-4769	224	14	safety	safety	NOUN
dpc-4769	224	15	evaluation	evaluation	NOUN
dpc-4769	224	16	of	of	ADP
dpc-4769	224	17	tildrakizumab	tildrakizumab	NOUN
dpc-4769	224	18	for	for	ADP
dpc-4769	224	19	psoriasis	psoriasis	NOUN
dpc-4769	224	20	:	:	PUNCT
dpc-4769	224	21	a	a	DET
dpc-4769	224	22	review	review	NOUN
dpc-4769	224	23	of	of	ADP
dpc-4769	224	24	the	the	DET
dpc-4769	224	25	current	current	ADJ
dpc-4769	224	26	knowledge	knowledge	NOUN
dpc-4769	224	27	.	.	PUNCT
dpc-4769	225	1	expert	expert	NOUN
dpc-4769	225	2	opin	opin	NOUN
dpc-4769	225	3	drug	drug	NOUN
dpc-4769	225	4	saf	saf	PROPN
dpc-4769	225	5	.	.	PROPN
dpc-4769	225	6	2022	2022	NUM
dpc-4769	225	7	dec;21(12):1445	dec;21(12):1445	NOUN
dpc-4769	225	8	-	-	PUNCT
dpc-4769	225	9	1451	1451	NUM
dpc-4769	225	10	.	.	PUNCT
dpc-4769	226	1	doi	doi	NOUN
dpc-4769	226	2	:	:	PUNCT
dpc-4769	226	3	10.1080/14740338.2022.2160447	10.1080/14740338.2022.2160447	NUM
dpc-4769	226	4	.	.	PUNCT
dpc-4769	227	1	epub	epub	NOUN
dpc-4769	227	2	2022	2022	NUM
dpc-4769	227	3	dec	dec	PROPN
dpc-4769	227	4	28	28	NUM
dpc-4769	227	5	.	.	PUNCT
dpc-4769	228	1	pmid	pmid	NOUN
dpc-4769	228	2	:	:	PUNCT
dpc-4769	228	3	36527300	36527300	NUM
dpc-4769	228	4	.	.	PUNCT
dpc-4769	229	1	17	17	NUM
dpc-4769	229	2	.	.	X
dpc-4769	230	1	bilal	bilal	PROPN
dpc-4769	230	2	j	j	PROPN
dpc-4769	230	3	,	,	PUNCT
dpc-4769	230	4	berlinberg	berlinberg	PROPN
dpc-4769	230	5	a	a	PRON
dpc-4769	230	6	,	,	PUNCT
dpc-4769	230	7	bhattacharjee	bhattacharjee	PROPN
dpc-4769	230	8	s	s	PROPN
dpc-4769	230	9	,	,	PUNCT
dpc-4769	230	10	et	et	PROPN
dpc-4769	230	11	al	al	PROPN
dpc-4769	230	12	.	.	PUNCT
dpc-4769	231	1	a	a	DET
dpc-4769	231	2	systematic	systematic	ADJ
dpc-4769	231	3	review	review	NOUN
dpc-4769	231	4	and	and	CCONJ
dpc-4769	231	5	meta	meta	NOUN
dpc-4769	231	6	-	-	PUNCT
dpc-4769	231	7	analysis	analysis	NOUN
dpc-4769	231	8	of	of	ADP
dpc-4769	231	9	the	the	DET
dpc-4769	231	10	efficacy	efficacy	NOUN
dpc-4769	231	11	and	and	CCONJ
dpc-4769	231	12	safety	safety	NOUN
dpc-4769	231	13	of	of	ADP
dpc-4769	231	14	the	the	DET
dpc-4769	231	15	interleukin	interleukin	NOUN
dpc-4769	231	16	(	(	PUNCT
dpc-4769	231	17	il)-12/23	il)-12/23	ADJ
dpc-4769	231	18	and	and	CCONJ
dpc-4769	231	19	il-17	il-17	NUM
dpc-4769	231	20	inhibitors	inhibitor	NOUN
dpc-4769	231	21	ustekinumab	ustekinumab	NOUN
dpc-4769	231	22	,	,	PUNCT
dpc-4769	231	23	the	the	DET
dpc-4769	231	24	safety	safety	NOUN
dpc-4769	231	25	profile	profile	NOUN
dpc-4769	231	26	of	of	ADP
dpc-4769	231	27	tildrakizumab	tildrakizumab	NOUN
dpc-4769	231	28	was	be	AUX
dpc-4769	231	29	favorable	favorable	ADJ
dpc-4769	231	30	,	,	PUNCT
dpc-4769	231	31	with	with	ADP
dpc-4769	231	32	few	few	ADJ
dpc-4769	231	33	adverse	adverse	ADJ
dpc-4769	231	34	events	event	NOUN
dpc-4769	231	35	and	and	CCONJ
dpc-4769	231	36	no	no	DET
dpc-4769	231	37	treatment	treatment	NOUN
dpc-4769	231	38	withdrawal	withdrawal	NOUN
dpc-4769	231	39	due	due	ADP
dpc-4769	231	40	to	to	ADP
dpc-4769	231	41	adverse	adverse	ADJ
dpc-4769	231	42	events	event	NOUN
dpc-4769	231	43	.	.	PUNCT
dpc-4769	232	1	this	this	PRON
dpc-4769	232	2	confirms	confirm	VERB
dpc-4769	232	3	previous	previous	ADJ
dpc-4769	232	4	clinical	clinical	ADJ
dpc-4769	232	5	trial	trial	NOUN
dpc-4769	232	6	data	datum	NOUN
dpc-4769	232	7	and	and	CCONJ
dpc-4769	232	8	supports	support	VERB
dpc-4769	232	9	the	the	DET
dpc-4769	232	10	use	use	NOUN
dpc-4769	232	11	of	of	ADP
dpc-4769	232	12	tildrakizumab	tildrakizumab	NOUN
dpc-4769	232	13	as	as	ADP
dpc-4769	232	14	a	a	DET
dpc-4769	232	15	safe	safe	ADJ
dpc-4769	232	16	and	and	CCONJ
dpc-4769	232	17	effective	effective	ADJ
dpc-4769	232	18	therapy	therapy	NOUN
dpc-4769	232	19	for	for	ADP
dpc-4769	232	20	moderate	moderate	ADJ
dpc-4769	232	21	-	-	PUNCT
dpc-4769	232	22	to	to	ADP
dpc-4769	232	23	-	-	PUNCT
dpc-4769	232	24	severe	severe	ADJ
dpc-4769	232	25	plaque	plaque	NOUN
dpc-4769	232	26	psoriasis	psoriasis	NOUN
dpc-4769	232	27	.	.	PUNCT
dpc-4769	233	1	limitations	limitation	NOUN
dpc-4769	233	2	the	the	DET
dpc-4769	233	3	study	study	NOUN
dpc-4769	233	4	limitations	limitation	NOUN
dpc-4769	233	5	were	be	AUX
dpc-4769	233	6	the	the	DET
dpc-4769	233	7	small	small	ADJ
dpc-4769	233	8	sample	sample	NOUN
dpc-4769	233	9	size	size	NOUN
dpc-4769	233	10	,	,	PUNCT
dpc-4769	233	11	the	the	DET
dpc-4769	233	12	lack	lack	NOUN
dpc-4769	233	13	of	of	ADP
dpc-4769	233	14	a	a	DET
dpc-4769	233	15	control	control	NOUN
dpc-4769	233	16	group	group	NOUN
dpc-4769	233	17	,	,	PUNCT
dpc-4769	233	18	and	and	CCONJ
dpc-4769	233	19	the	the	DET
dpc-4769	233	20	short	short	ADJ
dpc-4769	233	21	study	study	NOUN
dpc-4769	233	22	duration	duration	NOUN
dpc-4769	233	23	.	.	PUNCT
dpc-4769	234	1	future	future	ADJ
dpc-4769	234	2	research	research	NOUN
dpc-4769	234	3	should	should	AUX
dpc-4769	234	4	aim	aim	VERB
dpc-4769	234	5	to	to	PART
dpc-4769	234	6	further	far	ADV
dpc-4769	234	7	elucidate	elucidate	VERB
dpc-4769	234	8	the	the	DET
dpc-4769	234	9	pharmacokinetics	pharmacokinetic	NOUN
dpc-4769	234	10	of	of	ADP
dpc-4769	234	11	tildrakizumab	tildrakizumab	NOUN
dpc-4769	234	12	in	in	ADP
dpc-4769	234	13	obese	obese	ADJ
dpc-4769	234	14	patients	patient	NOUN
dpc-4769	234	15	,	,	PUNCT
dpc-4769	234	16	exploring	explore	VERB
dpc-4769	234	17	potential	potential	ADJ
dpc-4769	234	18	dose	dose	NOUN
dpc-4769	234	19	-	-	PUNCT
dpc-4769	234	20	response	response	NOUN
dpc-4769	234	21	relationships	relationship	NOUN
dpc-4769	234	22	and	and	CCONJ
dpc-4769	234	23	the	the	DET
dpc-4769	234	24	impact	impact	NOUN
dpc-4769	234	25	of	of	ADP
dpc-4769	234	26	obesity	obesity	NOUN
dpc-4769	234	27	on	on	ADP
dpc-4769	234	28	therapeutic	therapeutic	ADJ
dpc-4769	234	29	efficacy	efficacy	NOUN
dpc-4769	234	30	and	and	CCONJ
dpc-4769	234	31	safety	safety	NOUN
dpc-4769	234	32	.	.	PUNCT
dpc-4769	235	1	additionally	additionally	ADV
dpc-4769	235	2	,	,	PUNCT
dpc-4769	235	3	longterm	longterm	VERB
dpc-4769	235	4	studies	study	NOUN
dpc-4769	235	5	focusing	focus	VERB
dpc-4769	235	6	on	on	ADP
dpc-4769	235	7	the	the	DET
dpc-4769	235	8	durability	durability	NOUN
dpc-4769	235	9	of	of	ADP
dpc-4769	235	10	response	response	NOUN
dpc-4769	235	11	and	and	CCONJ
dpc-4769	235	12	the	the	DET
dpc-4769	235	13	management	management	NOUN
dpc-4769	235	14	of	of	ADP
dpc-4769	235	15	comorbid	comorbid	NOUN
dpc-4769	235	16	conditions	condition	NOUN
dpc-4769	235	17	in	in	ADP
dpc-4769	235	18	patients	patient	NOUN
dpc-4769	235	19	treated	treat	VERB
dpc-4769	235	20	with	with	ADP
dpc-4769	235	21	tildrakizumab	tildrakizumab	NOUN
dpc-4769	235	22	are	be	AUX
dpc-4769	235	23	needed	need	VERB
dpc-4769	235	24	to	to	PART
dpc-4769	235	25	fully	fully	ADV
dpc-4769	235	26	understand	understand	VERB
dpc-4769	235	27	its	its	PRON
dpc-4769	235	28	role	role	NOUN
dpc-4769	235	29	in	in	ADP
dpc-4769	235	30	the	the	DET
dpc-4769	235	31	comprehensive	comprehensive	ADJ
dpc-4769	235	32	care	care	NOUN
dpc-4769	235	33	of	of	ADP
dpc-4769	235	34	psoriasis	psoriasis	NOUN
dpc-4769	235	35	.	.	PUNCT
dpc-4769	236	1	conclusions	conclusion	NOUN
dpc-4769	236	2	this	this	DET
dpc-4769	236	3	study	study	NOUN
dpc-4769	236	4	demonstrates	demonstrate	VERB
dpc-4769	236	5	that	that	SCONJ
dpc-4769	236	6	the	the	DET
dpc-4769	236	7	200	200	NUM
dpc-4769	236	8	mg	mg	NOUN
dpc-4769	236	9	dose	dose	NOUN
dpc-4769	236	10	of	of	ADP
dpc-4769	236	11	tildrakizumab	tildrakizumab	NOUN
dpc-4769	236	12	is	be	AUX
dpc-4769	236	13	effective	effective	ADJ
dpc-4769	236	14	and	and	CCONJ
dpc-4769	236	15	safe	safe	ADJ
dpc-4769	236	16	for	for	ADP
dpc-4769	236	17	treating	treat	VERB
dpc-4769	236	18	moderate	moderate	ADJ
dpc-4769	236	19	-	-	PUNCT
dpc-4769	236	20	to	to	ADP
dpc-4769	236	21	-	-	PUNCT
dpc-4769	236	22	severe	severe	ADJ
dpc-4769	236	23	psoriasis	psoriasis	NOUN
dpc-4769	236	24	,	,	PUNCT
dpc-4769	236	25	particularly	particularly	ADV
dpc-4769	236	26	in	in	ADP
dpc-4769	236	27	obese	obese	ADJ
dpc-4769	236	28	patients	patient	NOUN
dpc-4769	236	29	.	.	PUNCT
dpc-4769	237	1	significant	significant	ADJ
dpc-4769	237	2	improvements	improvement	NOUN
dpc-4769	237	3	in	in	ADP
dpc-4769	237	4	pasi	pasi	PROPN
dpc-4769	237	5	,	,	PUNCT
dpc-4769	237	6	bsa	bsa	PROPN
dpc-4769	237	7	,	,	PUNCT
dpc-4769	237	8	and	and	CCONJ
dpc-4769	237	9	dlqi	dlqi	ADJ
dpc-4769	237	10	scores	score	NOUN
dpc-4769	237	11	were	be	AUX
dpc-4769	237	12	observed	observe	VERB
dpc-4769	237	13	as	as	ADV
dpc-4769	237	14	early	early	ADV
dpc-4769	237	15	as	as	ADP
dpc-4769	237	16	after	after	ADP
dpc-4769	237	17	the	the	DET
dpc-4769	237	18	first	first	ADJ
dpc-4769	237	19	few	few	ADJ
dpc-4769	237	20	weeks	week	NOUN
dpc-4769	237	21	of	of	ADP
dpc-4769	237	22	treatment	treatment	NOUN
dpc-4769	237	23	,	,	PUNCT
dpc-4769	237	24	with	with	ADP
dpc-4769	237	25	a	a	DET
dpc-4769	237	26	favorable	favorable	ADJ
dpc-4769	237	27	tolerability	tolerability	NOUN
dpc-4769	237	28	profile	profile	NOUN
dpc-4769	237	29	and	and	CCONJ
dpc-4769	237	30	few	few	ADJ
dpc-4769	237	31	adverse	adverse	ADJ
dpc-4769	237	32	events	event	NOUN
dpc-4769	237	33	.	.	PUNCT
dpc-4769	238	1	these	these	DET
dpc-4769	238	2	results	result	NOUN
dpc-4769	238	3	support	support	VERB
dpc-4769	238	4	the	the	DET
dpc-4769	238	5	use	use	NOUN
dpc-4769	238	6	of	of	ADP
dpc-4769	238	7	tildrakizumab	tildrakizumab	NOUN
dpc-4769	238	8	as	as	ADP
dpc-4769	238	9	a	a	DET
dpc-4769	238	10	long	long	ADJ
dpc-4769	238	11	-	-	PUNCT
dpc-4769	238	12	term	term	NOUN
dpc-4769	238	13	treatment	treatment	NOUN
dpc-4769	238	14	option	option	NOUN
dpc-4769	238	15	and	and	CCONJ
dpc-4769	238	16	highlight	highlight	VERB
dpc-4769	238	17	the	the	DET
dpc-4769	238	18	importance	importance	NOUN
dpc-4769	238	19	of	of	ADP
dpc-4769	238	20	personalized	personalized	ADJ
dpc-4769	238	21	medicine	medicine	NOUN
dpc-4769	238	22	in	in	ADP
dpc-4769	238	23	managing	manage	VERB
dpc-4769	238	24	psoriasis	psoriasis	NOUN
dpc-4769	238	25	.	.	PUNCT
dpc-4769	239	1	further	further	ADJ
dpc-4769	239	2	studies	study	NOUN
dpc-4769	239	3	are	be	AUX
dpc-4769	239	4	needed	need	VERB
dpc-4769	239	5	to	to	PART
dpc-4769	239	6	confirm	confirm	VERB
dpc-4769	239	7	these	these	DET
dpc-4769	239	8	findings	finding	NOUN
dpc-4769	239	9	and	and	CCONJ
dpc-4769	239	10	optimize	optimize	VERB
dpc-4769	239	11	dosing	dose	VERB
dpc-4769	239	12	strategies	strategy	NOUN
dpc-4769	239	13	.	.	PUNCT
dpc-4769	240	1	references	reference	NOUN
dpc-4769	240	2	1	1	NUM
dpc-4769	240	3	.	.	PUNCT
dpc-4769	240	4	parisi	parisi	PROPN
dpc-4769	240	5	r	r	PROPN
dpc-4769	240	6	,	,	PUNCT
dpc-4769	240	7	symmons	symmon	NOUN
dpc-4769	240	8	dp	dp	PROPN
dpc-4769	240	9	,	,	PUNCT
dpc-4769	240	10	griffiths	griffiths	PROPN
dpc-4769	240	11	ce	ce	PROPN
dpc-4769	240	12	,	,	PUNCT
dpc-4769	240	13	ashcroft	ashcroft	PROPN
dpc-4769	240	14	dm	dm	PROPN
dpc-4769	240	15	.	.	PUNCT
dpc-4769	240	16	identification	identification	NOUN
dpc-4769	240	17	and	and	CCONJ
dpc-4769	240	18	management	management	NOUN
dpc-4769	240	19	of	of	ADP
dpc-4769	240	20	psoriasis	psoriasis	NOUN
dpc-4769	240	21	and	and	CCONJ
dpc-4769	240	22	associated	associate	VERB
dpc-4769	240	23	comorbidity	comorbidity	NOUN
dpc-4769	240	24	(	(	PUNCT
dpc-4769	240	25	impact	impact	NOUN
dpc-4769	240	26	)	)	PUNCT
dpc-4769	240	27	project	project	NOUN
dpc-4769	240	28	team	team	NOUN
dpc-4769	240	29	.	.	PUNCT
dpc-4769	241	1	global	global	ADJ
dpc-4769	241	2	epidemiology	epidemiology	NOUN
dpc-4769	241	3	of	of	ADP
dpc-4769	241	4	psoriasis	psoriasis	NOUN
dpc-4769	241	5	:	:	PUNCT
dpc-4769	241	6	a	a	DET
dpc-4769	241	7	systematic	systematic	ADJ
dpc-4769	241	8	review	review	NOUN
dpc-4769	241	9	of	of	ADP
dpc-4769	241	10	incidence	incidence	NOUN
dpc-4769	241	11	and	and	CCONJ
dpc-4769	241	12	prevalence	prevalence	NOUN
dpc-4769	241	13	.	.	PUNCT
dpc-4769	242	1	j	j	PROPN
dpc-4769	242	2	invest	invest	VERB
dpc-4769	242	3	dermatol	dermatol	NOUN
dpc-4769	242	4	.	.	PUNCT
dpc-4769	243	1	2013	2013	NUM
dpc-4769	243	2	feb;133(2):377	feb;133(2):377	NOUN
dpc-4769	243	3	-	-	PUNCT
dpc-4769	243	4	85	85	NUM
dpc-4769	243	5	.	.	PUNCT
dpc-4769	244	1	doi	doi	NOUN
dpc-4769	244	2	:	:	PUNCT
dpc-4769	244	3	10.1038	10.1038	NUM
dpc-4769	244	4	/	/	SYM
dpc-4769	244	5	jid.2012.339	jid.2012.339	PROPN
dpc-4769	244	6	.	.	PUNCT
dpc-4769	245	1	epub	epub	PROPN
dpc-4769	245	2	2012	2012	NUM
dpc-4769	245	3	sep	sep	PROPN
dpc-4769	245	4	27	27	NUM
dpc-4769	245	5	.	.	PUNCT
dpc-4769	246	1	pmid	pmid	NOUN
dpc-4769	246	2	:	:	PUNCT
dpc-4769	246	3	23014338	23014338	NUM
dpc-4769	246	4	.	.	PUNCT
dpc-4769	247	1	2	2	X
dpc-4769	247	2	.	.	X
dpc-4769	247	3	ghoreschi	ghoreschi	PROPN
dpc-4769	247	4	k	k	NOUN
dpc-4769	247	5	,	,	PUNCT
dpc-4769	247	6	balato	balato	NOUN
dpc-4769	247	7	a	a	PRON
dpc-4769	247	8	,	,	PUNCT
dpc-4769	247	9	enerbäck	enerbäck	ADJ
dpc-4769	247	10	c	c	X
dpc-4769	247	11	,	,	PUNCT
dpc-4769	247	12	sabat	sabat	PROPN
dpc-4769	247	13	r.	r.	PROPN
dpc-4769	247	14	therapeutics	therapeutic	NOUN
dpc-4769	247	15	targeting	target	VERB
dpc-4769	247	16	the	the	DET
dpc-4769	247	17	il-23	il-23	NOUN
dpc-4769	247	18	and	and	CCONJ
dpc-4769	247	19	il-17	il-17	ADV
dpc-4769	247	20	pathway	pathway	NOUN
dpc-4769	247	21	in	in	ADP
dpc-4769	247	22	psoriasis	psoriasis	NOUN
dpc-4769	247	23	.	.	PUNCT
dpc-4769	248	1	lancet	lancet	NOUN
dpc-4769	248	2	.	.	PUNCT
dpc-4769	249	1	2021	2021	NUM
dpc-4769	249	2	;	;	PUNCT
dpc-4769	249	3	397(10275):754	397(10275):754	NUM
dpc-4769	249	4	-	-	SYM
dpc-4769	249	5	766	766	NUM
dpc-4769	249	6	.	.	PUNCT
dpc-4769	250	1	doi	doi	NOUN
dpc-4769	250	2	:	:	PUNCT
dpc-4769	250	3	10.1016	10.1016	NUM
dpc-4769	250	4	/	/	SYM
dpc-4769	250	5	s0140	s0140	PROPN
dpc-4769	250	6	-	-	PUNCT
dpc-4769	250	7	6736(21)00184	6736(21)00184	NOUN
dpc-4769	250	8	-	-	PUNCT
dpc-4769	250	9	7	7	NUM
dpc-4769	250	10	.	.	PUNCT
dpc-4769	251	1	pmid	pmid	NOUN
dpc-4769	251	2	:	:	PUNCT
dpc-4769	251	3	33515492	33515492	NUM
dpc-4769	251	4	.	.	PUNCT
dpc-4769	252	1	3	3	X
dpc-4769	252	2	.	.	X
dpc-4769	252	3	griffiths	griffiths	PROPN
dpc-4769	252	4	ce	ce	PROPN
dpc-4769	252	5	,	,	PUNCT
dpc-4769	252	6	barker	barker	PROPN
dpc-4769	253	1	jn	jn	PROPN
dpc-4769	253	2	.	.	PROPN
dpc-4769	254	1	pathogenesis	pathogenesis	PROPN
dpc-4769	254	2	and	and	CCONJ
dpc-4769	254	3	clinical	clinical	ADJ
dpc-4769	254	4	features	feature	NOUN
dpc-4769	254	5	of	of	ADP
dpc-4769	254	6	psoriasis	psoriasis	NOUN
dpc-4769	254	7	.	.	PUNCT
dpc-4769	255	1	lancet	lancet	PROPN
dpc-4769	255	2	.	.	PUNCT
dpc-4769	256	1	2007	2007	NUM
dpc-4769	256	2	jul	jul	PROPN
dpc-4769	256	3	21;370(9583):263	21;370(9583):263	NUM
dpc-4769	256	4	-	-	SYM
dpc-4769	256	5	271	271	NUM
dpc-4769	256	6	.	.	PUNCT
dpc-4769	257	1	doi	doi	NOUN
dpc-4769	257	2	:	:	PUNCT
dpc-4769	257	3	10.1016	10.1016	NUM
dpc-4769	257	4	/	/	SYM
dpc-4769	257	5	s0140	s0140	PROPN
dpc-4769	257	6	-	-	PUNCT
dpc-4769	257	7	6736(07)61128	6736(07)61128	NUM
dpc-4769	257	8	-	-	PUNCT
dpc-4769	257	9	3	3	NUM
dpc-4769	257	10	.	.	PUNCT
dpc-4769	258	1	pmid	pmid	NOUN
dpc-4769	258	2	:	:	PUNCT
dpc-4769	258	3	17658397	17658397	NUM
dpc-4769	258	4	.	.	PUNCT
dpc-4769	259	1	4	4	X
dpc-4769	259	2	.	.	X
dpc-4769	259	3	ni	ni	PROPN
dpc-4769	259	4	c	c	PROPN
dpc-4769	259	5	,	,	PUNCT
dpc-4769	259	6	chiu	chiu	PROPN
dpc-4769	259	7	mw	mw	PROPN
dpc-4769	259	8	.	.	PROPN
dpc-4769	259	9	psoriasis	psoriasis	NOUN
dpc-4769	259	10	and	and	CCONJ
dpc-4769	259	11	comorbidities	comorbiditie	NOUN
dpc-4769	259	12	:	:	PUNCT
dpc-4769	259	13	links	link	NOUN
dpc-4769	259	14	and	and	CCONJ
dpc-4769	259	15	risks	risk	NOUN
dpc-4769	259	16	.	.	PUNCT
dpc-4769	260	1	clin	clin	PROPN
dpc-4769	260	2	cosmet	cosmet	PROPN
dpc-4769	260	3	investig	investig	PROPN
dpc-4769	260	4	dermatol	dermatol	NOUN
dpc-4769	260	5	.	.	PUNCT
dpc-4769	261	1	2014	2014	NUM
dpc-4769	261	2	apr	apr	NOUN
dpc-4769	261	3	17;7:119	17;7:119	NUM
dpc-4769	261	4	-	-	SYM
dpc-4769	261	5	32	32	NUM
dpc-4769	261	6	.	.	PUNCT
dpc-4769	262	1	doi	doi	NOUN
dpc-4769	262	2	:	:	PUNCT
dpc-4769	262	3	10.2147	10.2147	NUM
dpc-4769	262	4	/	/	SYM
dpc-4769	262	5	ccid.s44843	ccid.s44843	NOUN
dpc-4769	262	6	.	.	PUNCT
dpc-4769	263	1	pmid	pmid	NOUN
dpc-4769	263	2	:	:	PUNCT
dpc-4769	263	3	24790463	24790463	NUM
dpc-4769	263	4	;	;	PUNCT
dpc-4769	263	5	pmcid	pmcid	NOUN
dpc-4769	263	6	:	:	PUNCT
dpc-4769	263	7	pmc4000177	pmc4000177	NOUN
dpc-4769	263	8	.	.	PUNCT
dpc-4769	264	1	5	5	X
dpc-4769	264	2	.	.	X
dpc-4769	264	3	di	di	PROPN
dpc-4769	264	4	brizzi	brizzi	PROPN
dpc-4769	264	5	ev	ev	PROPN
dpc-4769	264	6	,	,	PUNCT
dpc-4769	264	7	rocco	rocco	X
dpc-4769	264	8	a	a	PRON
dpc-4769	264	9	,	,	PUNCT
dpc-4769	264	10	babino	babino	PROPN
dpc-4769	264	11	g	g	PROPN
dpc-4769	264	12	,	,	PUNCT
dpc-4769	264	13	et	et	PROPN
dpc-4769	264	14	al	al	PROPN
dpc-4769	264	15	.	.	PUNCT
dpc-4769	264	16	evaluation	evaluation	NOUN
dpc-4769	264	17	of	of	ADP
dpc-4769	264	18	the	the	DET
dpc-4769	264	19	role	role	NOUN
dpc-4769	264	20	of	of	ADP
dpc-4769	264	21	faecal	faecal	ADJ
dpc-4769	264	22	calprotectin	calprotectin	NOUN
dpc-4769	264	23	in	in	ADP
dpc-4769	264	24	the	the	DET
dpc-4769	264	25	management	management	NOUN
dpc-4769	264	26	of	of	ADP
dpc-4769	264	27	psoriatic	psoriatic	ADJ
dpc-4769	264	28	patients	patient	NOUN
dpc-4769	264	29	under	under	ADP
dpc-4769	264	30	treatment	treatment	NOUN
dpc-4769	264	31	with	with	ADP
dpc-4769	264	32	biologic	biologic	ADJ
dpc-4769	264	33	drugs	drug	NOUN
dpc-4769	264	34	.	.	PUNCT
dpc-4769	265	1	biomedicines	biomedicine	NOUN
dpc-4769	265	2	.	.	PUNCT
dpc-4769	266	1	2022	2022	NUM
dpc-4769	266	2	nov	nov	NOUN
dpc-4769	266	3	8	8	NUM
dpc-4769	266	4	original	original	ADJ
dpc-4769	266	5	article	article	NOUN
dpc-4769	266	6	|	|	ADV
dpc-4769	266	7	dermatol	dermatol	ADJ
dpc-4769	266	8	pract	pract	NOUN
dpc-4769	266	9	concept	concept	NOUN
dpc-4769	266	10	.	.	PUNCT
dpc-4769	267	1	2024;14(4):e2024284	2024;14(4):e2024284	NUM
dpc-4769	267	2	24	24	NUM
dpc-4769	267	3	.	.	PUNCT
dpc-4769	268	1	paroutoglou	paroutoglou	PROPN
dpc-4769	268	2	k	k	PROPN
dpc-4769	268	3	,	,	PUNCT
dpc-4769	268	4	papadavid	papadavid	NOUN
dpc-4769	268	5	e	e	NOUN
dpc-4769	268	6	,	,	PUNCT
dpc-4769	268	7	christodoulatos	christodoulatos	PROPN
dpc-4769	268	8	gs	gs	NOUN
dpc-4769	268	9	,	,	PUNCT
dpc-4769	268	10	dalamaga	dalamaga	NOUN
dpc-4769	268	11	m.	m.	NOUN
dpc-4769	268	12	deciphering	decipher	VERB
dpc-4769	268	13	the	the	DET
dpc-4769	268	14	association	association	NOUN
dpc-4769	268	15	between	between	ADP
dpc-4769	268	16	psoriasis	psoriasis	NOUN
dpc-4769	268	17	and	and	CCONJ
dpc-4769	268	18	obesity	obesity	NOUN
dpc-4769	268	19	:	:	PUNCT
dpc-4769	268	20	current	current	ADJ
dpc-4769	268	21	evidence	evidence	NOUN
dpc-4769	268	22	and	and	CCONJ
dpc-4769	268	23	treatment	treatment	NOUN
dpc-4769	268	24	considerations	consideration	NOUN
dpc-4769	268	25	.	.	PUNCT
dpc-4769	269	1	curr	curr	PROPN
dpc-4769	269	2	obes	obes	PROPN
dpc-4769	269	3	rep	rep	PROPN
dpc-4769	269	4	.	.	PROPN
dpc-4769	269	5	2020	2020	NUM
dpc-4769	269	6	sep;9(3):165	sep;9(3):165	NOUN
dpc-4769	269	7	-	-	PUNCT
dpc-4769	269	8	178	178	NUM
dpc-4769	269	9	.	.	PUNCT
dpc-4769	270	1	doi	doi	NOUN
dpc-4769	270	2	:	:	PUNCT
dpc-4769	270	3	10.1007	10.1007	NUM
dpc-4769	270	4	/	/	SYM
dpc-4769	270	5	s13679	s13679	NOUN
dpc-4769	270	6	-	-	PUNCT
dpc-4769	270	7	020	020	NUM
dpc-4769	270	8	-	-	PUNCT
dpc-4769	270	9	00380	00380	NUM
dpc-4769	270	10	-	-	PUNCT
dpc-4769	270	11	3	3	NUM
dpc-4769	270	12	.	.	PUNCT
dpc-4769	271	1	pmid	pmid	NOUN
dpc-4769	271	2	:	:	PUNCT
dpc-4769	271	3	32418186	32418186	NUM
dpc-4769	271	4	.	.	PUNCT
dpc-4769	272	1	25	25	NUM
dpc-4769	272	2	.	.	PUNCT
dpc-4769	272	3	yıldırım	yıldırım	PROPN
dpc-4769	272	4	fe	fe	PROPN
dpc-4769	272	5	,	,	PUNCT
dpc-4769	272	6	hapa	hapa	PROPN
dpc-4769	272	7	fa	fa	PROPN
dpc-4769	272	8	.	.	PROPN
dpc-4769	272	9	clinical	clinical	ADJ
dpc-4769	272	10	efficacy	efficacy	NOUN
dpc-4769	272	11	and	and	CCONJ
dpc-4769	272	12	safety	safety	NOUN
dpc-4769	272	13	of	of	ADP
dpc-4769	272	14	secukinumab	secukinumab	NOUN
dpc-4769	272	15	for	for	ADP
dpc-4769	272	16	psoriasis	psoriasis	NOUN
dpc-4769	272	17	in	in	ADP
dpc-4769	272	18	a	a	DET
dpc-4769	272	19	real	real	ADJ
dpc-4769	272	20	-	-	PUNCT
dpc-4769	272	21	world	world	NOUN
dpc-4769	272	22	setting	setting	NOUN
dpc-4769	272	23	in	in	ADP
dpc-4769	272	24	turkey	turkey	NOUN
dpc-4769	272	25	.	.	PUNCT
dpc-4769	273	1	j	j	PROPN
dpc-4769	273	2	dermatolog	dermatolog	PROPN
dpc-4769	273	3	treat	treat	NOUN
dpc-4769	273	4	.	.	PUNCT
dpc-4769	274	1	2022	2022	NUM
dpc-4769	274	2	may;33(3):1531	may;33(3):1531	PROPN
dpc-4769	274	3	-	-	PUNCT
dpc-4769	274	4	1537	1537	NUM
dpc-4769	274	5	.	.	PUNCT
dpc-4769	275	1	doi	doi	NOUN
dpc-4769	275	2	:	:	PUNCT
dpc-4769	275	3	10.1080/09546634	10.1080/09546634	NUM
dpc-4769	275	4	.2020.1839009	.2020.1839009	PROPN
dpc-4769	275	5	.	.	PUNCT
dpc-4769	276	1	epub	epub	PROPN
dpc-4769	276	2	2020	2020	NUM
dpc-4769	276	3	nov	nov	PROPN
dpc-4769	276	4	1	1	NUM
dpc-4769	276	5	.	.	PUNCT
dpc-4769	277	1	pmid	pmid	NOUN
dpc-4769	277	2	:	:	PUNCT
dpc-4769	277	3	33074062	33074062	NUM
dpc-4769	277	4	.	.	PUNCT
dpc-4769	278	1	26	26	NUM
dpc-4769	278	2	.	.	PUNCT
dpc-4769	279	1	carrascosa	carrascosa	PROPN
dpc-4769	279	2	jm	jm	PROPN
dpc-4769	279	3	,	,	PUNCT
dpc-4769	279	4	rocamora	rocamora	PROPN
dpc-4769	279	5	v	v	NOUN
dpc-4769	279	6	,	,	PUNCT
dpc-4769	279	7	fernandez	fernandez	PROPN
dpc-4769	279	8	-	-	PUNCT
dpc-4769	279	9	torres	torres	PROPN
dpc-4769	279	10	rm	rm	PROPN
dpc-4769	279	11	,	,	PUNCT
dpc-4769	279	12	et	et	PROPN
dpc-4769	279	13	al	al	PROPN
dpc-4769	279	14	.	.	PROPN
dpc-4769	279	15	obesity	obesity	NOUN
dpc-4769	279	16	and	and	CCONJ
dpc-4769	279	17	psoriasis	psoriasis	NOUN
dpc-4769	279	18	:	:	PUNCT
dpc-4769	279	19	inflammatory	inflammatory	ADJ
dpc-4769	279	20	nature	nature	NOUN
dpc-4769	279	21	of	of	ADP
dpc-4769	279	22	obesity	obesity	NOUN
dpc-4769	279	23	,	,	PUNCT
dpc-4769	279	24	relationship	relationship	NOUN
dpc-4769	279	25	between	between	ADP
dpc-4769	279	26	psoriasis	psoriasis	NOUN
dpc-4769	279	27	and	and	CCONJ
dpc-4769	279	28	obesity	obesity	NOUN
dpc-4769	279	29	,	,	PUNCT
dpc-4769	279	30	and	and	CCONJ
dpc-4769	279	31	therapeutic	therapeutic	ADJ
dpc-4769	279	32	implications	implication	NOUN
dpc-4769	279	33	.	.	PUNCT
dpc-4769	280	1	actas	acta	NOUN
dpc-4769	280	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-4769	280	3	.	.	PUNCT
dpc-4769	281	1	2014	2014	NUM
dpc-4769	281	2	jan	jan	ADJ
dpc-4769	281	3	-	-	PUNCT
dpc-4769	281	4	feb;105(1):31	feb;105(1):31	NOUN
dpc-4769	281	5	-	-	PUNCT
dpc-4769	281	6	44	44	NUM
dpc-4769	281	7	.	.	PUNCT
dpc-4769	282	1	english	english	PROPN
dpc-4769	282	2	,	,	PUNCT
dpc-4769	282	3	spanish	spanish	PROPN
dpc-4769	282	4	.	.	PUNCT
dpc-4769	283	1	doi	doi	PROPN
dpc-4769	283	2	:	:	PUNCT
dpc-4769	283	3	10.1016	10.1016	NUM
dpc-4769	283	4	/	/	SYM
dpc-4769	283	5	j.ad.2012.08.003	j.ad.2012.08.003	PROPN
dpc-4769	283	6	.	.	PROPN
dpc-4769	284	1	epub	epub	PROPN
dpc-4769	284	2	2012	2012	NUM
dpc-4769	284	3	nov	nov	PROPN
dpc-4769	284	4	23	23	NUM
dpc-4769	284	5	.	.	PUNCT
dpc-4769	285	1	pmid	pmid	NOUN
dpc-4769	285	2	:	:	PUNCT
dpc-4769	285	3	23177976	23177976	NUM
dpc-4769	285	4	.	.	PUNCT
dpc-4769	286	1	27	27	NUM
dpc-4769	286	2	.	.	PUNCT
dpc-4769	287	1	puig	puig	PROPN
dpc-4769	287	2	l.	l.	PROPN
dpc-4769	287	3	obesity	obesity	NOUN
dpc-4769	287	4	and	and	CCONJ
dpc-4769	287	5	psoriasis	psoriasis	NOUN
dpc-4769	287	6	:	:	PUNCT
dpc-4769	287	7	body	body	NOUN
dpc-4769	287	8	weight	weight	NOUN
dpc-4769	287	9	and	and	CCONJ
dpc-4769	287	10	body	body	NOUN
dpc-4769	287	11	mass	mass	NOUN
dpc-4769	287	12	index	index	NOUN
dpc-4769	287	13	influence	influence	NOUN
dpc-4769	287	14	the	the	DET
dpc-4769	287	15	response	response	NOUN
dpc-4769	287	16	to	to	ADP
dpc-4769	287	17	biological	biological	ADJ
dpc-4769	287	18	treatment	treatment	NOUN
dpc-4769	287	19	.	.	PUNCT
dpc-4769	288	1	j	j	PROPN
dpc-4769	288	2	eur	eur	PROPN
dpc-4769	288	3	acad	acad	PROPN
dpc-4769	288	4	dermatol	dermatol	NOUN
dpc-4769	288	5	venereol	venereol	NOUN
dpc-4769	288	6	.	.	PUNCT
dpc-4769	289	1	2011	2011	NUM
dpc-4769	289	2	sep;25(9):1007	sep;25(9):1007	NOUN
dpc-4769	289	3	-	-	PUNCT
dpc-4769	289	4	11	11	NUM
dpc-4769	289	5	.	.	PUNCT
dpc-4769	290	1	doi	doi	NOUN
dpc-4769	290	2	:	:	PUNCT
dpc-4769	290	3	10.1111	10.1111	NUM
dpc-4769	290	4	/	/	SYM
dpc-4769	290	5	j.1468	j.1468	PROPN
dpc-4769	290	6	-3083.2011.04065.x	-3083.2011.04065.x	PROPN
dpc-4769	290	7	.	.	PUNCT
dpc-4769	291	1	epub	epub	PROPN
dpc-4769	291	2	2011	2011	NUM
dpc-4769	291	3	apr	apr	NOUN
dpc-4769	291	4	15	15	NUM
dpc-4769	291	5	.	.	PUNCT
dpc-4769	292	1	pmid	pmid	NOUN
dpc-4769	292	2	:	:	PUNCT
dpc-4769	292	3	21492252	21492252	NUM
dpc-4769	292	4	.	.	PUNCT
dpc-4769	293	1	28	28	NUM
dpc-4769	293	2	.	.	PUNCT
dpc-4769	294	1	gargiulo	gargiulo	PROPN
dpc-4769	294	2	l	l	NOUN
dpc-4769	294	3	,	,	PUNCT
dpc-4769	294	4	ibba	ibba	ADJ
dpc-4769	294	5	l	l	NOUN
dpc-4769	294	6	,	,	PUNCT
dpc-4769	294	7	malagoli	malagoli	NOUN
dpc-4769	294	8	p	p	NOUN
dpc-4769	294	9	,	,	PUNCT
dpc-4769	294	10	et	et	PROPN
dpc-4769	294	11	al	al	PROPN
dpc-4769	294	12	.	.	PUNCT
dpc-4769	295	1	a	a	DET
dpc-4769	295	2	risankizumab	risankizumab	NOUN
dpc-4769	295	3	super	super	ADJ
dpc-4769	295	4	responder	responder	NOUN
dpc-4769	295	5	profile	profile	NOUN
dpc-4769	295	6	identified	identify	VERB
dpc-4769	295	7	by	by	ADP
dpc-4769	295	8	long	long	ADJ
dpc-4769	295	9	-	-	PUNCT
dpc-4769	295	10	term	term	NOUN
dpc-4769	295	11	real	real	ADJ
dpc-4769	295	12	-	-	PUNCT
dpc-4769	295	13	life	life	NOUN
dpc-4769	295	14	observation	observation	NOUN
dpc-4769	295	15	-	-	PUNCT
dpc-4769	295	16	il	il	PROPN
dpc-4769	295	17	pso	pso	NOUN
dpc-4769	295	18	(	(	PUNCT
dpc-4769	295	19	italian	italian	ADJ
dpc-4769	295	20	landscape	landscape	NOUN
dpc-4769	295	21	psoriasis	psoriasis	NOUN
dpc-4769	295	22	)	)	PUNCT
dpc-4769	295	23	.	.	PUNCT
dpc-4769	296	1	j	j	PROPN
dpc-4769	296	2	eur	eur	PROPN
dpc-4769	296	3	acad	acad	PROPN
dpc-4769	296	4	dermatol	dermatol	NOUN
dpc-4769	296	5	venereol	venereol	NOUN
dpc-4769	296	6	.	.	PUNCT
dpc-4769	297	1	2024	2024	NUM
dpc-4769	297	2	jan;38(1):e113	jan;38(1):e113	PROPN
dpc-4769	297	3	-	-	PUNCT
dpc-4769	297	4	e116	e116	PROPN
dpc-4769	297	5	.	.	PUNCT
dpc-4769	297	6	doi	doi	NOUN
dpc-4769	297	7	:	:	PUNCT
dpc-4769	297	8	10.1111	10.1111	NUM
dpc-4769	297	9	/	/	SYM
dpc-4769	297	10	jdv	jdv	NOUN
dpc-4769	297	11	.19464	.19464	PROPN
dpc-4769	297	12	.	.	PUNCT
dpc-4769	298	1	epub	epub	PROPN
dpc-4769	298	2	2023	2023	NUM
dpc-4769	298	3	aug	aug	PROPN
dpc-4769	298	4	29	29	NUM
dpc-4769	298	5	.	.	PUNCT
dpc-4769	299	1	pmid	pmid	NOUN
dpc-4769	299	2	:	:	PUNCT
dpc-4769	299	3	37611277	37611277	NUM
dpc-4769	299	4	.	.	PUNCT
dpc-4769	300	1	29	29	NUM
dpc-4769	300	2	.	.	PUNCT
dpc-4769	301	1	schäkel	schäkel	PROPN
dpc-4769	301	2	k	k	PROPN
dpc-4769	301	3	,	,	PUNCT
dpc-4769	301	4	reich	reich	PROPN
dpc-4769	301	5	k	k	PROPN
dpc-4769	301	6	,	,	PUNCT
dpc-4769	301	7	asadullah	asadullah	PROPN
dpc-4769	301	8	k	k	PROPN
dpc-4769	301	9	,	,	PUNCT
dpc-4769	301	10	et	et	PROPN
dpc-4769	301	11	al	al	PROPN
dpc-4769	301	12	.	.	PROPN
dpc-4769	302	1	early	early	ADJ
dpc-4769	302	2	disease	disease	NOUN
dpc-4769	302	3	intervention	intervention	NOUN
dpc-4769	302	4	with	with	ADP
dpc-4769	302	5	guselkumab	guselkumab	NOUN
dpc-4769	302	6	in	in	ADP
dpc-4769	302	7	psoriasis	psoriasis	NOUN
dpc-4769	302	8	leads	lead	VERB
dpc-4769	302	9	to	to	ADP
dpc-4769	302	10	a	a	DET
dpc-4769	302	11	higher	high	ADJ
dpc-4769	302	12	rate	rate	NOUN
dpc-4769	302	13	of	of	ADP
dpc-4769	302	14	stable	stable	ADJ
dpc-4769	302	15	complete	complete	ADJ
dpc-4769	302	16	skin	skin	NOUN
dpc-4769	302	17	clearance	clearance	NOUN
dpc-4769	302	18	(	(	PUNCT
dpc-4769	302	19	‘	'	PUNCT
dpc-4769	302	20	clinical	clinical	ADJ
dpc-4769	302	21	super	super	ADJ
dpc-4769	302	22	response	response	NOUN
dpc-4769	302	23	’	'	PUNCT
dpc-4769	302	24	):	):	PUNCT
dpc-4769	302	25	week	week	NOUN
dpc-4769	302	26	28	28	NUM
dpc-4769	302	27	results	result	NOUN
dpc-4769	302	28	from	from	ADP
dpc-4769	302	29	the	the	DET
dpc-4769	302	30	ongoing	ongoing	ADJ
dpc-4769	302	31	phase	phase	NOUN
dpc-4769	302	32	iiib	iiib	NOUN
dpc-4769	302	33	randomized	randomize	VERB
dpc-4769	302	34	,	,	PUNCT
dpc-4769	302	35	double	double	ADJ
dpc-4769	302	36	-	-	PUNCT
dpc-4769	302	37	blind	blind	ADJ
dpc-4769	302	38	,	,	PUNCT
dpc-4769	302	39	parallel	parallel	NOUN
dpc-4769	302	40	-	-	PUNCT
dpc-4769	302	41	group	group	NOUN
dpc-4769	302	42	,	,	PUNCT
dpc-4769	302	43	guide	guide	NOUN
dpc-4769	302	44	study	study	NOUN
dpc-4769	302	45	.	.	PUNCT
dpc-4769	303	1	j	j	PROPN
dpc-4769	303	2	eur	eur	PROPN
dpc-4769	303	3	acad	acad	PROPN
dpc-4769	303	4	dermatol	dermatol	NOUN
dpc-4769	303	5	venereol	venereol	NOUN
dpc-4769	303	6	.	.	PUNCT
dpc-4769	304	1	2023	2023	NUM
dpc-4769	304	2	oct;37(10):2016	oct;37(10):2016	PROPN
dpc-4769	304	3	-	-	PUNCT
dpc-4769	304	4	2027	2027	NUM
dpc-4769	304	5	.	.	PUNCT
dpc-4769	305	1	doi	doi	NOUN
dpc-4769	305	2	:	:	PUNCT
dpc-4769	305	3	10.1111	10.1111	NUM
dpc-4769	305	4	/	/	SYM
dpc-4769	305	5	jdv.19236	jdv.19236	PROPN
dpc-4769	305	6	.	.	PUNCT
dpc-4769	306	1	epub	epub	PROPN
dpc-4769	306	2	2023	2023	NUM
dpc-4769	306	3	jul	jul	PROPN
dpc-4769	306	4	18	18	NUM
dpc-4769	306	5	.	.	PUNCT
dpc-4769	307	1	pmid	pmid	NOUN
dpc-4769	307	2	:	:	PUNCT
dpc-4769	307	3	37262309	37262309	NUM
dpc-4769	307	4	.	.	PUNCT
dpc-4769	308	1	secukinumab	secukinumab	NOUN
dpc-4769	308	2	,	,	PUNCT
dpc-4769	308	3	ixekizumab	ixekizumab	NOUN
dpc-4769	308	4	,	,	PUNCT
dpc-4769	308	5	brodalumab	brodalumab	NOUN
dpc-4769	308	6	,	,	PUNCT
dpc-4769	308	7	guselkumab	guselkumab	NOUN
dpc-4769	308	8	and	and	CCONJ
dpc-4769	308	9	tildrakizumab	tildrakizumab	NOUN
dpc-4769	308	10	for	for	ADP
dpc-4769	308	11	the	the	DET
dpc-4769	308	12	treatment	treatment	NOUN
dpc-4769	308	13	of	of	ADP
dpc-4769	308	14	moderate	moderate	ADJ
dpc-4769	308	15	to	to	ADP
dpc-4769	308	16	severe	severe	ADJ
dpc-4769	308	17	plaque	plaque	NOUN
dpc-4769	308	18	psoriasis	psoriasis	NOUN
dpc-4769	308	19	.	.	PUNCT
dpc-4769	309	1	j	j	PROPN
dpc-4769	309	2	dermatolog	dermatolog	PROPN
dpc-4769	309	3	treat	treat	NOUN
dpc-4769	309	4	.	.	PUNCT
dpc-4769	310	1	2018	2018	NUM
dpc-4769	310	2	sep;29(6):569	sep;29(6):569	NOUN
dpc-4769	310	3	-	-	PUNCT
dpc-4769	310	4	578	578	NUM
dpc-4769	310	5	.	.	PUNCT
dpc-4769	311	1	doi	doi	NOUN
dpc-4769	311	2	:	:	PUNCT
dpc-4769	311	3	10.1080/09546634.2017.1422591	10.1080/09546634.2017.1422591	NUM
dpc-4769	311	4	.	.	PUNCT
dpc-4769	312	1	epub	epub	PROPN
dpc-4769	312	2	2018	2018	NUM
dpc-4769	312	3	mar	mar	PROPN
dpc-4769	312	4	28	28	NUM
dpc-4769	312	5	.	.	PUNCT
dpc-4769	313	1	pmid	pmid	NOUN
dpc-4769	313	2	:	:	PUNCT
dpc-4769	313	3	29532693	29532693	NUM
dpc-4769	313	4	.	.	PUNCT
dpc-4769	314	1	18	18	NUM
dpc-4769	314	2	.	.	X
dpc-4769	315	1	assan	assan	PROPN
dpc-4769	315	2	f	f	AUX
dpc-4769	315	3	,	,	PUNCT
dpc-4769	315	4	tubach	tubach	VERB
dpc-4769	315	5	f	f	X
dpc-4769	315	6	,	,	PUNCT
dpc-4769	315	7	arlegui	arlegui	VERB
dpc-4769	315	8	h	h	NOUN
dpc-4769	315	9	,	,	PUNCT
dpc-4769	315	10	et	et	PROPN
dpc-4769	315	11	al	al	PROPN
dpc-4769	315	12	.	.	PUNCT
dpc-4769	316	1	first	first	ADJ
dpc-4769	316	2	-	-	PUNCT
dpc-4769	316	3	line	line	NOUN
dpc-4769	316	4	biologic	biologic	NOUN
dpc-4769	316	5	therapy	therapy	NOUN
dpc-4769	316	6	and	and	CCONJ
dpc-4769	316	7	obesity	obesity	NOUN
dpc-4769	316	8	in	in	ADP
dpc-4769	316	9	moderate	moderate	ADJ
dpc-4769	316	10	-	-	PUNCT
dpc-4769	316	11	to	to	ADP
dpc-4769	316	12	-	-	PUNCT
dpc-4769	316	13	severe	severe	ADJ
dpc-4769	316	14	psoriasis	psoriasis	NOUN
dpc-4769	316	15	:	:	PUNCT
dpc-4769	316	16	results	result	VERB
dpc-4769	316	17	from	from	ADP
dpc-4769	316	18	the	the	DET
dpc-4769	316	19	prospective	prospective	ADJ
dpc-4769	316	20	multicenter	multicenter	NOUN
dpc-4769	316	21	cohort	cohort	NOUN
dpc-4769	316	22	psobioteq	psobioteq	NOUN
dpc-4769	316	23	.	.	PUNCT
dpc-4769	317	1	dermatology	dermatology	NOUN
dpc-4769	317	2	.	.	PUNCT
dpc-4769	318	1	2021;237(3):338	2021;237(3):338	NUM
dpc-4769	318	2	-	-	SYM
dpc-4769	318	3	346	346	NUM
dpc-4769	318	4	.	.	PUNCT
dpc-4769	319	1	doi	doi	NOUN
dpc-4769	319	2	:	:	PUNCT
dpc-4769	319	3	10.1159/000513398	10.1159/000513398	NUM
dpc-4769	319	4	.	.	PUNCT
dpc-4769	320	1	epub	epub	NOUN
dpc-4769	320	2	2021	2021	NUM
dpc-4769	320	3	feb	feb	NOUN
dpc-4769	320	4	3	3	NUM
dpc-4769	320	5	.	.	PUNCT
dpc-4769	320	6	pmid	pmid	NOUN
dpc-4769	320	7	:	:	PUNCT
dpc-4769	320	8	33535213	33535213	NUM
dpc-4769	320	9	.	.	PUNCT
dpc-4769	321	1	19	19	NUM
dpc-4769	321	2	.	.	PUNCT
dpc-4769	322	1	kaushik	kaushik	PROPN
dpc-4769	322	2	sb	sb	PROPN
dpc-4769	322	3	,	,	PUNCT
dpc-4769	322	4	lebwohl	lebwohl	VERB
dpc-4769	322	5	mg	mg	PROPN
dpc-4769	322	6	.	.	PUNCT
dpc-4769	323	1	psoriasis	psoriasis	NOUN
dpc-4769	323	2	:	:	PUNCT
dpc-4769	323	3	which	which	DET
dpc-4769	323	4	therapy	therapy	NOUN
dpc-4769	323	5	for	for	ADP
dpc-4769	323	6	which	which	PRON
dpc-4769	323	7	patient	patient	NOUN
dpc-4769	323	8	:	:	PUNCT
dpc-4769	323	9	psoriasis	psoriasis	NOUN
dpc-4769	323	10	comorbidities	comorbiditie	NOUN
dpc-4769	323	11	and	and	CCONJ
dpc-4769	323	12	preferred	preferred	ADJ
dpc-4769	323	13	systemic	systemic	ADJ
dpc-4769	323	14	agents	agent	NOUN
dpc-4769	323	15	.	.	PUNCT
dpc-4769	324	1	j	j	PROPN
dpc-4769	324	2	am	be	AUX
dpc-4769	324	3	acad	acad	ADJ
dpc-4769	324	4	dermatol	dermatol	NOUN
dpc-4769	324	5	.	.	PUNCT
dpc-4769	325	1	2019	2019	NUM
dpc-4769	325	2	jan;80(1):27	jan;80(1):27	NOUN
dpc-4769	325	3	-	-	PUNCT
dpc-4769	325	4	40	40	NUM
dpc-4769	325	5	.	.	PUNCT
dpc-4769	326	1	doi	doi	NOUN
dpc-4769	326	2	:	:	PUNCT
dpc-4769	326	3	10.1016	10.1016	NUM
dpc-4769	326	4	/	/	SYM
dpc-4769	326	5	j	j	PROPN
dpc-4769	326	6	.jaad.2018.06.057	.jaad.2018.06.057	PUNCT
dpc-4769	326	7	.	.	PUNCT
dpc-4769	327	1	epub	epub	PROPN
dpc-4769	327	2	2018	2018	NUM
dpc-4769	327	3	jul	jul	PROPN
dpc-4769	327	4	11	11	NUM
dpc-4769	327	5	.	.	PUNCT
dpc-4769	328	1	pmid	pmid	NOUN
dpc-4769	328	2	:	:	PUNCT
dpc-4769	328	3	30017705	30017705	NUM
dpc-4769	328	4	.	.	PUNCT
dpc-4769	329	1	20	20	NUM
dpc-4769	329	2	.	.	PUNCT
dpc-4769	330	1	jensen	jensen	PROPN
dpc-4769	330	2	p	p	PROPN
dpc-4769	330	3	,	,	PUNCT
dpc-4769	330	4	skov	skov	NOUN
dpc-4769	330	5	l.	l.	NOUN
dpc-4769	330	6	psoriasis	psoriasis	NOUN
dpc-4769	330	7	and	and	CCONJ
dpc-4769	330	8	obesity	obesity	NOUN
dpc-4769	330	9	.	.	PUNCT
dpc-4769	331	1	dermatology	dermatology	NOUN
dpc-4769	331	2	.	.	PUNCT
dpc-4769	332	1	2016;232(6):633	2016;232(6):633	X
dpc-4769	332	2	-	-	SYM
dpc-4769	332	3	639	639	NUM
dpc-4769	332	4	.	.	PUNCT
dpc-4769	333	1	doi	doi	NOUN
dpc-4769	333	2	:	:	PUNCT
dpc-4769	333	3	10.1159/000455840	10.1159/000455840	NUM
dpc-4769	333	4	.	.	PUNCT
dpc-4769	334	1	epub	epub	PROPN
dpc-4769	334	2	2017	2017	NUM
dpc-4769	334	3	feb	feb	NOUN
dpc-4769	334	4	23	23	NUM
dpc-4769	334	5	.	.	PUNCT
dpc-4769	335	1	pmid	pmid	NOUN
dpc-4769	335	2	:	:	PUNCT
dpc-4769	335	3	28226326	28226326	NUM
dpc-4769	335	4	.	.	PUNCT
dpc-4769	336	1	21	21	NUM
dpc-4769	336	2	.	.	PUNCT
dpc-4769	336	3	barros	barros	PROPN
dpc-4769	336	4	g	g	PROPN
dpc-4769	336	5	,	,	PUNCT
dpc-4769	336	6	duran	duran	NOUN
dpc-4769	336	7	p	p	NOUN
dpc-4769	336	8	,	,	PUNCT
dpc-4769	336	9	vera	vera	NOUN
dpc-4769	336	10	i	i	NOUN
dpc-4769	336	11	,	,	PUNCT
dpc-4769	336	12	bermúdez	bermúdez	PROPN
dpc-4769	336	13	v.	v.	ADP
dpc-4769	336	14	exploring	explore	VERB
dpc-4769	336	15	the	the	DET
dpc-4769	336	16	links	link	NOUN
dpc-4769	336	17	between	between	ADP
dpc-4769	336	18	obesity	obesity	NOUN
dpc-4769	336	19	and	and	CCONJ
dpc-4769	336	20	psoriasis	psoriasis	NOUN
dpc-4769	336	21	:	:	PUNCT
dpc-4769	336	22	a	a	DET
dpc-4769	336	23	comprehensive	comprehensive	ADJ
dpc-4769	336	24	review	review	NOUN
dpc-4769	336	25	.	.	PUNCT
dpc-4769	337	1	int	int	PROPN
dpc-4769	337	2	j	j	PROPN
dpc-4769	337	3	mol	mol	ADP
dpc-4769	337	4	sci	sci	PROPN
dpc-4769	337	5	.	.	PROPN
dpc-4769	337	6	2022	2022	NUM
dpc-4769	337	7	jul	jul	PROPN
dpc-4769	337	8	6;23(14):7499	6;23(14):7499	PROPN
dpc-4769	337	9	.	.	PUNCT
dpc-4769	337	10	doi	doi	NOUN
dpc-4769	337	11	:	:	PUNCT
dpc-4769	337	12	10.3390	10.3390	NUM
dpc-4769	337	13	/	/	SYM
dpc-4769	337	14	ijms23147499	ijms23147499	PROPN
dpc-4769	337	15	.	.	PUNCT
dpc-4769	338	1	pmid	pmid	NOUN
dpc-4769	338	2	:	:	PUNCT
dpc-4769	338	3	35886846	35886846	NUM
dpc-4769	338	4	;	;	PUNCT
dpc-4769	338	5	pmcid	pmcid	ADJ
dpc-4769	338	6	:	:	PUNCT
dpc-4769	338	7	pmc9321445	pmc9321445	NOUN
dpc-4769	338	8	.	.	PUNCT
dpc-4769	339	1	22	22	NUM
dpc-4769	339	2	.	.	X
dpc-4769	340	1	owczarczyk	owczarczyk	VERB
dpc-4769	340	2	-	-	PUNCT
dpc-4769	340	3	saczonek	saczonek	NOUN
dpc-4769	340	4	a	a	PRON
dpc-4769	340	5	,	,	PUNCT
dpc-4769	340	6	placek	placek	PROPN
dpc-4769	340	7	w.	w.	NOUN
dpc-4769	340	8	compounds	compound	NOUN
dpc-4769	340	9	of	of	ADP
dpc-4769	340	10	psoriasis	psoriasis	NOUN
dpc-4769	340	11	with	with	ADP
dpc-4769	340	12	obesity	obesity	NOUN
dpc-4769	340	13	and	and	CCONJ
dpc-4769	340	14	overweight	overweight	NOUN
dpc-4769	340	15	.	.	PUNCT
dpc-4769	341	1	postepy	postepy	PROPN
dpc-4769	341	2	hig	hig	PROPN
dpc-4769	341	3	med	med	ADJ
dpc-4769	341	4	dosw	dosw	NOUN
dpc-4769	341	5	(	(	PUNCT
dpc-4769	341	6	online	online	ADJ
dpc-4769	341	7	)	)	PUNCT
dpc-4769	341	8	.	.	PUNCT
dpc-4769	342	1	2017	2017	NUM
dpc-4769	342	2	aug	aug	PROPN
dpc-4769	342	3	24;71(1):761	24;71(1):761	NUM
dpc-4769	342	4	-	-	SYM
dpc-4769	342	5	772	772	NUM
dpc-4769	342	6	.	.	PUNCT
dpc-4769	342	7	doi	doi	NOUN
dpc-4769	342	8	:	:	PUNCT
dpc-4769	342	9	10.5604/01.3001.0010.3854	10.5604/01.3001.0010.3854	NUM
dpc-4769	342	10	.	.	PUNCT
dpc-4769	343	1	pmid	pmid	NOUN
dpc-4769	343	2	:	:	PUNCT
dpc-4769	343	3	28894050	28894050	NUM
dpc-4769	343	4	.	.	PUNCT
dpc-4769	344	1	23	23	NUM
dpc-4769	344	2	.	.	PUNCT
dpc-4769	345	1	chiricozzi	chiricozzi	PROPN
dpc-4769	345	2	a	a	NOUN
dpc-4769	345	3	,	,	PUNCT
dpc-4769	345	4	gisondi	gisondi	NOUN
dpc-4769	345	5	p	p	NOUN
dpc-4769	345	6	,	,	PUNCT
dpc-4769	345	7	girolomoni	girolomoni	ADJ
dpc-4769	345	8	g.	g.	NOUN
dpc-4769	345	9	the	the	DET
dpc-4769	345	10	pharmacological	pharmacological	ADJ
dpc-4769	345	11	management	management	NOUN
dpc-4769	345	12	of	of	ADP
dpc-4769	345	13	patients	patient	NOUN
dpc-4769	345	14	with	with	ADP
dpc-4769	345	15	comorbid	comorbid	NOUN
dpc-4769	345	16	psoriasis	psoriasis	NOUN
dpc-4769	345	17	and	and	CCONJ
dpc-4769	345	18	obesity	obesity	NOUN
dpc-4769	345	19	.	.	PUNCT
dpc-4769	346	1	expert	expert	NOUN
dpc-4769	346	2	opin	opin	NOUN
dpc-4769	346	3	pharmacother	pharmacother	NOUN
dpc-4769	346	4	.	.	PUNCT
dpc-4769	347	1	2019	2019	NUM
dpc-4769	347	2	may;20(7):863	may;20(7):863	X
dpc-4769	347	3	-	-	SYM
dpc-4769	347	4	872	872	NUM
dpc-4769	347	5	.	.	PUNCT
dpc-4769	348	1	doi	doi	NOUN
dpc-4769	348	2	:	:	PUNCT
dpc-4769	348	3	10.1080/14656566.2019.1583207	10.1080/14656566.2019.1583207	NUM
dpc-4769	348	4	.	.	PUNCT
dpc-4769	349	1	epub	epub	PROPN
dpc-4769	349	2	2019	2019	NUM
dpc-4769	349	3	feb	feb	NOUN
dpc-4769	349	4	22	22	NUM
dpc-4769	349	5	.	.	PUNCT
dpc-4769	350	1	pmid	pmid	NOUN
dpc-4769	350	2	:	:	PUNCT
dpc-4769	350	3	30794469	30794469	NUM
dpc-4769	350	4	.	.	PUNCT